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Chemokine Ligand 5 (CCL5), also known as RANTES (Regulated Upon Activation T-cell 
Expressed and Secreted), was originally thought to be a T-cell specific protein, however, it is 
now known to be synthesized by a variety of cells such as smooth muscle cells, neurons and 
endothelial cells. CCL5 is a potent chemoattractive cytokine (chemokine) that attracts 
leukocytes such as monocytes and eosinophils and lymphocytes such as T-cells to sites of 
inflammation and infection by acting via inhibitory G-protein coupled chemokine receptors 
CCR1, CCR3 and CCR5. Most studies have focused on the pro-inflammatory role of CCL5 and 
its role towards beta cell destruction in type 1 diabetes but in this instance we present evidence 
for an alternative role for CCL5 emphasized on improving beta cell function by activating the 
atypical chemokine receptor, GPR75.    
Our initial studies demonstrated that CCL5 was expressed and endogenously synthesized by 
mouse and human islets and that GPR75 was the most abundantly expressed CCL5 receptor, 
compared to CCR1, CCR3 and CCR5, in mouse and human islets, and mouse insulinoma beta 
cell line (MIN6). It has been established that GPR75 couples to the Gαq protein and 
subsequently elevates intracellular calcium, a vital signal for stimulus-secretion coupling of 
insulin in beta cells. This led us to investigate whether the GPR75 signal transduction pathway 
was elicited in beta cells by CCL5 and whether it had any influence on beta cell physiology. 
Immunohistochemistry revealed that GPR75 localized to the alpha and beta cells of mouse and 
human islets whereas CCL5 was localized to the alpha and beta cells of human islets but only to 
alpha cells of mouse islets. Functional studies focusing on beta cell function revealed that CCL5 
stimulated insulin secretion and elevated intracellular calcium in beta cells at sub-stimulatory and 
stimulatory glucose levels. Down-regulation of GPR75 using siRNAs significantly perturbed the 
stimulatory effect of CCL5 highlighting GPR75 as the predominant CCL5 receptor activated by 
CCL5 for elevating cytosolic calcium and stimulating insulin secretion. Furthermore, the 
stimulatory effect of CCL5 was abrogated in mouse and human islets following inhibition of 
Phospholipase C (PLC), removal of calcium from the extracellular environment, blockade of L-
type calcium channels, depletion of PKC and inhibition of calcium- calmodulin kinase II 
(CAMK II). 
CCL5 also stimulates glucagon secretion from alpha cells suggesting a possible paracrine role in 
regulating CCL5 induced stimulation of insulin secretion. Furthermore, CCL5 has significant 
cell protective effects in MIN6 beta cells as well as isolated mouse and human islets by 
protecting against cytokine-induced apoptosis. This protective effect is lost when GPR75 is 
down-regulated in MIN6 beta cells. This supports previous findings that GPR75 activation 
 15 
 
enhances cell viability in murine hippocampal cells by activating the pro survival pathway of 
PLC/PI3K/Akt/MAPK.  
In summary, our studies reveal a novel role for CCL5 in improving beta cell function and beta 
cell mass via GPR75 activation. We have identified that GPR75 predominantly acts via the Gq 
pathway and subsequent PKC activation along with calcium influx via L-type calcium channels 
and CAMK II activation, are central to the stimulus secretion-coupling between CCL5 and 
insulin. CCL5 also influences glucagon secretion suggesting an expansive role for CCL5 within 
the intra islet environment and has considerable cell protective and proliferative effects on beta 
cells possibly via GPR75 activation. This makes GPR75 an attractive therapeutic target for 
improving beta cell function and beta cell mass, two features that contribute towards the onset 
of type 2 diabetes (T2DM).  
 16 
 
Chapter 1: Introduction 
  




1.1: Diabetes Mellitus  
1.1.1: What is Diabetes Mellitus? 
Diabetes Mellitus (DM) is a chronic disorder that is characterised by high blood glucose levels 
(hyperglycaemia) as a result of defects in insulin secretion and/or insulin action (ADA, 2010, 
Hoppener and Lips, 2006). The majority of DM cases fall into two major categories: Type 1 
DM (T1DM), which is responsible for 5-10% of DM cases, and is defined by the absolute 
deficiency of insulin secretion. Type 2 DM (T2DM), accounts for 90-95% of those with DM, 
and is defined by the relative deficiency of insulin secretion and impairment of insulin action, 
known as insulin resistance (ADA, 2010). According to the World Health Organisation (WHO), 
DM is only diagnosed if fasting plasma glucose concentration exceeds 7mM or plasma glucose 
concentration exceeds 11mM two hours after consuming 75g of glucose in an oral glucose 
tolerance test (OGTT) or random venous plasma glucose concentrations exceed 11mM. 
Hyperglycaemia can cause pathological and functional changes in various metabolic tissues 
without clinical symptoms before diabetes is diagnosed (ADA, 2010). This pre-DM state is 
defined by impaired glucose tolerance (IPGT) and/or impaired fasting glucose (IFG). 
Individuals with IPGT are diagnosed if fasting plasma glucose is below 7mM but remains 
between >7mM and <11mM after OGTT (WHO/IDF, 2006). 
The current estimate for the number of adults with DM has reached 382 million with a global 
increase in fasting plasma glucose levels of 0.07mM per decade (Danaei et al., 2011, IDF, 2013). 
DM is predicted to reach 592 million by 2035 and contributed to more than 4.6 million deaths 
in 2011 (IDF, 2011, IDF, 2013). Although the global prevalence of DM has generally increased 
there is disparity in the incidence of DM between regions, countries and gender of populations 
as illustrated by Figure 1, which may implicate genetic or environmental factors associated with 
DM (Danaei et al., 2011). It is predicted that by 2030, DM will be the seventh leading cause of 
global death, accounting for 3% of total deaths, and fourth leading cause in high-income 
countries, accounting for 4.8% of total deaths (Mathers and Loncar, 2006). In the UK 3.2 
million people have been diagnosed with DM and is estimated to increase to 5 million by 2025 
of which 90% of these cases are estimated to be T2DM (DUK, 2014). Chronic hyperglycaemia 
in DM has been linked to an increase in risk of cardiovascular diseases, foot neuropathy that 
can result in ulcers and possible limb amputation, kidney failure and retinopathy, which is an 
important cause for blindness (Forbes and Cooper, 2013).  
  











Figure 1: Trends in age-standardised DM prevalence (%) for men (A) and women (B) between 1980 and 
2008 in different geographical regions (High income regions of Australia, North America, and Western 
Europe, Central and eastern Europe, Sub-Saharan Africa, Central Asia, north Africa and Middle East, 
South Asia, East Asia and southwest Asia, Southern and tropical Latin America, Central and Andean 
Latin America and the Caribbean, High-income Asia-Pacific, Oceania) and the overall global prevalence 
of  DM  (Danaei et al., 2011).  
  




1.1.2: Type 1 DM 
T1DM is a chronic autoimmune disorder in which the body’s own immune system attacks 
pancreatic beta cells in islets of Langerhans leading to their destruction and this results in 
absolute depletion of insulin (Van Belle et al., 2011, Atkinson and Eisenbarth, 2001). At the 
point of clinical diagnosis, approximately 60-80% of beta cells have been destroyed by 
infiltrating immune cells such as CD8 T cells and macrophages (Notkins et al., 2001). T1DM is 
often diagnosed in patients younger than 30 years of age including children (Van Belle et al., 
2011). The incidence of T1DM is highly variable between different regions and ethnic 
populations and is on the increase in countries that have historically displayed a low incidence 
of T1DM (LaPorte et al., 1985). The disparity of T1DM incidence between regions and/or 
ethnic populations suggest that genetic or environmental factors may contribute to the onset of 
this disease (Atkinson and Eisenbarth, 2001). For example, Human leukocyte antigen (HLA) 
class II genes located on chromosome 6 (also known as the IDDM1, insulin-dependent DM 
locus 1) has been linked to T1DM susceptibility. These genes promote the encoding of 
antigenic peptides, which present themselves to T-cells, and account for approximately 45% of 
the genetic susceptibility to T1DM (Noble et al., 1996, Buzzetti et al., 1998, Atkinson and 
Eisenbarth, 2001). A non-HLA loci known as IDDM2 is located on chromosome 11, which 
also contains the insulin gene region, and contributes approximately 10% towards the genetic 
susceptibility to T1DM (Van Belle et al., 2011). Another T1DM risk allele (IDDM12) is CTLA-
4 (cytotoxic T lymphocyte associated protein 4), which is located on chromosome 2 (Nisticò et 
al., 1996, Ueda et al., 2003). It is important for negative regulation of immune responses and 
CTLA-4 knock-out mice have been shown to increase lymphocyte proliferation (Waterhouse et 
al., 1995). To date no environmental factors have been associated with triggering T1DM. 
However, there is growing evidence that certain factors increase the risk of developing T1DM, 
which can be classified into three groups: viral infections (e.g. coxsackievirus), early infant diet 
(e.g. early introduction of cow’s milk) and toxins (Ellis and Atkinson, 1996, Dahlquist, 1997, 
Knip and Akerblom, 1999, Lang et al., 2008).  
1.1.3: Type 2 DM 
There are approximately 360 million people who have T2DM worldwide and global health 
expenditure due to T2DM is in excess of one trillion US dollars (IDF, 2013). T2DM is 
characterised by insulin resistance of metabolically active tissues, reduction in insulin synthesis 
in beta cells, reduction in beta cell mass and eventual beta cell failure (Kahn, 1994, Robertson, 
1995, Lingohr et al., 2002). Beta cell failure coupled with insulin resistance results in elevated 
fasting and post-prandial blood glucose levels as a result of increased glucose production from 
the liver and decrease in glucose transport into muscle and adipose tissue (Olokoba et al., 2012, 
Fujioka, 2007). Beta cells also show remarkable ability of plasticity, in which they can adjust beta 




cell growth and survival to maintain a balance between metabolic demand and insulin supply. 
For example, in obese individuals who do not develop T2DM, their beta cell mass increases to 
compensate for the increase in metabolic demand. However, this adaptation is lost in obese 
individuals that develop T2DM (Butler et al., 2003a, Maclean and Ogilvie, 1955, Lingohr et al., 
2002). The rise in the incidence of T2DM is largely attributed to lifestyle, environmental and 
genetic factors (Hu et al., 2001). Environmental factors include sedentary lifestyle, alcohol 
consumption, physical inactivity, excess calorie consumption and smoking (Hu et al., 2001). 
Environmental toxins such as bisphenol A (bpA), which is a constituent of plastics, has also 
been associated with increased concentrations in urine and the incidence of T2DM (Mean bpA 
concentration in healthy control: 4.53-4.66ng/ml; T2DM: 8ng/ml) (Lang et al., 2008). Several 
genetic factors have also been associated with the increased incidence of T2DM. For example, 
KCNJ11 (potassium inwardly rectifying channel, subfamily J, member 11), which encodes the 
islet ATP-sensitive potassium channel Kir.6.2 pore-forming subunit and TCL7L2 (transcription 
factor 7-like 2), which regulates expression of glucagon and glucagon-like peptide-1 (GLP-1) 
synthesis are known risk factor genes for T2DM (McCarthy, 2010). As mentioned earlier, 
approximately 90-95% of all DM cases are related to T2DM (ADA, 2010) and thus there is an 
onus within the biomedical, medical and pharmaceutical profession to develop therapies that 
not only both stimulate insulin secretion but also maintain or increase beta cell mass by either 
stimulating beta cell proliferation or suppressing beta cell apoptosis. 
1.1.4: Therapies for DM 
Treatment for T1DM patients involve insulin replacement therapy, in which the administered 
insulin directly compensates for the loss of insulin secretion from beta cells by reducing blood 
glucose levels through stimulation of glucose uptake and storage, and suppression of hepatic 
glucose production. The introduction of long lasting (glargine) and rapid acting (lispro and 
aspart) insulin analogues provides alternative options for improved glycaemic control compared 
to regular insulin (Burge and Schade, 1997, Cameron and Bennett, 2009). Recent U.S. Food and 
Drug Administration (FDA) approval of an inhaled form of insulin can be used for T1DM and 
T2DM treatment, which is more effective and rapidly acting than intravenously administered 
short acting insulin (Black et al., 2007, Rosenstock et al., 2010).   
Treatment of T2DM is managed by modifications to lifestyle management and/or in 
combination with hypoglycaemic drugs. Maintenance of body mass index (BMI) of 25kg/m2 as 
well as dietary modifications such as increased fibre consumption, increased unsaturated fats, 
reduced saturated fats and diets low in glycaemic index coupled with regular exercise and 
abstinence from smoking and alcohol consumption have been shown to significantly reduce the 
incidence of T2DM (Hu et al., 2001, Willi et al., 2007, Yoon et al., 2006, Boffetta et al., 2011). 




However, failure to make lifestyle modifications can exacerbate complications associated with 
sustained hyperglycaemia such as atherosclerosis, obesity, dyslipidaemia and hypertension 
(Ferrannini et al., 1991, Modan et al., 1985, Swislocki et al., 1989, Reaven et al., 1967, Zavaroni 
and Reaven, 1981). Therefore, glycaemic control by hypoglycaemic agents has become the front 
line of T2DM therapeutic intervention, which fall into four major categories: insulin sensitisers, 
insulin secretagogues, glucose absorption inhibitors and glucose excretion stimulators (Figure 
2). 
Insulin sensitisers  
Biguanides such as, metformin, are commonly used in overweight and obese patients. Their 
principal function is to enhance sensitivity of hepatic and other peripheral insulin-sensitive 
tissues. Biguanides inhibit hepatic glycogenolysis and gluconeogenesis, resulting in an overall 
reduction in blood glucose levels. They also enhance the uptake of glucose into muscle due to 
increased expression of GLUT4. Although, metformin has been reported to cause Lactic 
acidosis as a rare side-effect associated with its use, it is effective in reducing macrovascular 
complications and reducing weight (DeFronzo et al., 1991, Stumvoll et al., 1995, Wollen and 
Bailey, 1988, Rossetti et al., 1990, Viollet et al., 2012, DeFronzo, 1999). 
Insulin secretagogues 
Sulphonylureas have been the main therapy for treating T2DM and have been in commercial 
use for over 50 years. Their principal mechanism of action is to stimulate insulin secretion by 
binding to the sulphonylurea receptor 1 (SUR1) on the beta cell, and subsequently close the 
KATP channel. This causes a decrease in potassium efflux and elicits depolarisation of the beta 
cell membrane resulting in calcium influx via VOCCs, which promote insulin granule exocytosis 
(Siconolfi-Baez et al., 1990). Although, sulphonylureas are the least expensive of all oral 
hypoglycaemic drugs, they have notable side effects of weight gain and hypoglycaemia 
(DeFronzo, 1999). Glimepride, is a third generation sulphonylurea currently used clinically. 
However, there are concerns associated with the use of sulphonylureas as they stimulate insulin 
secretion in the absence of elevated blood glucose levels resulting in hypoglycaemic episodes, 
weight gain and have been implicated in increased beta cell apoptosis (Efanova et al., 1998, 
Maedler et al., 2005). 
Meglitinides such as repaglinide and nateglinide are non-sulphonylurea secretagogues that have 
a similar mode of action to sulphonylureas. They close KATP channels via an alternative binding 
site to sulphonylureas (Fuhlendorff et al., 1998). They have a rapid onset and short duration (4-
6 hours) making them ideal for post-prandial glycaemic control and they are associated with a 
lower risk of hypoglycaemia (DeFronzo, 1999). 




Thiazolidinediones (TZDs) such as troglitazone, pioglitazone and rosiglitazone, are a class of 
peroxisome proliferator activated receptor γ (PPARγ) agonists, which enhance sensitivity to 
insulin especially in muscle by stimulating GLUT4 expression (Saltiel and Olefsky, 1996) and 
they also reduce hepatic glucose production. In addition, TZDs have been reported to improve 
beta cell function (Ovalle and Bell, 2002, Gastaldelli et al., 2007) However, TZDs also increase 
adipocyte numbers, which explains the weight gain associated with its use (Spiegelman, 1998). 
Troglitazone was associated with liver toxicity and has since been withdrawn (Gitlin et al., 1998, 
DeFronzo, 1999). Recent developments have also resulted in the withdrawal of rosiglitazone in 
the UK due to significant risk of myocardial infarction associated with its use (Nissen and 
Wolski, 2007) and the use of pioglitazone is also associated with an increased risk of bladder 
cancer in T2DM subjects (Azoulay et al., 2012), which has also led to its withdrawal in India, 
Germany and France. 
Glucagon-like peptide 1 (GLP-1) mimetics such as exenatide and liraglutide form the 
foundation of incretin-based therapies, which were adopted for clinical use in 2005 in the US 
and 2007 in the UK. Endogenous GLP-1 is released by L-cells in response to food intake and it 
is detected by islet GLP-1 receptors (GLP-1R). It potentiates nutrient-induced insulin secretion, 
suppresses glucagon secretion, and also enhances insulin sensitivity by up-regulating GLUT 1 
and GLUT 4 expression (Wang et al., 1997). However, GLP-1 is rapidly degraded by dipeptidyl-
peptidase IV (DPP-4), which significantly reduces its half-life and therefore its efficacy. The 
GLP-1 analogue exenatide shares approximately 50% amino acid sequence homology to GLP-1 
and activation of the GLP-1R results in cAMP elevations, which is the prominent mechanism 
of stimulating insulin secretion in beta cells. GLP-1 also stimulates insulin secretion via cAMP-
independent effects by closing the KATP channels (Suga et al., 2000). Exenatide has recently 
been implicated in the increased risk of acute pancreatitis (Denker and Dimarco, 2006, Singh et 
al., 2013) and has been issued with a safety alert by the FDA. 
DPP-4 inhibitors such as sitagliptin and vildagliptin have been developed to prolong the half-
life of GLP-1 and therefore the use of long lasting GLP-1 analogues and DPP-4 inhibitors serve 
as an attractive therapy for T2DM. Furthermore, their ability to improve insulin secretion in a 
glucose-dependent manner, increase beta cell mass and their once-daily administration are 
making them attractive therapeutic options. However, approval of vildagliptin has been delayed 
by the FDA in the US due to reduced renal function observed in animal studies (Hughes, 2008). 
Glucose absorption inhibitors 
Alpha-glucosidase inhibitors (acarbose, miglitol) inhibit the activity of digestive enzymes 
(maltase, isomaltase, sucrase and glucoamylase), located in the brush border of the 




gastrointestinal (GI) tract. These enzymes are responsible for breaking down carbohydrate 
disaccharides into monosaccharides, and their inhibition delays the absorption of glucose into 
the systemic circulation. This provides the beta cells ample time to release insulin to cope with 
the blunted elevation in plasma glucose levels and they are therefore effective post-prandial 
hyperglycaemic agents (Clissold and Edwards, 1988, Coniff et al., 1995). However, they are 
associated with side-effects such as diarrhoea and flatulence but they are not associated with 
weight gain (DeFronzo, 1999). 
Glucose excretion stimulators 
Inhibitors of sodium glucose co-transporter 2 (SGLT-2) such as, Dapagliflozin (Forxiga), 
Canagliflozin (Invokana) and Empagliflozinare (Jardiance), are used to lower blood glucose 
levels by inhibiting glucose reabsorption in the proximal convoluted tubule of the kidney, which 
accounts for 90% of glucose reabsorption (Marsenic, 2009). However, there are certain 
limitations associated with their use, for example, SGLT-1 is expressed in various tissues 
including kidney and thus restrict the use of SGLT inhibitors that are not selective for SGLT-2. 
Furthermore, glycosuria associated with use of SGLT-2 inhibitors has been implicated in the 
development of bacterial urinary tract infections and genital infections (Geerlings et al., 2014).  
  
















Figure 2: Different classes of therapies currently available for T2DM. 
  




1.2: Regulation of hormone secretion from islets of Langerhans 
1.2.1: Islet cytoarchitecture 
Pancreatic islets are highly-vascularised micro-organs and form the endocrine portion of the 
pancreas, which is crucial for glucose homeostasis (Bonner-Weir, 1988, Lammert et al., 2003). 
Islets typically consist of four major endocrine cell types, insulin-secreting beta (β) cells, 
glucagon-secreting alpha (α) cells, somatostatin-secreting delta (δ) cells and pancreatic 
polypeptide-secreting (PP) cells. As illustrated in Figure 3, mouse (Mus musculus) and rat (Rattus 
norvegicus) islets exhibit distinct islet architecture compared to human islets, with a clear 
segregation between beta cells and non-beta cells. Rodent islets retain 60-80% of beta cells in 
the core of the islet whereas non-beta cells such as alpha cells (10-20%), delta cells (<10%) and 
PP cells (<1%) are predominantly localised to the periphery (mantle) of the islet. Human islets, 
which are composed of a higher proportion of alpha cells (40%) and lower proportion of beta 
cells (<50%), have a more disorganised cytoarchitecture compared to rodent islets and do not 
retain a segregated formation between beta cells and non-beta cells like their rodent 
counterparts. The dispersed nature of beta cells in human islets has been suggested to improve 
islet sensitivity to low blood glucose concentrations (1mM) to which mouse islets are insensitive 
(Cabrera et al., 2006, Brissova et al., 2005).  
As mentioned earlier, islets are highly-vascularised micro-organs and it has been theorised that 
islet cytoarchitecture could influence intra-islet microcirculatory patterns. Three models have 
been proposed; (1) Mantle to core: non-beta cells are able to detect changes in glucose 
concentrations before signalling to the beta cell core to invoke an appropriate insulin secretory 
response (Ballian and Brunicardi, 2007), (2) Core to mantle: beta cells detect changes in glucose 
concentrations first and initiate an insulin secretory response for it to be appropriately 
modulated by non-beta cells localised to the mantle (Samols et al., 1988), and (3) Artery to vein: 
blood enters the islets from the artery and is drained away into a vein irrespective of cellular 
composition (Liu et al., 1993).  
The number of cells that form an islet and islet size can vary from between 10 or fewer cells to 
thousands of cells in the same population, with mean size 116±80µm for mouse islets and 
50±29µm for human islets (Kim et al., 2009). The multicellular environment within islets, 
containing beta cells and non-beta cells, enables integrative secretory responses to various 
nutrient and non-nutrient stimuli (section 1.1.4 and 1.1.5). Single islet cells can regulate their 
own physiological action in response to their own by-products (autocrine effect) or by exerting 
their effects on neighbouring islet cells (paracrine effect), which are essential for maintaining 
proper islet function. For example, the dissociation of rodent islets into monolayers results in 




beta cells being unable to respond to stimulatory glucose concentrations but re-aggregation into 
pseudoislets restores normal secretory function (Hopcroft et al., 1985, Halban et al., 1982, 
Lernmark, 1974, Hauge-Evans et al., 1999). The presence of gap junctions, adhesion molecules 
(E-cadherins, N-CAM) and connexins 36 and 43 have also been attributed to normal islet 
secretory function and islet morphology, which permit a synchronised mechanism of cell to cell 
communication and allows for an appropriate beta cell response to various stimuli (Leite et al., 
2005, Dahl et al., 1996, Yamagata et al., 2002, Esni et al., 1999, Meda, 2003, Hauge-Evans et al., 
1999). Insulin secretion, which is a multicellular process, requires sufficient release of insulin 
under normal physiological and pathophysiological conditions that cannot be achieved by 
individual cells alone (Bavamian et al., 2007). Therefore, the co-ordinated cytoarchitecture, cell-
cell communication and the prominent intra-islet vasculature enable islets to serve as the 
primary micro-organ to effectively regulate glucose homeostasis. 
 
Figure 3: Confocal micrographs of immunostained mouse and human islets (Left panel). Immunoreactive 
insulin (red), immunoreactive glucagon (green) and immunoreactive somatostatin (blue) cells are 
randomly distributed throughout the human islet. In contrast the insulin containing cells (red) were 
located in the core of the mouse islet surrounded by a mantle of glucagon (green) and somatostatin (blue) 
containing cells. Scale bar, 50µm. Comparison of the cell composition of human islets with that of mouse 
islets (Right panel). Human islets had more glucagon-immunoreactive cells and fewer insulin-
immunoreactive cells (n=3 mice and 5 humans; mean± SEM). Images acquired from (Cabrera et al., 
2006). 




1.2.2: Glucose homeostasis: Insulin and glucagon action 
Glucose is the main energy source for mammalian cells with the mammalian brain requiring a 
constant supply of glucose to function appropriately (Bogan, 2012). Plasma glucose 
concentration is finely balanced between glucose entry into the circulatory system from the 
absorption of glucose in the gastrointestinal (GI) tract and glucose clearance from the 
circulatory system. Circulating glucose is derived from three sources; gastric emptying after food 
intake, which accounts for the majority of glucose entry into the circulatory system as well as 
hepatic processes such as gluconeogenesis, which is the synthesis of glucose from amino acids 
and lactate, and glycogenolysis, which is the breakdown of the polymerised form of glucose 
(Aronoff et al., 2004). Physiological glucose concentrations are tightly regulated to prevent 
chronic elevations in glucose, which is detrimental to beta cell health (glucotoxicity) and can 
promote the onset of type 2 diabetes mellitus (T2DM), and thus underlies the importance of 
glucoregulatory hormones such as insulin, glucagon, GLP-1, GIP, adrenaline, cortisol and 
amylin (Aronoff et al., 2004, Bensellam et al., 2012).  
Insulin, the primary hormone secreted from beta cells of islets, lowers postprandial blood 
glucose concentrations by promoting the storage and synthesis of carbohydrates, lipids and 
proteins (Saltiel and Kahn, 2001). The physiological action of insulin is mediated by its binding 
to the insulin receptor (InsR), which is a heterotetrameric structure consisting of two 
extracellular insulin-binding alpha subunits, and two transmembrane beta subunits with tyrosine 
kinase activity. Insulin binding to the alpha subunits results in the trans-phosphorylation of beta 
subunit tyrosine residues in an activation loop (autophosphorylation), which increases the 
overall catalytic activity of the kinase (Watson et al., 2004, Saltiel and Pessin, 2003). Activation 
of InsR phosphorylates downstream intracellular targets such as insulin receptor substrate (IRS) 
on multiple tyrosine residues. IRS-1 and IRS-2 are widely expressed throughout insulin-sensitive 
tissues (Taniguchi et al., 2005), whilst IRS-3 is predominantly expressed in adipocytes (Lavan et 
al., 1997). IRS-1 knock out mice show signs of growth retardation (Tamemoto et al., 1994) but 
do not develop DM, but IRS-2 knockout mice are insulin resistant, develop T2DM and show 
impaired beta cell function (Withers et al., 1998). IRS phosphorylation recruits downstream 
effectors that influence phosphatidylinositol-kinase 3 (PI3K), PKB/Akt or MAPK cascades. 
IRS1/2 recruits PI3K at the plasma membrane, which produces PIP3 and activates a 
serine/threonine phosphorylation cascade targeting PDK1, PKB/Akt and PKC (White, 2002, 
Alessi and Downes, 1998, Vanhaesebroeck and Alessi, 2000, Beeson et al., 2003), which 
stimulate the translocation of glucose transporter-4 (GLUT-4) to the plasma membrane and 
thus enhance glucose uptake. PKB/Akt activation can also activate glycogen synthase to 
promote glycogen synthesis, which prevents glucose release into the circulation (Brady et al., 
1998, Sano et al., 2003, Beeson et al., 2004). 




Elevations in plasma glucose levels increase glucose uptake and utilisation predominantly by 
skeletal muscle, which is responsible for 75% of all glucose uptake at euglycaemia and 95% at 
hyperglycaemia, and to a lesser extent adipose tissue (Baron et al., 1988). Glucose is a 
hydrophilic molecule, which cannot cross the plasma membrane freely, and is rapidly 
phosphorylated by hexokinase much faster than its uptake into the cell. Furthermore, 
intracellular glucose concentration is negligible compared to the extracellular compartment 
(5mM) and therefore large glucose concentration gradients are established between the 
intracellular and extracellular compartments (Klip and Paquet, 1990). Glucose transporters 1 
and 4 (GLUT 1 and GLUT 4) are expressed by skeletal muscle (Zorzano et al., 1996), and the 
fructose transporter (GLUT 5) is also expressed in human skeletal muscle (Hundal et al., 1992). 
GLUT 4 is responsible for 60-70% of basal glucose uptake (Rudich et al., 2003). Under basal 
conditions most of the GLUT 4 are localised in their intracellular membranes but their 
translocation from the endosomal compartment to the cell membrane is induced by InsR 
activation by insulin and thus facilitates glucose uptake into the skeletal muscle. The liver is an 
important tissue for glucose homeostasis as it is responsible for glucose production, glucose 
utilisation, and it is the sole site for the glucoregulatory action of glucagon. GLUT 2 is 
responsible for the major glucose transport role in hepatocytes, as well as beta cells, whilst 
insulin stimulates glycogen synthesis as well as inhibiting glycogenolysis and gluconeogenesis by 
stimulating glycogen synthase and simultaneously inhibiting liver glycogen phosphorylase, thus 
regulating blood glucose levels. (Ortmeyer et al., 1997, Chiasson et al., 1976).  
Glucagon, which is secreted by islet alpha cells, is a key glucoregulatory hormone that opposes 
the physiological actions of insulin. Glucagon release is stimulated in response to low blood 
glucose concentrations and its main function is to stimulate hepatic glucose production (Jiang 
and Zhang, 2003). This is achieved by promoting glycogenolysis and gluconeogenesis (Rosa et 
al., 1992). Glucagon binds to the G-protein coupled glucagon receptor (GluR), which is 
associated with two classes of G-proteins, Gαs and Gαq (Jiang and Zhang, 2003). Glucagon 
promotes glycogenolysis by binding to the GluR resulting in its association with Gαs, which 
stimulates adenylate cyclase (AC) to generate cAMP, which activates the downstream effector 
protein kinase A (PKA), resulting in decreased glycogen synthesis, increased glycogenolysis and 
gluconeogenesis, and elevated circulating blood glucose levels (Jiang and Zhang, 2003).  
1.2.3: Biosynthesis and storage of insulin and glucagon 
Insulin is a 51 amino acid protein with a molecular weight of 5.8kDa and it contains two chains: 
A chain (21 residues) and B chain (30 residues) joined together by a 31 amino acid C-peptide. 
The insulin gene encodes a 110 amino acid insulin precursor known as preproinsulin (PPI) 
(Egea et al., 2005). Translocation of PPI across the rough endoplasmic reticulum (ER) and into 




the lumen results in the cleavage of the signal peptide by a signal peptidase to liberate 
proinsulin. The proinsulin undergoes protein folding along with the formation of three 
disulphide bonds, which are essential for insulin stability and bioactivity, and the action of 
prohormone convertase (PC) 1/3 and PC2, cleave the C-peptide away from the A and B chains 
(Ozawa et al., 2014, Huang and Arvan, 1994). Proinsulin is then transported from the ER to the 
golgi apparatus where it enters immature secretory granules for it to be cleaved into insulin and 
C-peptide (Huang and Arvan, 1994). The insulin stored in these secretory granules await 
exocytosis in response to an external stimuli (Weiss, 2009, Nishi et al., 1990). 
Glucose metabolism is the most important regulator of insulin gene transcription and 
translation (Poitout et al., 2006). A mouse beta cell contains approximately 13,000 insulin 
granules, occupying 10% of total cell volume. Each granule contains approximately 200,000 
insulin molecules (Dean, 1973, Howell, 1984). Insulin content of beta cells is a dynamic event 
and increases in response to nutrients and decreases in response to nutrient suppression. As the 
insulin concentration in secretory granules increases the insulin monomer form dimers and then 
hexamers, which are secreted from the beta cell and pass into the circulatory system, where 
insulin dissociates into monomers. Therefore, the monomer is the active form of insulin and the 
hexamer is the storage form of insulin (Fu et al., 2013).  
Glucagon is a 29 amino acid protein that is secreted by islet alpha cells. It is derived from the 
precursor molecule proglucagon, which is expressed in brain, pancreas and intestine (Jiang and 
Zhang, 2003). Proglucagon is processed differentially in pancreatic alpha cells and intestinal L-
cells, in that it is converted to mature glucagon in alpha cells and glucagon-like peptide-1 (GLP-
1) in L-cells. A prohormone converatase (PC2) is responsible for the proteolytic processing of 
proglucagon to the biologically active glucagon (Rouille et al., 1997). 
  




1.2.4: Nutrient regulation of insulin and glucagon secretion. 
In T2DM the secretion of glucagon and insulin are perturbed, which results in elevated plasma 
glucose levels (Nolan and O’Dowd, 2009). The reduction in glucose-induced insulin secretion is 
attributed to a defect in glucose sensing by beta cells (Cerasi, 1975). In normal healthy subjects, 
glucose entry into beta cells is a carrier-mediated process through GLUT 2 in rodents and 
GLUT 1, 2 and 3 in humans (De Vos et al., 1995, Coppieters et al., 2011). Once inside the beta 
cells the glucose is phosphorylated by a series of enzymatic steps. The rate limiting step of 
glucose metabolism is its phosphorylation to glucose-6-phosphate. Mouse islet beta cells 
express three enzymes that regulate this step; 1) hexokinase, which has a low Km for glucose 
(0.1mM); 2) glucokinase, which has a high Km for glucose (10mM); 3) glucose-6-phosphatase, 
which is inhibited by glucose (Hedeskov, 1980).  
In brief, glucose-6-phosphate undergoes glycolysis and results in the generation of the end 
product pyruvate, which enters the tricarboxylic (TCA) cycle in the mitochondria, resulting in 
the elevation of cytosolic ATP:ADP ratio, which is essential for nutrient-induced insulin 
exocytosis. Inhibition of oxidative phosphorylation, the process in which the majority to ATP is 
generated, using anoxia or 2,4-dinitrophenol inhibits glucose-induced insulin secretion (Coore 
and Randle, 1964). The elevation in intracellular ATP concentration inhibits potassium (K+) 
efflux due to the binding of ATP to the pore-forming Kir6.2 subunit of ATP-sensitive K+ 
channels (KATP). This results in beta cell membrane depolarisation, which activates voltage 
operated calcium channels (VOCCs), predominantly L-type VOCCs (Rorsman and Renström, 
2003, Wiser et al., 1999). The influx of calcium into the cytosol triggers insulin exocytosis 
(Sakurada et al., 1993), and it has been shown that a readily releasable pool (RRP) of insulin 
containing granules are tightly coupled to the L-type VOCCs, with evidence of synaptic proteins 
of the insulin exocytotic machinery such as syntaxin 1A and SNAP-25 that interact with L-type 
VOCCs and tether and direct calcium entry via VOCCs to the RRP insulin containing granules 
(Wiser et al., 1999, Wiser et al., 1996).  
Insulin granule fusion at the beta cell membrane is due to the interaction of soluble N-
ethylmaleimide-sensitive factor attachment protein receptors (SNAREs), which form complexes 
at the cell membrane. SNARE proteins are expressed on the plasma membrane (T-SNARES) 
such as syntaxin and synaptosomal-associated protein of 25kDa (SNAP-25). SNARES are also 
expressed on the vesicle membrane (V-SNARES) such as vesicle-associated membrane protein 
2 (VAMP-2) and synaptobrevin-2. Synaptotagmins are believed to be important for calcium 
sensing in vesicle fusion, which contain two calcium binding sites (C2A and C2B). Although 
synaptotagmins I and II are expressed by beta cell lines they are not present in primary beta cells 
and therefore their role in insulin exocytosis is unclear (Rorsman and Renström, 2003). In beta 




cells, a family of small GTP-binding Rab proteins such as Rab3A have been implicated in 
regulating insulin exocytosis. Rab3A localises to the cytoplasmic face of secretory granules and 
is thought to act as a ‘brake’ on insulin granule exocytosis. The Rab3-interacting  molecule 
(Rim) is also present in beta cells and has the ability to interact with L-type VOCCs, SNAP-25 
and synaptotagmin (Rorsman and Renström, 2003).  
As illustrated by Figure 4, glucose-induced insulin release from beta cells exhibits a biphasic 
pattern, which involves an initial transient first phase followed by a sustained second phase. 
This characteristic biphasic response of insulin secretion is attributed to the activation of 
different pools of insulin granules. The first phase involves the RRP of granules and typically 
accounts for 1-5% of total granules in the beta cell. The second pool of insulin containing 
granules is known as the non-readily releasable pool, which accounts for >95% of total 
granules. These granules become release-competent by mobilisation from the reserve pool, 
docking to the beta cell membrane and priming prior to release (Rorsman and Renström, 2003).   
 
Figure 4: Schematic diagram illustrating biphasic glucose-induced insulin secretion. The transient first 
phase is attributed to the release of insulin from the readily releasable pool (RRP) of granules (green). The 
sustained second phase is attributed to the mobilisation of secretory granules from the reserve pool (red), 
and these granules must undergo docking and priming at the beta cell membrane before release 
competency is achieved. Image acquired and modified from (Rorsman and Renström, 2003). 
  




Glucagon secretion is maximally inhibited at blood glucose levels of 3mM in mouse and human 
islets, which are concentrations known not to stimulate insulin secretion. Alpha cells contain a 
set of sodium and calcium channels that generate action potentials in the absence of glucose or 
at low glucose concentrations, which triggers calcium influx and glucagon secretion (Gromada 
et al., 1997a). Elevations in glucose concentration inhibit all these events. As illustrated in Figure 
5, glucose enters the alpha cell through the GLUT 1 transporter. At low glucose concentrations, 
the activity of KATP channels remains moderate and this maintains the membrane potential 
within a range that can open VOCCs (Quesada et al., 2008). Calcium entry through the N-type 
VOCCs induces glucagon secretion. However, in human alpha cells the P/Q-type VOCCs are 
predominantly responsible for promoting glucagon secretion (Walker et al., 2011). An increase 
in extracellular glucose results in the elevation of ATP:ADP ratio, which blocks KATP channels 
and depolarises the alpha cell to a membrane potential where channels involved in action 
potential generation are inactivated which consequently inhibits electrical activity, calcium influx 
and glucagon secretion (Gromada et al., 1997a, MacDonald et al., 2007, Quesada et al., 2008). 
Furthermore, alpha cells contain more voltage gated sodium channels than beta cells and they 
are inactivated at membrane potentials more positive than -50mV, leading to reduced action 
potential firing and subsequent glucagon secretion (Göpel et al., 2000). The repolarisation of 
alpha cells is mediated by the efflux of potassium (K+) via K+ channels (Quesada et al., 2008). 
  





Figure 5: Schematic diagram of glucose-dependent regulation of glucagon secretion from alpha 
cells low glucose concentrations. Glucose enters alpha cells through glucose transporter 1 (GLUT1) 
resulting in the generation of ATP from the mitochondria. At low glucose concentrations the activity of 
KATP channels is moderate, which keeps the membrane potential within range to activate VOCCs. This 
results in the influx of calcium and subsequently triggers glucagon secretion. The repolarisation of alpha 
cells is mediated by the efflux of potassium (K+) via K+ channels. 
  








Parasympathetic, sympathetic and sensory nerves innervate islet endocrine cells that regulate 
islet hormone secretion (Ahrén et al., 2006). Parasympathetic innervation of islets emanates 
from the pancreatic ganglia, which are innervated from the preganglionic nerves stemming from 
the dorsal motor nucleus of the vagus (Ahrén et al., 2006). The cholinergic nerves enter the 
pancreas along blood vessels and terminate at the intrapancreatic ganglia, from which post-
ganglionic nerves penetrate the islet and innervate endocrine cells. Cholinergic stimulation 
elevates both insulin and glucagon secretion (Ahrén, 2000, Bloom and Edwards, 1981, Honey 
and Weir, 1980, Duttaroy et al., 2004). Activation of parasympathetic nerves releases the 
neurotransmitter acetylcholine (Ach), which transmits its stimulatory effect on glucose-induced 
insulin secretion by binding to the Gq coupled muscarinic (M3) receptor expressed on beta cells. 
M3 activation in islets stimulates protein kinase C (PKC) following phospholipid hydrolysis 
(Persaud et al., 1989). Neuropeptides are also released by parasympathetic nerves, which include 
vasoactive intestinal peptide (VIP), gastrin-releasing peptide (GRP) and pituitary adenylate 
cyclase activating polypeptide (PACAP), which stimulate both insulin and glucagon secretion 
(Honey and Weir, 1980, Ahren and Lundquist, 1981, Filipsson et al., 1998a, Schebalin et al., 
1977, Filipsson et al., 1997). VIP and PACAP stimulate insulin secretion by binding to their 
respective Gs-coupled receptors VIP2 and PAC1, which are  expressed by beta cells (Filipsson et 
al., 1998b), and elevate cAMP levels as a result of adenylate cyclase (AC) activation (Klinteberg 
et al., 1996). GRP stimulates glucose-induced insulin secretion by binding to the GRP receptor, 
activating phospholipase C and D, promoting the release of calcium from intracellular stores 
and calcium influx from the extracellular compartment by stimulating DAG-sensitive PKC 
isoforms (Gregersen and Ahren, 1996). 
Post ganglionic sympathetic nerves, which stem from the preganglionic nerves originating from 
the hypothalamus, also innervate islets. Activation of sympathetic nerves, which release the 
neurotransmitter noradrenaline, inhibits glucose-induced insulin secretion (Porte and Williams, 
1966). Activation of the α2-adrenoreceptor results in the hyperpolarisation of beta cells by 
opening KATP channels and thereby inhibiting calcium influx (Nilsson et al., 1988). α2-
adrenoreceptor activation has also been shown to reduce islet cAMP levels (Nakaki et al., 1981) 
whereas activation of β2-adrenoreceptor has been reported to increase cAMP formation and 
stimulate insulin secretion in beta cells (Kuo et al., 1973). Furthermore, β2-adrenoreceptor 
activation can also stimulate insulin secretion indirectly by directly stimulating β2-
adrenoreceptor-mediated glucagon secretion from alpha cells (Lacey et al., 1991). 




Neuropeptides such as neuropeptide Y (NPY) and galanin are also released upon sympathetic 
stimulation. NPY inhibits insulin secretion most likely through the activation of NPY receptor 
1(Y1), which is known to reduce cAMP levels by inhibiting AC (Morgan et al., 1998). Galanin is 
a potent inhibitor of insulin secretion, through activation of the galanin receptor 1 (GalR1) 
expressed by beta cells (Parker et al., 1995), resulting in hyperpolarisation, reduction in cytosolic 
calcium and reduction in cAMP formation (Ahrén and Lindskog, 1992).  
Insulin 
Glucose is the main regulator of insulin secretion from beta cells. Moreover, intra-islet 
communication via paracrine or autocrine processes can also influence islet hormone secretion. 
Insulin can act in an autocrine fashion on beta cells by binding to beta cell InsR (Gazzano et al., 
1985, Verspohl and Ammon, 1980, Harbeck et al., 1996), to stimulate insulin gene transcription, 
elevate insulin biosynthesis and insulin content (Xu and Rothenberg, 1998). It can also stimulate 
InsR tyrosine kinase activity followed by IRS-1 phosphorylation to transmit the insulin signal in 
the beta cell and stimulate insulin secretion via a calcium-dependent mechanism (Aspinwall et 
al., 1999), however it has been reported that insulin does not have an autocrine effect on insulin 
secretion but has been shown to decrease apoptosis in human islets (Persaud et al., 2008)  
Insulin also inhibits glucagon mRNA expression and glucagon secretion from neighbouring 
alpha cells, by stimulating IRS-1 phosphorylation and activation of phosphatidylinositol 3-kinase 
(PI3K) in R1-G9 cells, a pancreatic alpha cell line (Kawamori et al., 2009, Diao et al., 2005, 
Kaneko et al., 1999). Insulin also stimulates somatostatin (SST) secretion (Honey and Weir, 
1979). It has also been shown that insulin can suppress SST secretion in the presence of SST 
stimulators such as glucose and arginine (Gerber et al., 1981). 
Glucagon   
Glucagon stimulates insulin and somatostatin secretion, and GluR are expressed by beta cells 
and delta cells (Kawai et al., 1995, Wojtusciszyn et al., 2008, Kieffer et al., 1996). Binding of 
glucagon to the Gαs-coupled GluR results in activation of AC and elevations of two second 
messengers; cAMP and calcium (Jelinek et al., 1993, Huypens et al., 2000, Authier and 
Desbuquois, 2008). Studies have shown that the increases in intracellular calcium may be 
mediated through cAMP-dependent (Staddon and Hansford, 1989) or cAMP-independent 
signal transduction pathways (Mine et al., 1988, Wakelam et al., 1986), such as stimulation of 
inositol triphosphate (IP3), a component of the Gq signalling pathway associated with calcium 
mobilisation (Wakelam et al., 1986). Glucagon can also regulate glucagon synthesis and 
secretion in an autocrine fashion by signalling through its own receptor followed by PKC or 
PKA activation (Leibiger et al., 2012, Ma et al., 2005). 
  





SST secreted from delta cells is a potent inhibitor of insulin and glucagon. In rats, SST is also 
secreted from D-cells of the gastrointestinal tract, brain and pancreas, which account for 65%, 
25% and 5% of its production, respectively (Patel and Reichlin, 1978). SST exerts its effects 
through SST receptors (SSTRs), which are G-protein coupled receptors (GPCRs). To date, five 
members of the SSTR (SSTR1 – SSTR5) family have been identified (Watt et al., 2008, 
Ludvigsen et al., 2004), all of which are expressed by rodent islets. SSTR1, SSTR2 and SSTR5 
are expressed by beta cells in mouse islets whereas SSTR1-SSTR5 are expressed by alpha cells, 
with abundant expression of SSTR2 and SSTR5 (Ludvigsen et al., 2004). SSTRs couple to the 
Gαi protein, to decrease cAMP levels, inhibit VOCCs and activate KATP channels, which tightly 
couple SSTRs to exocytotic vesicle release from delta cells (Watt et al., 2008).  
Pancreatic polypeptide 
Pancreatic polypeptide (PP) is secreted from islet PP cells, but its physiological significance in 
regulating islet hormone secretion remains unclear. However, PP has been shown to stimulate 
gastric motility (McTigue and Rogers, 1995) and stimulate food intake in rats (Clark et al., 1984).  
Ghrelin 
Ghrelin is 28-amino acid protein secreted by a small population of islet ε-cells, which stimulates 
beta cells to elevate cytosolic calcium concentrations as well as insulin secretion (Date et al., 
2002). However, it has been shown that ghrelin released into the intra islet microcirculation 
inhibits insulin release in rodents and humans (Tong et al., 2010, Reimer et al., 2003). Ghrelin 
signals through Gαi, which attenuates glucose-induced cAMP elevations and PKA activation 
subsequently supressing glucose-induced insulin secretion (Dezaki et al., 2011). Furthermore, 
ghrelin has also been shown to stimulate food intake in rats (Wren et al., 2000).  
  





Incretins are peptide hormones secreted from the gastrointestinal tract and into the 
bloodstream in response to ingestion of food, which modulate insulin secretion and thus is 
known as the incretin effect. It accounts for at least 50% of total insulin secretion after an oral 
glucose intake (Holst and Gromada, 2004, Kim and Egan, 2008). Two major candidates 
responsible for the insulinotropic properties of incretins are glucagon-like peptide-1 (GLP-1) 
and gastric inhibitory polypeptide (GIP).  
GLP-1 is a product of the glucagon gene and is transcribed and synthesised in L-cells located in 
the intestinal mucosa, in which the translational product proglucagon is cleaved to generate 
GLP-1 and GLP-2, and not glucagon as in pancreatic islet alpha cells (Mojsov et al., 1986). Both 
GLPs share approximately 50% sequence homology to that of glucagon and GLP-1 secretion is 
stimulated by nutrients in the lumen of the gut as well as neural and endocrine mechanisms 
(Holst and Gromada, 2004). GLP-1 is a highly potent glucose-dependent insulinotropic peptide 
with half-maximal effective concentrations observed in beta cells as low as 10pM (Fehmann et 
al., 1995). Mice with targeted deletion of GLP-1 exhibit glucose intolerance and fasting 
hyperglycaemia (Scrocchi et al., 1996). GLP-1 activity is transmitted via the G-protein coupled 
GLP-1 receptor (GLP-1R), which is expressed by beta cells. Upon GLP-1R activation cAMP 
levels are increased by AC activation, which subsequently activates the downstream effectors 
PKA and Epac2 (cAMP-regulated guanine nucleotide exchange factor II), to regulate ion 
channel conductance, cytosolic calcium handling and promote exocytosis of insulin-containing 
granules (Holz, 2004). GLP-1 also stimulates insulin gene transcription by up-regulating 
transcription factors such as pancreatic duodenal homeobox-1 (PDX-1), which promotes 
insulin biosynthesis and up-regulates components associated with the insulin secretory 
machinery such as glucokinase and GLUT 2 (Fehmann and Habener, 1992, Buteau et al., 1999).  
GIP, which has insulinotropic properties, is secreted from intestinal K-cells and is abundantly 
localised in the duodenum and the intestinal mucosa.. The GIP receptor (GIP-R) is a G-protein 
coupled receptor, which is expressed by islets, brain, adipose tissue, heart, gut, pituitary and 
adrenal cortex (Mayo et al., 2003, Mortensen et al., 2003). GIP secretion is stimulated by 
carbohydrates and lipids and is usually elevated 10-20 fold following meal ingestion (Holst and 
Gromada, 2004). The activation of GIP-R by GIP causes elevations in cAMP levels in beta 
cells, which increases cytosolic calcium and promotes insulin exocytosis (Ding and Gromada, 
1997, Wheeler et al., 1995). Other signal transduction pathways have been implicated in the 
secretagogue effects of GIP including activation of mitogen-activated protein kinases (MAPK) 
and PI3K (Trumper et al., 2001, Ehses et al., 2002). 




1.2.6: Importance of calcium and protein kinases in beta cell stimulus-secretion 
coupling  
 
Calcium-dependent regulation of insulin secretion 
Intracellular calcium concentration in beta cells are maintained between 50-100nM in an 
unstimulated state and can increase to 500nM when stimulated by secretagogues (Draznin, 
1988, Henquin, 2000). Elevations in intracellular calcium concentrations are central to 
stimulating insulin exocytosis (Figure 6). The second messenger property of calcium lies in the 
capability of beta cells to rapidly elevate cytosolic calcium levels when challenged with a 
stimulus that either opens VOCCs in the plasma membrane or mobilises calcium from the 
endoplasmic reticulum (ER) membrane. The influx of calcium down large electrochemical 
gradients elevates cytosolic calcium by entering via L-type, P/Q-type, T-type and R-type 
VOCCs in beta cells (Braun et al., 2008). The L-type VOCCs are considered to be the 
predominant VOCC responsible for mediating glucose-induced insulin secretion with up to 
90% decrease in insulin secretion observed following their pharmacological blockade in human 
beta cells, and it has been suggested that they are important for first-phase insulin secretion 
(Braun et al., 2008, Schulla et al., 2003). The R-type VOCCs play a more important role in 
second-phase insulin secretion (Jing et al., 2005). Calcium plays an important role in second-
phase insulin secretion, which is responsible for sustaining insulin secretion by translocating 
insulin-containing vesicles from the reserve pool to the readily releasable pool (RRP) and 
maturation of insulin secretory granules (Henquin, 2000). It has also been shown that there are 
calcium pools highly sensitive to calcium such as high calcium-sensitive pool (HCSP) and 
immediately releasable pool (IRP), which are believed to be in close proximity and/or tethered 
to L-type and R-type VOCCs or the insulin secretory machinery (Pedersen and Sherman, 2009, 
Wiser et al., 1999).  
Furthermore, the second messenger action of calcium can further stimulate calcium release 
from the ER (calcium mobilisation). The ER is filled with calcium from the cytosol by 
sarcoplasmic/ER calcium ATPase (SERCA), which is responsible for up to 64% of calcium 
removal from the cytosol in mouse beta cells (Chen et al., 2003). The release of calcium from 
the ER into the cytosol in beta cells can be achieved by two mechanisms. Firstly, calcium can be 
mobilised by IP3 generation in response to receptors coupled to PLC, which activates IP3 
receptor-gated calcium channels present in the ER membrane (Biden et al., 1984, Prentki et al., 
1984). Secondly, calcium can also be mobilised from the ER via ryanodine (RyR)-sensitive 
calcium stores, which are located in the ER membrane and are gated by calcium itself (Zucchi 
and Ronca-Testoni, 1997). This allows increases in cytosolic calcium to further mobilise calcium 
from the ER, a process known as calcium-induced calcium release (CICR) (Graves and Hinkle, 




2003). The functional importance of calcium mobilisation was made evident when inhibiting the 
SERCA pump with thapsigargin, which showed an inhibition of cytosolic calcium in response 
to depolarising concentrations of potassium chloride (KCl) in islet cells of ob/ob mice, implying 
CICR from the ER is essential to elevating cytosolic calcium concentrations upon activation of 
L-type VOCCs (Lemmens et al., 2001). 
The role of calcium/calmodulin-dependent protein kinases (CAMKs) in the regulation 
of insulin secretion from beta cells. 
 
Changes in intracellular calcium concentrations are central to nutrient and non-nutrient 
regulation of insulin secretion. Beta cells express calcium-sensitive proteins that sense and 
respond to changing calcium concentrations within the cytosol. A family of calcium-sensitive 
kinases, known as calcium/calmodulin-dependent proteins kinase (CaMK), are activated by 
calcium and the calcium-binding protein calmodulin (CaM) and are involved in transducing 
calcium mobilising signals into a secretory response (Figure 6). In particular CAMK II and 
CAMK IV have been identified as being expressed by islet beta cells (Jones and Persaud, 
1998b). Glucose and depolarising concentrations of K+ cause rapid increases in CAMK II 
activity due to calcium entry through VOCCs (Wenham et al., 1994, Babb et al., 1996, Dadi et 
al., 2014). Furthermore, KN-62, which is a CAMK II inhibitor that competitively binds to the 
calmodulin binding site, blocks nutrient-induced insulin secretion (Li et al., 1992, Wenham et al., 
1992, Wenham et al., 1994, Niki et al., 1993). CAMK II also mediates its downstream effect on 
insulin exocytosis by phosphorylating serine/threonine residues of synapsin-1 and microtubule-
associated protein-2 (MAP-2), which are involved in the trafficking of insulin containing vesicles 
(Easom, 1999). 
  




The role of calcium/phospholipid-dependent kinases in the regulation of insulin 
secretion. 
As illustrated by Figure 6, glucose also stimulates calcium-dependent phospholipase C (PLC) 
under physiological conditions, which generates two second messengers as a result of 
phosphatidylinositol 4,5-bisphosphate (PIP2) hydrolysis: inositol,3,4,5-triphosphate (IP3) and 
diacylglycerol (DAG). DAG is an endogenous activator of calcium/phospholipid-dependent 
kinases known as protein kinase C (PKC) (Biden et al., 1987). The PKC family is classified into 
three groups: 1) Calcium-dependent and DAG-sensitive (conventional) PKC isoforms: α, β, γ: 
2) Calcium-independent and DAG-sensitive (novel) PKC isoforms: δ, ε, η, θ, and 3) Calcium 
and DAG-insensitive (atypical) PKC isoforms: ζ, λ, ι, μ (Jones and Persaud, 1998b). Islets 
express and insulin secreting beta cell lines express PKC α, β, δ, ε, ι and ζ (Lord and Ashcroft, 
1984, Tanigawa et al., 1982, Knutson and Hoenig, 1994, Tian et al., 1996, Tang and Sharp, 1998, 
Kaneto et al., 2002, Carpenter et al., 2004). Stimulation of DAG-sensitive PKC isoforms results 
in translocation of PKC from a predominantly cytosolic form to a membrane-bound form 
(Persaud et al., 1989). A variety of beta cell receptor-operated secretagogues such as CCh and 
CCK, activate PLC via Gαq interaction leading to generation of DAG (Biden et al., 1987, 
Zawalich and Zawalich, 1996). Nutrient secretagogues can also increase DAG content in beta 
cells via direct stimulation of DAG synthesis and calcium-dependent activation of PLC (Peter-
Riesch et al., 1988, Wolf et al., 1990). DAG-sensitive PKC isoforms are also activated by AA, 
which can be converted to DAG by the activation of DAG lipase (Band et al., 1992, Landt et 
al., 1992). Nutrient and non-nutrient secretagogues also stimulate PLA2 by generating AA from 
phosphatidylcholine hydrolysis (Konrad et al., 1993, Konrad et al., 1992), however it has been 
reported that PLA2 is not required for initiating insulin secretion but is important for 
maintaining normal insulin stores in beta cells (Jones et al., 2004). Activation of conventional 
PKC isoforms modestly stimulates glucose-induced insulin secretion, with targeted inhibition of 
conventional PKC isoforms showing only minor alterations in glucose-induced insulin secretion 
(Carpenter et al., 2004, Harris et al., 1996). However, deletion of novel PKCδ isoform and 
atypical PKC ι/λ isoforms have been shown to inhibit glucose-induced insulin secretion 
(Hashimoto et al., 2005, Uchida et al., 2007). PKC modulates the insulin secretory process by 
phosphorylating proteins such as SUR1 subunit of KATP channels (Inagaki et al., 1995a, 
Wollheim et al., 1988), VOCCs (Wang et al., 1993, Wollheim et al., 1988) and cytosolic PLA2 
(Dunlop and Clark, 1995). Furthermore, PKCε associates with insulin secretory granules and it 
is reported to be essential for stimulating insulin secretion (Mendez et al., 2003, Yu et al., 2000, 
Brocklehurst and Hutton, 1984). 
  





Figure 6: Schematic diagram demonstrating signalling pathways involved in glucose-induced 
insulin secretion. Glucose enters beta cells via GLUT2 and is metabolised inside the mitochondria to 
increase the ATP:ADP ratio, which closes ATP-sensitive K+ channels. This results in membrane 
depolarisation and stimulates opening of L-type voltage-dependent calcium channels (VOCCs). The 
calcium influx causes primed vesicles containing insulin to fuse with the plasma membrane and secrete 
insulin. Glucose-induced elevation in [Ca2+]i and ligand-induced activation of Gq-dependent G protein-
coupled receptors (GPCRs) activate phospholipase C (PLC), which catalyses the breakdown of 
phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol 
(DAG). IP3 mobilises Ca2+ from the ER by binding to IP3 receptors (IP3R). DAG activates DAG-
sensitive calcium (Ca2+)-dependent protein kinase C (PKC) isoforms, which phosphorylate and activate a 
set of substrates, such as the SUR1 subunit of KATP channels and VOCCs. Both IP3 and DAG elevate 
[Ca2+]i and thus promote insulin granule exocytosis and stimulate insulin secretion. 
  




The role of PKA in the regulation of insulin secretion. 
The second messenger cyclic adenosine monophosphate (cAMP) mediates diverse cellular 
processes such as exocytosis, cell proliferation and gene transcription by activating cAMP-
dependent protein kinase A (PKA) (Skalhegg and Tasken, 2000, Daniel et al., 1998). cAMP is 
generated from ATP hydrolysis following activation of adenylate cyclases (ACs). Activation of 
PKA occurs when cAMP binds to two regulatory subunits of the tetrameric PKA holoenzyme, 
which results in the release of the catalytic subunits. Three catalytic subunit Cα, Cβ and Cγ 
isoforms and four regulatory subunit RIα, RIβ, RIIα and RIIβ isoforms have been identified 
(Gamm et al., 1996). The PKA isoforms that are expressed by islet beta cells have not been 
investigated in detail although it has been shown that RI and RII PKA subunit isoforms are 
expressed by rat islets (Sugden et al., 1979). Eight AC isoforms (type I-VIII) have been 
identified in islets and beta cell lines (Delmeire et al., 2003, Guenifi et al., 2000). Furthermore, 
cAMP levels can also be regulated by cAMP degradation by phosphodiesterases (PDEs), which 
hydrolyse the phosphodiester bond of cyclic nucleotides. There are approximately 50 PDEs and 
some such as PDE1C, PDE3B, PDE4A, PDE4D and PDE10A have been identified in islets 
and beta cell lines. They are physiologically important for glucose-induced insulin secretion, 
supported by the observation of enhanced cAMP-induced potentiation of insulin secretion 
following inhibition of PDE1C (Han et al., 1999, Härndahl et al., 2002, Pyne and Furman, 
2003). Stimuli that signal through the Gαs/AC pathway, such as glucagon and GLP-1, can 
potentiate glucose-mediated insulin secretion by elevating cAMP levels, but elevation in cAMP 
in the absence of calcium is not sufficient to stimulate insulin secretion (Szaszák et al., 2008).  
Elevations in cAMP levels potentiate glucose-induced insulin secretion via PKA-dependent and 
PKA-independent mechanisms (Figure 7). Activation of PKA results in the phosphorylation of 
substrate serine/threonine residues, such as the L-type VOCCs and IP3-receptor gated calcium 
channels that elevate intracellular calcium, thus potentiating insulin secretion (Bünemann et al., 
1999, Ding and Gromada, 1997, Skelin and Rupnik, 2011). PKA decreases KATP channel activity 
by phosphorylating the pore-forming Kir6.2 subunit and regulatory SUR1 subunit of the KATP 
channel resulting in KATP channel closure (Gromada et al., 1997b, Ribalet et al., 1989, Béguin et 
al., 1999). 
As illustrated in Figure 7, an alternative signalling mechanism of cAMP that is independent of 
PKA activation has been identified in beta cells, and it has been shown to be mediated by 
cAMP-regulated guanine nucleotide exchange factors are directly activated by cAMP (Epacs) 
(Holz, 2004, Holz et al., 2006). Epac variants Epac1 and Epac2 couple cAMP production via 
Rap1 activation, which is a small GTPase of the ras family (Holz, 2004, de Rooij et al., 1998, 
Bos, 2006). Epac2 knock-out studies in mouse have shown a marked reduction in first-phase 




insulin secretion showing the essential role of Epac2-mediated activation of Rap1 in cAMP-
dependent potentiation of glucose-induced insulin secretion from beta cells, in which 
Epac2/Rap1 signalling has also been implicated in the regulation of granule density at the 
plasma membrane (Shibasaki et al., 2007). Epac2 also interacts with Rim2 and Rab3 (Ozaki et 
al., 2000, Kashima et al., 2001), which are proteins involved in the docking of vesicles to the 
plasma membrane. Furthermore, Epac2 controls ryanodine-sensitive calcium channels activated 
in calcium-induced calcium release from the endoplasmic reticulum of beta cells (Kang et al., 
2001, Holz et al., 1999).  
  





Figure 7: Schematic diagram showing proposed function of cAMP-dependent signalling 
involving PKA-dependent and PKA-independent mechanisms in the regulation of glucose-
stimulated insulin secretion. Glucose enters beta cells via GLUT2 and closes ATP-sensitive K+ 
channels (KATP), which results in membrane depolarisation and stimulates opening of L-type voltage-
dependent calcium channels (VOCCs). The calcium influx causes primed vesicles containing insulin to 
fuse with the plasma membrane and secrete insulin. Incretins such as GLP-1 are released from the GI 
tract in response to nutrient ingestion and modulate insulin secretion by regulating calcium mobilisation 
from internal stores via cAMP-mediated activation of PKA or Epac. Epac2 can regulate nutrient and 
non-nutrient-induced insulin secretion by cAMP-induced calcium mobilisation from internal calcium 
stores by regulating ryanodine (RyR)-sensitive calcium channels, regulate vesicle fusion and docking 
involving interaction with Rim2, Rab3 and Piccolo, and can also inhibit KATP channels through interacting 
with SUR1 subunit.  
  




1.3: Regulation of beta cell mass 
1.3.1: Beta cell mass in DM 
Beta cell mass is maintained by a balance between cell proliferation and/or neogenesis and 
apoptosis and/or necrosis and thus dysregulation of any of these processes can alter beta cell 
mass (Lupi and Del Prato, 2008, Stefan et al., 1982). The decline in beta cell secretory function 
in T2DM is paralleled by a progressive decline in beta cell mass and it has been shown that 
obese patients with impaired fasting glucose and T2DM have a 50% and 63% reduction in beta 
cell mass, respectively, compared to non-diabetic controls, whereas lean diabetic patients show a 
41% deficit in beta cell mass (Butler et al., 2003a). Although beta cell proliferation is important 
in maintaining beta cell mass (Hussain et al., 2006) it is widely accepted that apoptosis is the 
predominant mediator of beta cell mass regulation as obese and lean T2DM patients show 
elevated levels of beta cell apoptosis (Butler et al., 2003a, Marchetti et al., 2004).  
1.3.2: Beta cell apoptosis and apoptotic signalling pathways 
Apoptosis is a series of cellular events present in all cell types and results in self-destruction of 
the cell. It is a rapid process, which is 20 times faster than the rate of mitosis (Lawen, 2003). It is 
associated with distinct changes to the nucleus, cytoplasm and plasma membrane. Early 
morphological features of an apoptotic cell involve cells losing their contact with neighbouring 
cells, cell shrinkage, ER dilation in the cytoplasm, plasma membrane cell junctions are 
disintegrated and the membrane itself starts to become convoluted and show signs of blebbing 
(Lawen, 2003). Furthermore, chromatin condenses and aggregates into dense compact masses 
and exhibits nuclear fragmentation by the action of endonucleases within the nucleus. The 
nucleus itself starts to become convoluted and buds off into several fragments that are 
incorporated inside encapsulated apoptotic bodies, which are formed due to cell disruption 
(Lawen, 2003). These apoptotic bodies stimulate the recruitment of phagocytic cells such as 
macrophages resulting in their engulfment but without triggering an inflammatory response 
(Lawen, 2003). The trigger for apoptosis-induced events inside the cell requires the activation of 
a family of proteases known as caspases.  
Caspases are cysteine proteases that exhibit primary specificity for aspartic acid residues of 
protein substrates, and they are expressed as single chain pro-enzymes, known as pro-caspases 
(zymogens). Pro-caspases are converted to their active caspase form via autoproteolysis of 
aspartic acid residues or proteolysis by other caspases. The caspase family can be subdivided 
into two groups: those that are activated during apoptosis (caspase 2, 3, 6, 7, 8, 9 and 10) and 
those that are activated during inflammation (caspase 1, 4, 5 and 11). The caspases activated 
during apoptosis can be further subdivided into caspases responsible for initiating activation-
cascades (caspase 2, 8, 9 and 10), which contain long pro-domains containing protein-protein 




interaction motifs such as caspase recruitment domains (CARDs) exhibited by caspase 2 and 9 
or death effector domains (DED) exhibited by caspase 8 and 10. The other group contains the 
executioner or effector caspases (caspase 3, 6 and 7), which contain short or absent pro-
domains and are responsible for the actual dismantling and/or destruction of the cell (Lawen, 
2003, Creagh et al., 2003). One of the final targets of caspases is the inhibitor of caspase-
activated DNase (ICAD). These are inactivated by caspases resulting in the release of their 
DNAase subunits (CAD), which enter the nucleus and fragment the DNA, a hallmark of cell 
apoptosis (Creagh et al., 2003). It has been reported that a loss in beta cell number is due to 
increased activation of caspase 3 and caspase 8 (Marchetti et al., 2004, Liadis et al., 2005, 
Yamada et al., 1999), although other caspases are likely to be involved. 
Apoptosis can be triggered by various stimuli, which induce caspase activation by four major 
pathways: 1) mitochondrial/apoptosome pathway (intrinsic), 2) death-receptor pathway 
(extrinsic), 3) ER stress pathway and 4) granzyme B-mediated cell death. It is worth noting that 
both intrinsic and extrinsic apoptotic signals converge at the levels of caspase activation (Lawen, 
2003), as illustrated by Figure 8. 
Mitochondrial/apoptosome pathway  
This intrinsic apoptotic pathway can be triggered by various stimuli such as heat shock, 
cytotoxicity and ionising radiation, which result in the permeabilisation of the outer 
mitochondrial membrane. This causes the release of mitochondrial content into the cell cytosol 
such as cytochrome c, which primes caspase-9 activating complex. Release of cytochrome c 
results in its binding to apoptosis protease-activating factor-1 (Apaf-1), and together with pro-
caspase-9 and deoxyadenosine triphosphate (dATP) a caspase-activating wheel-like complex 
referred to as an apoptosome is formed. The permeability of the mitochondrial membrane and 
regulation of cytochrome c release depends on the Bcl-2 family, which contains anti- (Bcl-2 and 
Bcl-XL) and pro-apoptotic members (Bax, Bad, Bim, Bak and Bid). Apoptosome activation of 
caspase-9 propagates the death signal by activating downstream effector caspase 3 and caspase 
7. Caspase 3 goes on to activate caspase 2 and caspase 6, of which caspase 6 further activates 
caspase 8 and caspase 10 (Creagh et al., 2003).  It has been reported that chronic high glucose 
levels induce cytochrome c release by increasing Bax binding to the mitochondrial membrane 
(Kim et al., 2005).   
Death receptor pathway 
Death receptors, which are part of the tumour necrosis factor (TNF) receptor superfamily, are 
cell surface receptors that transduce the death signal induced by extracellular ligands such as 
TNF, Fas ligand and TNF-related apoptosis-inducing ligand (TRAIL). Upon death receptor 




activation an intracellular death receptor-inducing signalling complex (DISC) is formed by the 
recruitment of adaptor molecules such as FADD (Fas-associated death domain protein). 
Caspase 8 is recruited by DISC due to caspase 8 and FADD interaction via the death effector 
domain (DED) present in both proteins. DISC/caspase-8 activation propagates the death signal 
by two mechanisms which are dependent on cell type (Scaffidi et al., 1998). In type I cells, the 
death signal is propagated after death receptor activation robustly activates caspase 8 resulting in 
downstream activation of effector caspases (Scaffidi et al., 1998). In type II cells, caspase 8 is 
not sufficiently activated within the DISC to allow direct activation of effector caspases but 
instead it propagates the death signal by proteolysis of Bid, a pro-apoptotic member of the Bcl-
2 family, which translocates to the mitochondria where it promotes Bax/Bak-dependent release 
of cytochrome c, resulting in the apoptosome formation (Scaffidi et al., 1998). This 
demonstrates the amplifying potential of an apoptotic signal by cross-talk between extrinsic and 
intrinsic apoptotic pathways (Creagh et al., 2003). Furthermore, evidence of this pathway has 
been identified in islet beta cells, which show that Fas ligand interaction with its receptor 
triggers beta cell apoptosis by activating caspase-3 (Yamada et al., 1999, Zhang et al., 2008). 
Granzyme B-mediated cell death 
Another major apoptotic pathway that triggers apoptosis in target cells involves the release of 
cytotoxic granules. These granules contain perforin, which is a pore-forming protein that 
facilitates the entry of granule components into target cells. Furthermore, another granule 
component is granzyme B, which is a serine protease for aspartic acid-containing caspase 3 and 
caspase 8 (Froelich et al., 1998, Van De Craen et al., 1997). Granzyme B can promote the 
release of cytochrome c and induce apoptosome assembly (Creagh et al., 2003, Barry et al., 
2000, Heibein et al., 2000, Sutton et al., 2000, Pinkoski et al., 2001). This pathway has been 
implicated in pancreatic beta cells in which granzyme B has been shown to cleave Bid and 
promote cytochrome C release from the mitochondria to initiate caspase activation and thus 
apoptosis (Estella et al., 2006).   
ER stress-mediated caspase activation 
The ER is an important organelle for the post-translational modifications, folding and assembly 
of newly synthesised proteins as well as serving as an internal calcium store. Therefore, defects 
in its function result in ER stress followed closely by cell death. ER stress can be induced by 
various events such as misfolding of proteins, calcium depletion, formation of disulphide bonds, 
protein glycation and impairment of protein transportation from ER and the golgi apparatus. 
The transcription of the growth arrest and DNA damage-inducible gene (GADD) such as 
GADD153 is up-regulated in response to ER stress. This reduces anti-apoptotic Bcl2 protein 




expression and stimulates Bax translocation into the mitochondria to promote cytochrome c 
release. It has been shown that inducing ER stress in beta cells using nitric oxide results in 
apoptosis via the GADD153-mediated pathway and contributes to the beta cell failure observed 
in T2DM (Araki et al., 2003, Laybutt et al., 2007). In addition, a majority of the insulin 
biosynthesis events occur in the ER lumen such as proinsulin protein folding and thus any 
imbalance between the demand for insulin translation and the protein folding capacity of the 
ER results in defective beta cell function and induces ER stress (Fonseca et al., 2007). This 
results in the preference to activate ER stress-dependent caspase 12, which is only localised to 
the ER and functions as an initiator caspase, which activates caspase 9 independent of Apaf-1 
stimulation (Creagh et al., 2003, Araki et al., 2003). 
Inhibitors of apoptosis (IAPs) 
Another family of proteins termed inhibitors of apoptosis (IAPs) are important in regulating 
beta cell apoptosis. They are anti-apoptotic proteins that are activated by nuclear factor κB (NF-
κB) and act as endogenous inhibitors of caspases (Wei et al., 2008). So far eight IAPs have been 
identified in humans with XIAP being the best characterised and most potent IAP. It inhibits 
caspase 3 activation, interferes with apoptosome formation by binding to pro-caspase 9 and 
directly inhibits caspase 9. XIAP expression is up-regulated by pro-apoptotic members of the 
Bcl2 family (Bax), which promotes cytochrome c release from the mitochondria (Wei et al., 
2008). IAPs also inhibit caspase 2 and caspase 9 in the ER-stress mediated pathway (Cheung et 
al., 2006). It has been reported that over expression of XIAP enhances beta cell survival by 
inhibiting apoptosis (Emamaullee et al., 2005, Plesner et al., 2010).  
  





Figure 8: Schematic diagram showing the major apoptotic signalling pathways identified in beta 
cells. The apoptotic signal in beta cells can be induced by: (1) death receptor activation forms the 
intracellular death receptor-inducing signalling complex (DISC), which activates caspase 8 (Cas8). This 
goes onto activate downstream effector Cas to propagate the death signal. (2) Bcl2 family of pro-
apoptotic proteins (Bid, Bad, Bak, and Bim) are countered by the effects of the Bcl2 anti-apoptotic 
proteins (Bcl-2 and Bcl-xl), which permeabilise the mitochondrial membrane to release cytochrome c 
(Cyto C), which forms an apoptosome by binding to the apoptosis protease-activating factor-1 (Apaf-1). 
This activates Cas9, which activates Cas3 and Cas7 to execute cell apoptosis. This pathway is elicited in 
response to chronic high glucose in beta cells (3) Granzyme B propagates the death signal by activating 
Cas3 and Cas8 as well as activating Bcl2 pro-apoptotic proteins to promote apoptosome formation by 
inducing the release of Cyto C from the mitochondria. (4) ER stress can up-regulate growth arrest and 
DNA damage-inducible gene (GADD153), which activates the pro-apoptotic Bcl2 proteins and can also 
activate the ER-specific Cas12, which activates Cas9. The transcription factor nuclear factor κB (NF-κB) 
up-regulates inhibitors of apoptosis (IAPs), which regulate cell survival by inhibiting Cas2, 3, and 9 as well 
as being up-regulated by pro-apoptotic Bcl2 proteins. There is also cross-talk between these apoptotic 
signalling pathways.  
  




1.3.3: Beta cell proliferation 
Beta cell replication is another major event responsible for maintaining beta cell mass. Although 
the molecular mechanisms remain unclear, mounting evidence suggests that stimulation of 
PI3K is important for regulating beta cell mass (Fatrai et al., 2006, Hakonen et al., 2014, Li et 
al., 2014). PI3K can activate Akt/PKB, a serine/threonine kinase and Akt overexpression in 
mouse beta cells has been reported to increase beta cell proliferation, mass, neogenesis and cell 
size (Tuttle et al., 2001, Bernal-Mizrachi et al., 2001).  
 
PI3K/Akt cell survival pathway 
PI3K exists as a heterodimer consisting of a catalytic (110kDa) and regulatory (85kDa) subunit, 
and it is activated by receptor tyrosine kinases (Kim and Chung, 2002). Receptor tyrosine kinase 
autophosphorylation following ligand binding recruits PI3K to the cytosolic side of the plasma 
membrane, which phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) to generate 
phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 recruits Akt and PDK1 to the plasma 
membrane resulting in Akt activation (Kim and Chung, 2002, Franke et al., 1997, Stokoe et al., 
1997). PI3K activity can be regulated by a variety of stimuli such as growth factors, GPCR 
activation, cAMP and zinc (Murga et al., 1998, Kim et al., 2000, Kim et al., 2001, Wang et al., 
2001). CAMK can also directly phosphorylate Akt, independently of PI3K activation (Yano et 
al., 1998). Akt regulates cell survival by regulating the activity of proteins associated with 
apoptosis (Figure 9a).  
Akt has been shown to block cytochrome c release from the mitochondria by inhibiting the 
association of anti-apoptotic Bad with the pro-survival Bcl-XL, which would normally induce cell 
death (Kharbanda et al., 1997, Kennedy et al., 1999) as well as up-regulating anti-apoptotic Bcl-2 
family members (Pugazhenthi et al., 2000). Akt also phosphorylates pro-apoptotic Bcl-2 family 
member Bad by Akt prevents its binding to Bcl-XL on the mitochondrial membrane and pro-
caspase 9, which is activated by cytochrome c and Apaf-1, and thus prevents the propagation of 
the caspase 9-induced apoptotic cascade (Cardone et al., 1998). Akt can also directly 
phosphorylate and inhibit caspases, and several caspases have been identified to contain Akt-
specific phosphorylation sites (Lawlor and Alessi, 2001). Akt can inhibit the action of caspase 9 
and it has been reported that activation of caspase 9 cleaves procaspase 3 to form the bioactive 
caspase 3, which further cleaves downstream proteins in order to execute cell death (Slee et al., 
1999). Forkhead transcription factors, which normally enter the nucleus and transcribe cell 
death-related genes such as Fas, are also phosphorylated by Akt, which sequesters these pro-
apoptotic transcription factors to the cell cytosol (Brunet et al., 1999, Biggs et al., 1999). As 
mentioned earlier, NF-κB, which are transcription factors that induce the expression of genes 
involved in cell survival such as anti-apoptotic Bcl2 family members (Bfl-1), regulate IAP 




expression such as c-IAP1 and c-IAP2 by activating endogenous IAPs, and has been shown to 
regulate beta cell survival (Wang et al., 1998, Zong et al., 1999). NF-κB is usually sequestered to 
the cell cytosol when bound to IκB. However, phosphorylation of IκB results in its dissociation 
from NF-κB allowing NF-κB to enter the nucleus and promote expression of pro-survival 
genes. Although the exact involvement of Akt activation of NF-κB remains unclear it has been 
reported that Akt may phosphorylate IκB to indirectly activate NF-κB (Ozes et al., 1999, Kane 
et al., 1999).  
Akt also regulates cell-cycle progression (Figure 9b). The cell cycle consists of a quiescent phase 
(G0), followed by cell entry into the G1 phase in which protein synthesis begins. Once the cells 
reach the late G1 phase they reach restriction point (R); beyond this point the cells are 
irreversibly committed to DNA replication (S phase), in which they progress to the cell dividing 
phase (M phase) (Kim and Chung, 2002). Cell cycle progression is coordinated by interaction of 
regulatory proteins which include cyclin, cyclin-dependent kinases (cdks) and cdk inhibitors 
(Braun-Dullaeus et al., 1998). Akt can activate various targets such as the oncogene c-myc, 
which promotes cell progression from the G0 phase to the G1 replication phase (Ahmed et al., 
1997). Akt also phosphorylates cyclin D1 and promotes cell cycle progression by allowing the 
cell to exit the G0 phase and progress past the G1 phase. This is achieved by binding to cyclin 
dependent kinases (cdks) to form cyclin/cdk complexes, which inactivate tumour suppressing 
protein retinoblastoma (Rb) (Hatakeyama et al., 1994, Resnitzky and Reed, 1995). In addition, 
Akt can also regulate and thus inhibit cdk inhibitors such as p21, p27 and the downstream 
effector p57, which prevent the formation of cyclin/cdk complexes (Kim and Chung, 2002). 
Furthermore, Akt can sequester cdk inhibitors to the cytosolic compartment and thus inhibits 
their entry into the nucleus and prevent p21 from inhibiting cell proliferation (Zhou et al., 
2001).  
Mitogen-activated protein kinases (MAPK) 
Mitogen-activated protein kinases (MAPK) are serine/threonine protein kinases that can 
mediate the effects of extracellular signals on a variety of biological processes such as apoptosis, 
proliferation, motility, metabolism and gene expression (Cargnello and Roux, 2011). In 
mammals, 14 MAPKs have been characterised to date, and classified into conventional and 
atypical groups (Cargnello and Roux, 2011). The conventional group is split into three 
subfamilies and is the most widely studied MAPK group, which consists of MAPKs p38, 
p42/p44 or ERK1/2 and the stress-activated c-Jun amino (N)-terminal kinase (JNKs) 
(Cargnello and Roux, 2011, Robinson and Dickenson, 2001). The p42/p44 MAPKs pathway is 
associated with regulation of cell proliferation and differentiation, whereas the p38 and JNKs 
are associated with environmental stress, apoptosis and inflammation (Ono and Han, 2000, Paul 




et al., 1997). Many Gαq-coupled protein receptors are involved in the regulation of p42/p44, 
p38 and JNK signalling pathways (Sugden and Clerk, 1997, van Biesen et al., 1996). p42/p44 
MAPK nuclear translocation is predominant in relaying the mitogenic signal from the cytoplasm 
into the nucleus (Chen et al., 1992, Lenormand et al., 1993) and is activated by a cascade of 
small G protein Ras-Raf followed by MAP3K activation. Gαs and Gαq-protein coupled 
receptors have been implicated in regulating Raf activity, and it has been reported that Raf 
activity is attenuated in cardiac myocytes when treated with PTX or DAG-sensitive PKCs are 
depleted (Bogoyevitch et al., 1995). Although the coupling of GPCRs to p42/p44 are yet to be 
identified in beta cells it has been reported that ghrelin, which is a peptide hormone also 
secreted by islets, has been shown to activate p42/p44 MAPKs by activating growth hormone 
secretagogue receptor type 1a (GHS-R1a) in HEK293 cells, which is also expressed by rodent 
and human islets (Granata and Ghigo, 2013), in a Gαq –dependent pathway involving calcium-
dependent PKC isoforms (PKCα/β) (Camina et al., 2007). It has been reported that p42/p44 
MAPK activation promotes MIN6 beta cell proliferation upon activation (Burns et al., 2000). In 
addition, p42/p44 promotes cell cycle progression from the G1 to the S-phase in fibroblasts 
(Brondello et al., 1995) via cyclin D1 stimulation (Lavoie et al., 1996). Moreover, p42/p44 
MAPK can also inhibit pro-apoptotic Bcl-2 family members Bad (Harada et al., 2001) and Bim 
(Biswas and Greene, 2002).  
 
  











Figure 9: Schematic diagram representing PI3K/Akt-mediated signalling pathways involved in 
cell survival. (a) PI3K can be stimulated by various stimuli such as zinc, cAMP and CAMK, to 
phosphorylate PIP2 to PIP3, which recruits Akt and the Akt activator PDK1 to the plasma membrane to 
mediate downstream effectors. Akt and enhance cell survival by interfering with apoptotic signalling 
pathways by inhibiting Caspase (Cas) 9 (Cas9) activation by the apoptosome and thus inhibits the 
propagation of the death signal along downstream Cas cascades. It can also inhibit the prop-apoptotic 
Bcl2 family members (Bid, Bad, Bak and Bax), which would normally promote apoptosome formation by 
promoting the release of cytochrome C from the mitochondria. Akt can also sequester forkhead 
transcription factors, which transcribe pro-apoptotic proteins such as Fas, to the cytosolic compartment 
and prevent its entry in to the nucleus as well as promoting entry of the transcription factor nuclear factor 
κB (NF-κB) by releasing it from IκB, and thus up-regulate inhibitors of apoptosis (IAPs), which regulate 
cell survival by inhibiting Cas2, 3, and 9. (b) Akt can also promote cell proliferation by stimulating cell 
cycle progression. It can activate cdk/cyclinD1 complex, which promote the cell to exit the G0 phase and 
enter cell cycle G1 phase. Akt can also inhibit cdk inhibitors (p21, p27 and P57), which would normally 
prevent cdk/cyclinD1 complex formation and thus cell cycle progression. 
  




1.4: G-protein coupled receptor (GPCR) signalling  
1.4.1: GPCRs as potential T2DM therapeutic targets 
The use of hypoglycaemic agents mentioned in section 1.1.4, have limitations associated with 
their use such as cost and side-effects such as hypoglycaemic episodes, weight gain and GI 
discomfort, and there is some evidence that GLP-1 analogues induce pancreatitis (Ahren, 2009, 
Rendell, 2004, Diamant and Heine, 2003, Hussein et al., 2004). Existing treatments do not kerb 
T2DM progression, which has now reached approximately 360 million cases worldwide (IDF, 
2013, Bailey, 2005). A major limitation with current T2DM treatment is deterioration of long-
term glycaemic control. In addition, patient constraints such as age, organ function, and timing 
of drug administration may affect therapeutic effectiveness. This partially explains why 
combination therapies are required to achieve an acceptable level of glycaemic control in 
patients. Therefore, in order to kerb the rapid increase in the global incidence of T2DM, future 
therapeutic approaches will require multiple levels of action by not only focusing to maintain 
normoglycaemia but to also minimise side-effects especially weight gain. They must also be 
cost-effective so that they are available to all socio-economic groups. New therapies that can 
correct glycaemia over a long period of time with minimised side-effects are highly desirable and 
actively sought by the pharmaceutical industry. Therapeutic strategies that counteract the 
reduction in insulin secretion and beta cell mass are  key to the development of effective T2DM 
therapies (Ahren, 2009). 
One such strategy has been the successful targeting of GPCRs, which are the largest family of 
cell surface receptors and they represent the single largest set of membrane proteins in the 
human genome. Their sole physiological function is to transmit extracellular stimuli into an 
intracellular signal. There are over 800 GPCRs encoded by the human genome and a large 
majority of these GPCRs are of unknown physiological function (orphan GPCRs), which makes 
them a promising group of targets for the pharmaceutical industry. GPCRs share a common 
structural identity of seven hydrophobic alpha helical transmembrane domains with an 
extracellular N-terminal and an intracellular C-terminal. Their respective ligands range from 
photons, ions, small organic molecules to peptides and proteins, and they therefore regulate 
many physiological functions such as vision, taste, smell, cardiovascular function, energy 
homeostasis, hormone regulation, learning and memory. Approximately 40-50% of drugs within 
the pharmaceutical industry target GPCRs and thus have become the most common drug 
target. For example, GLP-1 mimetics have become a successful therapy for T2DM by acting at 
GLP-1 receptors to stimulate insulin secretion, inhibit glucagon secretion, and regulate beta cell 
mass. (Dunning et al., 2005, Heller and Aponte, 1995, Stoffers et al., 2000, Buteau et al., 1999). 




However, exenatide has recently been implicated in the increased risk of acute pancreatitis, as 
mentioned in section 1.1.4. 
Human islets have been shown to express approximately 300 GPCRs and 28% of these are 
classified as orphan receptors (Amisten et al., 2013). GPCR ligands can be classified into four 
main categories according to their molecular structures: peptides/proteins, small organic 
molecules (free fatty acids, nucleotides, amino acids), monatomic ions (H+, Zn2+, Ca2+) and 
large biological macromolecules (Amisten et al., 2013). To date several GPCRs expressed by 
islets have shown potential as future T2DM therapeutic targets. For example, GPR54 is 
activated by the neuropeptide kisspeptin, is expressed by islets and activation of the 
GPR54/kisspeptin system in beta cells potentiates glucose-induced insulin secretion by 
stimulating signalling cascades involving  PLC, calcium and p42/p44 MAPKs (Hauge-Evans et 
al., 2006, Bowe et al., 2009). GPR40 is expressed by beta cells and long chain free-fatty acids 
that bind to this receptor potentiate glucose-induced insulin secretion by signalling via a calcium 
influx-dependent mechanism (Itoh and Hinuma, 2005, Itoh et al., 2003). GPR119, another 
GPCR that is expressed by beta cells has been shown to potentiate glucose-induced insulin 
secretion and it also stimulates GLP-1 secretion via an AC/cAMP-dependent pathway. It also 
has potent anti-diabetic effects in ICR mice and db/db mice when activated by endogenous 
ligands such as lysophosphatidylcholine (LPC), oleylethanol amide (OEA) as well as the novel 
ligand AS1669058 (Oshima et al., 2013, Jones et al., 2009, Soga et al., 2005). Furthermore, 
endocannabinoid CB1 and CB2 receptors are also expressed by human islet beta cells and their 
activation by the endocannabinoid 2-arachidonoylglycerol (2-AG) and the CB1 selective agonist 
(ACEA) and CB2 selective agonist (JWH015), have all been shown to stimulate insulin secretion 
(Li et al., 2011).  
  




1.4.2: GPCR-mediated stimulus secretion coupling in beta cells 
Although there are many GPCRs they interact with only a small number of G-proteins to 
transmit their extracellular stimuli into intracellular signalling cascades. There are three G-
protein subunits namely Gα, Gβ and Gγ, and in humans there are 21 Gα subunits (Downes and 
Gautam, 1999), 6 Gβ subunits and 12 Gγ subunits, which usually co-exist together as 
heterotrimers in an unstimulated state. There are four main classes of Gα subunits: Gαs, Gαi, 
Gαq and Gα12/13, which bind to guanosine diphosphate (GDP) to form a complex with the Gβγ 
subunits. Each Gα subunit contains a highly conserved GTPase domain, and upon GPCR 
activation the conformational change to the receptor results in the Gα subunit releasing GDP in 
exchange for GTP. This results in the dissociation of the Gα subunit from the newly formed 
Gβγ complex, and both can affect various downstream signalling cascades that regulate islet 
hormone secretion in islets, as outlined below. 
Gαs subunits 
Activation of islet GPCRs coupled to Gαs elevate cAMP through adenylyl cyclase (AC) 
activation, which subsequently stimulates PKA and/or Epacs to further transmit the 
intracellular signal required for insulin secretion. For example, GLP-1 and GIP stimulate insulin 
secretion via a cAMP-dependent signalling cascade (Heller and Aponte, 1995, Szecówka et al., 
1982, Miura and Matsui, 2003). Glucagon also signals via the Gαs-subunit coupled glucagon 
receptor (GluR), and its activation in the liver promotes glycogenolysis and gluconeogenesis 
while inhibiting glycogen synthesis via a PKA-dependent mechanism (Jiang and Zhang, 2003). 
The GluR is also expressed by beta cells and its activation stimulates insulin secretion (Kawai et 
al., 1995) by elevating cAMP (Moens et al., 1998), while GluR knockout impairs beta cell 
function (Sorensen et al., 2006). GPR119, which is activated by free fatty acids, is also coupled 
to Gαs and stimulates insulin secretion in a cAMP-dependent manner (Moran et al., 2014, 
Oshima et al., 2013).  
Gαi subunits 
The Gαi subunits act in an opposite manner to that of Gαs by inhibiting AC and thus decreasing 
cAMP levels. Activation of islet GPCRs coupled to Gαi results in the inhibition of insulin 
secretion. The neuropeptide Y receptor, which couples to the Gαi subunit, inhibits insulin 
secretion in a calcium-independent manner by blocking AC activation (Morgan et al., 1998, 
Schwetz et al., 2013). The α2A-adrenoreceptor subtype, which is activated by the 
neurotransmitter noradrenaline, inhibits insulin secretion by lowering cAMP via inhibition of 
AC in mouse islets (Peterhoff et al., 2003). 
  





Islet GPCRs coupled to the Gαq subunit stimulate insulin exocytosis by elevating intracellular 
calcium levels and/or activation of PKC via PLC activation, which enzymatically promotes IP3 
and DAG formation from the hydrolysis of PIP2. The M3 muscarinic receptor is coupled to the 
Gαq subunit and is expressed by beta cells. Ach-induced M3 receptor activation stimulates 
insulin secretion by IP3-mediated calcium mobilisation from the ER as well as DAG-mediated 
activation of PKC (Gautam et al., 2006, Gilon and Henquin, 2001, Persaud et al., 1989). The 
kisspeptin receptor GPR54, also potentiates glucose-induced insulin secretion via PLC 
activation and elevations in intracellular calcium (Bowe et al., 2009). 
Gα12/13 subunits 
Activation of GPCRs coupled to Gα12/13 subunit results in activation of the Rho small GTPase 
family such as Rac, Rho and Cdc42, which are involved in the dynamic remodelling and 
organisation of the actin cytoskeleton of cells. Both Rac and Cdc42 have been shown to 
stimulate insulin secretion from beta cells (Kowluru et al., 1997b, Li et al., 2004, Nevins and 
Thurmond, 2005), whilst Rho inhibits insulin secretion via its downstream effector ROCK 
(Rho-associated kinase) (Hammar et al., 2009). 
Gβγ subunits 
The focus of this section up to now has been entirely on the ability of Gα subunits to regulate 
insulin secretion via multiple signalling cascades. However, mounting evidence suggests that the 
Gβγ subunit complex, which dissociates from the Gα subunit upon GPCR activation, can also 
regulate insulin secretion. The Gγ subunit is modified in the presence of glucose and calcium in 
beta cells implying an important role in beta cell function (Kowluru et al., 1997a). Furthermore, 
the Gβγ subunit complex has been shown to elevate cAMP in human fibroblasts (Ahmed and 
Heppel, 1997) and thus it is plausible that it may play an important role in regulating cAMP 
levels and insulin exocytosis via PKA-dependent mechanisms. The Gβγ complex can also 
activate L-type VOCCs in rat vascular myocytes by activating PLC and PI3K (Viard et al., 
2001), which as mentioned earlier, have been implicated in improving beta cell function and cell 
survival.  
  




1.4.3: GPCR-mediated regulation of beta cell mass 
In T2DM, pathways regulating and maintaining beta cell mass (proliferation, neogenesis, 
apoptosis, necrosis) are perturbed. GPCRs expressed by islets can regulate signalling pathways 
that are important in controlling beta cell mass as mentioned below. This makes GPCRs 
attractive therapeutic drug targets for the treatment of T2DM. For example, GLP-1 activation 
of GLP-1R, stimulates beta cell proliferation in vitro (Buteau et al., 1999, Buteau et al., 2001), 
while acute and chronic administration of GLP-1 in vivo increased beta cell mass by up to 2-fold 
in normal and diabetic mice, which is further supported by the ability of GLP-1R agonists to 
augment beta cell mass in glucose-intolerant rats (Stoffers et al., 2000, Rolin et al., 2002, Perfetti 
et al., 2000). The mechanism(s) by which GLP-1 regulates beta cell mass involves three 
potential pathways that: 1) enhance beta cell proliferation, 2) inhibit apoptosis and 3) stimulate 
neogenesis. The proliferative effect of GLP-1 and GIP on beta cells has been associated with 
the activation of PI3K, MAPK and PKCζ (Buteau et al., 1999, Buteau et al., 2001, Trumper et 
al., 2002, Hui et al., 2003). GLP-1 also inhibits beta cell apoptosis in a PI3K/cAMP/PKA-
dependent manner by inhibiting DNA fragmentation, and it enhances cell survival by up-
regulating the expression of anti-apoptotic proteins Bcl-2 and Bcl-XL (Hui et al., 2003). GLP-1 
also up-regulates the expression of beta cell transcription factor PDX-1 (pancreatic-duodenum 
homeobox-1), which is important for pancreatic development, and it has been implicated in 
stimulating beta-cell neogenesis (Stoffers et al., 2000). 
GPR119 is another potential T2DM therapeutic target as it is highly expressed by islet beta cells 
(Soga et al., 2005) and intestinal L-cells (Chu et al., 2008). Phospholipids such as LPC and OEA 
are endogenous ligands for GPR119, and they elevate cAMP levels to promote insulin secretion 
in response to receptor activation (Overton et al., 2006, Soga et al., 2005). GPR119 agonists 
have been shown to stimulate GLP-1 secretion from the L-cells and its activation stimulates 
beta cell proliferation in vitro and in vivo (Gao et al., 2011).  
  




1.4.4: Why target GPR75? 
A novel human chemokine GPCR identified as GPR75 was shown to be expressed at the 
mRNA level by various tissues of mouse such as brain, skeletal muscle and liver (Ignatov et al., 
2006), as illustrated by Figure 10. Many are tissues implicated in the regulation of glucose 
homeostasis, as mentioned in section 1.2.2. GPR75 mRNAs were also shown to be expressed 
by human islets (Amisten et al., 2013). The corresponding GPR75 gene locates to human 
chromosome 2p16, and encodes for a 540 amino acid protein that shares 87% amino acid 
sequence homology with mouse GPR75 located on chromosome 11A4 (Tarttelin et al., 1999, 
Ignatov et al., 2006).  
GPR75 serves as a receptor for a large family of cytokines known as chemokines that play 
regulatory roles in the inflammatory process by recruiting lymphocytes to sites of inflammation 
(Schall et al., 1990, Conti et al., 1997). GPR75 is activated by chemokine ligand 5 (CCL5), also 
known as Regulated Upon Activation T-Cell Expressed And Secreted (RANTES), which is a 68 
amino acid protein that belongs to the CC-chemokine subfamily (Schall et al., 1988, Cartier et 
al., 2005). CCL5 is synthesised and secreted by a variety of non T-cells such as endothelial cells, 
platelets, and neurons (Johnstone et al., 1999) and it activates conventional Gαi-protein coupled 
chemokine receptors (CCRs) 1, 3 and 5 in addition to GPR75. GPR75 exhibits atypical 
characteristics compared to conventional CCRs. Thus, it is almost 200 amino acids longer, 
shares only 12-16% amino acid sequence homology with CCRs, and it has a considerably longer 
C-terminal tail and a longer third intracellular loop (Pease, 2006), as illustrated by Figure 11. 
Furthermore, GPR75 has been established as a Gαq coupled receptor, and its activation leads to 
IP3 formation and elevations in cytosolic calcium (Myers et al., 1995, Ignatov et al., 2006), which 
are second messengers involved in the stimulus-secretion coupling of insulin (Section 1.1.6). As 
mentioned earlier (Section 1.3.3), activation of Akt and MAPK promote cell survival and 
proliferation, and GPR75 activation by CCL5 has been shown to enhance viability of mouse 
hippocampus cells, which is a primary target for patients with Alzheimer’s disease (Ignatov et 
al., 2006). Proliferative and protective effects have been identified in cells that overexpress 
GPR75, and this is mediated through the activation of a PLC/PI3K/Akt/MAPK cell survival 
pathway. Consistent with this GPR75-mediated cell protection via this pathway is lost when 
cells are treated with a PLC inhibitor (U73122) and a PI3K inhibitor (wortmannin) (Ignatov et 
al., 2006).  
CCL5 has been implicated in promoting autoimmune destruction of beta cells in T1DM by 
recruiting lymphocytes and stimulating secretion of other inflammatory cytokines. These effects 
of CCL5 are mediated by the activation of conventional CCL5 receptors (Carvalho-Pinto et al., 
2004). In addition, chronic low-grade inflammation normally precedes the development of 




T2DM and circulating concentrations of CCL5 are significantly elevated it T2DM (Herder et al., 
2005), which have been associated with an increase in T2DM incidence (Nomura et al., 2000). 
Therefore, earlier studies have focused on the pro-inflammatory role of CCL5 in the 
pathogenesis of T2DM, which is predominantly mediated through the activation of 
conventional CCL5 receptors (CCR1, CCR3 and CCR5).  
The pharmaceutical potential of islet GPCRs, have been implicated in the regulation of islet 
hormone secretion, which regulate blood glucose levels. The identification of a novel CCL5 
receptor, GPR75, which has been implicated in signalling through the Gq/PLC, elevating 
cytosolic calcium and activating a PLC/PI3K/Akt/MAPK cell survival pathway (Figure 12), 
suggests a potential role for GPR75 for improving beta cell function and beta cell mass and thus 
makes GPR75 a potential therapeutic target for T2DM.  
  









Figure 10: GPR75 mRNA expression in various mouse tissues detected by PCR GPR75 specific primers 
(upper panel). GAPDH specific primers were used as a positive control (lower panel). Image acquired 
and adapted from (Ignatov et al., 2006). 
 
 
Figure 11: Schematic representation showing amino acid sequence of the seven transmembrane domains 










Figure 12: Schematic diagram showing the 
proposed CCL5 signalling pathway mediated by 
GPR75 and its possible role in regulating beta 
cell secretory function and beta cell mass.  





The primary objective of the experiments described in this thesis was to determine the 
expression and function of GPR75 in islets of Langerhans. The focus on islet function centred 
around the influence of GPR75 activation on regulation of beta cell secretory function and beta 
cell mass. Furthermore, experiments detailed in this thesis were aimed at identifying the 
intracellular signalling mechanisms mediated by CCL5 activation of GPR75. An outline of the 
aims of this thesis is given below. 
 To determine the mRNA expression of CCL5 and CCL5 receptors (CCR1, CCR3, 
CCR5 and GPR75) in islets of Langerhans and MIN6 beta cells. 
 To determine the protein expression and localisation of CCL5 and GPR75 in mouse 
and human islets of Langerhans. 
 To identify the effect of exogenous CCL5 on islet hormone secretion and beta cell 
mass. 
 To investigate the effect of GPR75 down-regulation on islet hormone secretion and 
beta cell mass.  
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2.1: MIN6 beta-cells 
There are many resource and technical limitations for the use of primary beta cells in research 
such as the availability of pancreatic endocrine tissue, isolation of individual pancreatic cells, cell 
purification from islets, which are a mixture of several cell types, and maintenance of 
characteristics native to beta cells (Miyazaki et al., 1990, Skelin et al., 2010). Cell lines offer an 
animal-free alternative to study cell physiology and pathophysiology. The advantages of the use 
of cell lines range from investigating physiological and biochemical properties of a cell, 
identifying the effects of chemical compounds or drugs, the ability to manipulate cells to 
determine the role of various genes and their ability to reproduce consistent results (Skelin et al., 
2010). However, there are disadvantages associated with the use of cell lines. For example, cell 
to cell interaction is disrupted, which influences cell function especially within islets, which are 
3D micro-organs. Also changes in cell characteristics such as abnormalities in chromosomal 
content, genetic mutations, abnormal protein expression and altered cell metabolism have all 
been associated with the use of MIN6 beta cells (Skelin et al., 2010).  
The MIN6 beta cell line was derived from a transgenic C57BL/6 mouse insulinoma, which 
expresses an insulin promoter/SV40 T-antigen construct. It is one of a few beta cell lines that 
display appropriate beta cell characteristics. For example, MIN6 beta cells express GLUT-2 and 
glucokinase, which are both pivotal to glucose uptake and metabolism, they retain high levels of 
insulin mRNA, all cells stain for insulin in immunohistochemical analyses and most importantly, 
they secrete mature insulin in response to increasing glucose concentrations (Miyazaki et al., 
1990, Skelin et al., 2010, Cheng et al., 2012). MIN6 beta cells, which generally grow as 
monolayers, also have the ability to aggregate into islet-like structures termed pseudo islets, 
which have been shown to enhance glucose-stimulated insulin secretion (GSIS) compared to 
MIN6 beta cells grown as monolayers (Hauge-Evans et al., 1999, Luther et al., 2006). 
The use of MIN6 beta cells also has its limitations, especially those used at high passage (60-70) 
at which MIN6 beta cells exhibit impaired GSIS, reduced glucose uptake and oxidation as well 
as reduced expression of genes involved in glucose and lipid utilization (Cheng et al., 2012). 
High passage MIN6 beta cells have decreased insulin content attributed to reduced insulin 
granule formation and pro-insulin mRNA expression (Cheng et al., 2012). In addition, a 
reduction in ATP generation following glucose stimulation of MIN6 beta cells has been related 
to decreased glucose uptake. This has been attributed to reduced glut2 gene expression, and to 
decreased glucose oxidation due to lower levels of genes encoding glucokinase and 
phosphofructokinase, which are pivotal in providing substrates to the Krebs cycle and ATP 
generation via oxidative phosphorylation (Cheng et al., 2012). It is important to note that MIN6 
beta cells do retain normal beta cell function at lower passages generally between 30-40 (Cheng 
et al., 2012). Therefore, MIN6 beta cells are a useful tool in beta cell research towards 




elucidation of beta cell function and the molecular mechanisms involved in regulating GSIS but 
only if they are used over a range in which beta cell-like function is retained (Miyazaki et al., 
1990, Cheng et al., 2012). 
2.1.1: Cryopreservation and thawing of MIN6 cells from frozen storage 
Cell lines are susceptible to genetic mutations as generation number (passage number) increases. 
They become more vulnerable to microbial contamination, and some cell lines have a finite 
generation number, therefore, it is vital to maintain the supply of cells for experimental use. 
This can be achieved by cryopreservation, which involves slow programmable freezing and long 
term storage of cells at -196°C in liquid nitrogen. Cells at this temperature are rendered 
biologically and biochemically inactive but can be recovered again in the future simply by 
thawing the cells when required. For experiments described in this thesis, MIN6 beta cells were 
cryopreserved once they had reached 70-80% confluence and were trypsinised and re-
suspended in 10ml Dulbecco’s Modified Eagles Medium (DMEM), see Table 1. The cells were 
then centrifuged and the supernatant aspirated before re-suspending them in freezing media 
(Table 1). DMSO is a cryoprotective agent, which reduces the freezing point of the medium, 
and allows for a slower cooling rate, thereby greatly reducing the risk of ice crystal formation, 
which can cause cell damage and death. Cells were re-suspended by pipetting up and down and 
aliquoted into cryovials at a density of 1x106 cells/ml, which were placed into a Nalgene “Mr. 
Frosty” cryogenic freezing container containing 100% isopropanol that allows for a cooling rate 
of -1°C/minute, which is optimal for cell preservation. The cells were left overnight at -80°C 
and the cryovials were placed in liquid nitrogen for long term storage. 
Thawing of MIN6 beta cells involved removing the cryovials from liquid nitrogen storage and 
they were immediately placed in a water bath at 37°C and gently shaken until thawed. Cells were 
removed from the cryovials and placed in a sterile 15ml centrifuge tube followed by gentle 
addition of 10ml chilled DMEM (Table 1). The cells were then centrifuged and the supernatant 
discarded before re-suspending with fresh medium and then pipetted into a T25 tissue culture 
flask and incubated overnight at 37°C. Once the cells had adhered to the flask surface the media 
was replaced to remove any non-adherent cells, replenish nutrients, and remove any residual 
DMSO.  
  











10% FBS     
10%NCS     
2mM L-gluatmine     
100U/ml penicillin     
0.1mg/ml streptomycin     
10% DMSO     
 
Table 1: Different culture media used for maintaining MIN6 beta cells, and isolated mouse and human 
islets. All media were supplemented with L-glutamine, penicillin and streptomycin. 
2.1.2: Maintaining and sub-culturing MIN6 cells 
MIN6 beta cells were used for several experiments described in this thesis due to their 
functional similarities with primary beta cells as previously mentioned (Section 2.1). It was 
necessary to mimic the in vivo extracellular environment of beta cells in culture in order to 
maintain healthy and viable cells. Thus, MIN6 beta cells were maintained using DMEM 
containing 25mM glucose, which was supplemented with 10% fetal bovine serum (FBS), 2mM 
L-glutamine and 100U/ml penicillin/0.1mg/ml streptomycin, at 37°C in an atmosphere of 95% 
air/5% CO2. The medium was changed every 2-3 days to ensure the removal of cell metabolites 
and replenishment of essential cell nutrients. MIN6 beta cells were grown as monolayers on 
negatively charged NUNC tissue culture flask surfaces, with growing areas of either 25cm2, 
75cm2 or 175cm2, which provided ideal conditions for cell adhesion and growth as well as 
maintaining an aseptic environment due to the hydrophobic sterile filter cap that prevents 
microorganisms from contaminating the in vitro cell environment. MIN6 beta cells used for 
experiments throughout this thesis were maintained at passages 25 to 49. Higher passage 




numbers (50-70) were refrained from use due to reported alterations in beta cell functionality 
(Cheng et al., 2012).  
Continuous growth of MIN6 beta cells within a limited growth area such as that of a tissue 
culture flask requires cells to be sub-cultured, so cells that had reached a confluence of 70-80% 
were detached from the culture surface by trypsinisation using 0.1% trypsin/0.02% EDTA. 
Briefly, medium was aspirated from the cells and briefly washed with phosphate buffered saline 
(PBS) to remove residual media supplemented with serum, which inhibits the action of trypsin. 
The PBS was aspirated and the cells were incubated for 3-4 minutes with 0.04ml/cm2 of 
trypsin/EDTA at 37°C, which provided ample time for cell detachment. The cells were re-
suspended with 7ml DMEM (Table 1), which inhibited further action of trypsin. The cell 
suspension was pipetted into a 15ml sterile centrifuge tube and centrifuged for 3 minutes at 
1500rpm before discarding the supernatant and re-suspending the cells with fresh DMEM. The 
cells were either sub-cultured into fresh tissue culture flasks for continued growth or counted 
for experimental use (2.1.3: Cell counting). 




Figure 13: Image of MIN6 β-cells maintained in culture as a monolayer (Passage 34). Cells were visualised 
under a light microscope with a x10 objective.  
2.1.3: Cell counting 
A Neubauer haemocytometer was used to quantify the number of cells used for experiments. 
Briefly, MIN6 beta cells were re-suspended in 1ml DMEM following trypsinisation and a 10µl 
aliquot of cell suspension was added to 190µl DMEM (1:20 dilution), from which 10µl was 
loaded onto a haemocytometer grid via capillary action. Cells were counted in four chambers of 
equivalent volumes of 0.1mm3 each. The total cell number per ml was calculated using the 
formula below: 
Total cell number per ml = Mean cell number per 0.1mm3 x 104 x dilution factor 
  




2.2: Islet isolation 
2.2.1: Mouse islet isolation 
The three stages towards successful islet isolation and their functional use involve: (1) 
collagenase digestion of surrounding exocrine tissue connected to islets; (2) purification of islets 
from non-islet tissue; (3) maintenance of viable islets in culture. 
Mouse islets used for functional experiments throughout this thesis were isolated from male 
(25g) ICR mice aged 6-8 weeks (Figure 14). Briefly, mice were terminated by cervical dislocation 
followed by surgical exposure of the abdominal cavity. The duodenum was exposed and 
clamped at the ampulla of Vater (hepatopancreatic ampulla), which is formed by the unification 
of the pancreatic duct and the common bile duct, upon joining the duodenum. Ice cold 
collagenase (3mg/3ml/mouse) was injected via the common bile duct to perfuse the pancreas, 
which was then carefully extracted from the abdominal cavity and placed in a 50ml centrifuge 
tube and stored on ice. The collagenase-perfused pancreatic tissue was placed in a water bath at 
37°C for 10 minutes to promote digestion, which was terminated by transferring the tissue onto 
ice and re-suspending the digest with chilled Minimum Eagles Medium (MEM) supplemented 
with 10% NCS, 2mM L-glutamine and 100U/ml penicillin/0.1mg/ml streptomycin. The tubes 
containing the pancreatic tissue were shaken vigorously and centrifuged (1400rpm, 10°C, 1.5 
minutes) before passing the suspension through a sieve to separate non-digested fat and 
exocrine tissue from passing through. Islets were further purified by gradient centrifugation 
using histopaque, a polysucrose solution adjusted to a density of 1.077g/ml. Islets were 
collected at the interface between the histopaque and MEM, washed several times in MEM 
before being hand-picked and washed with sterile RPMI, supplemented with 10% NCS, 2mM 
L-glutamine and 100U/ml penicillin/0.1mg/ml streptomycin. Islets were maintained in culture 





Figure 14: Image of mouse islets isolated from ICR mice. Mouse islets were isolated from collagenase 
digested pancreta before being sterile washed several times with MEM and maintained in RPMI and 
cultured at 37°C (95% air/ 5% CO2). x10 magnification.   
  




2.2.2: Human islet isolation 
Human islets (Figure 15) were generously provided by Dr GC Huang at the King’s College 
Hospital islet isolation unit. Pancreata were donated from healthy, non-diabetic, heart-beating 
cadavers and islets were isolated by collagenase digestion of the pancreas under aseptic 
conditions (Huang et al., 2004). Isolated islets were maintained in culture in Connaught Medical 
Research Laboratories (CMRL) medium at 37C° (95% air/ 5% CO2) for up to 48 hours. 
Consent for the use of human islets was acquired from the relatives of donors and the Ethical 










Figure 15: Image of isolated human islets. Human islets were isolated from collagenase digested pancreata 
of healthy heart beating cadavers before being sterile washed several times with MEM and maintained in 
CMRL and cultured at 37°C (95% air/ 5% CO2). x10 magnification.   
  




2.3: Gene expression 
2.3.1: Total RNA extraction 
RNA isolation is critical for downstream applications such as reverse transcription and cDNA 
amplification, which enable gene expression profiling. RNA was isolated from MIN6 beta cells, 
mouse islets, human islets and mouse acinar cells using Qiagen RNeasy mini kits, which utilises 
a high affinity special silica-based membrane and its high affinity allows for mRNAs to separate 
from smaller RNAs such as transfer RNA, ribosomal RNA and micro RNA, which are shorter 
than 200 nucleotides. Details of the kit components are provided in Table 2. Briefly, MIN6 beta 
cells were trypsinised (Section 2.1.2) and counted (Section 2.1.3). The maximum number of cells 
used for RNA isolation was 1x107, which was to prevent overloading of the silica membrane 
and to ensure optimal RNA yield. MIN6 beta cells, islets and exocrine tissue were briefly 
washed with PBS, centrifuged (12,000 rpm, 2 minutes) and the supernatant was aspirated before 
re-suspending the cells in 350-600l RLT lysis buffer (Table 2), which was supplemented with 
beta-mercaptoethanol (0.01%v/v), and vortexed for 2-3 minutes. Islets and exocrine tissue were 
homogenised using a QIAshredder spin column. The supernatant, which contained the RNA 
was transferred to a fresh 1.5ml tubes and an equivalent volume of ethanol was added before 
the lysed cell suspension was transferred to an RNeasy spin column and centrifuged at 12,000 
rpm for 2 minutes. The flow through containing RNA was discarded and 350l RW1 buffer 
(Table 2) was added to the spin column. The flow through was discarded after brief 
centrifugation (12,000 rpm, 2 minutes) and the RNA bound to the column was treated with 
DNase (10l DNase in 70l RDD buffer), see table 2, for 15 minutes before 350l RW1 buffer 
was added and the flow through was discarded again after centrifugation. The spin column was 
centrifuged to dry the column to remove any residual buffer and the RNA was eluted by adding 
30l of RNase free water to the column before a final centrifugation process. The flow through, 
which contained the RNA, was transferred to a fresh 1.5ml tube and being quantified and 
reverse transcribed to cDNA before being stored at -80 C.  
  








Cell lysis buffer containing guanidine thiocyanate, which promotes the binding of RNA 
to the silica membrane. If the cell number is less than 5 x 106 cells then 350μl of RLT 
lysis buffer was added. However, if the cell number was between 5 x 106- 1 x 107 cells 
then 600μl was added. 
RW1 buffer 
Contains a guanidine salt and ethanol, which is used as a wash buffer to remove 
carbohydrates, fatty acids and proteins etc, that are non-specifically bound to the silica 
membrane but at the same time leaving the bound RNA (longer than 200bp) intact. 
DNase Provides on-column digestion of DNA during the RNA extraction process. 
RDD buffer 
Buffer RDD ensures efficient digestion of DNA on the column and also ensures that 
the RNA remains bound to the column. 
 
Table 2: Reagents used during the RNA extraction process. Briefly, an appropriate volume of RLT lysis 
buffer was added to MIN6 beta cells, mouse and human islets, and mouse acinar tissue extracts. Tissue 
extracts were homogenised by passing through a QIAshredder spin column and the lysates were loaded 
into a Qiagen RNeasy RNA extraction spin column. Through a series of wash and centrifugation steps 
including DNase treatment the RNA was eluted from the spin column and RNA content was measured 
using Nanodrop -1000 spectrophotometer. 
  




2.3.2: Measuring RNA concentration and integrity 
A Nanodrop-1000 spectrophotometer was used to measure RNA concentration and integrity of 
a 1.5µl sample retrieved from the spin column of the RNA extraction process (2.3.1: Total RNA 
extraction). The sample was pipetted onto the end of a fibre optic cable (receiving fibre) and a 
second fibre (source fibre) was brought into contact with the sample allowing the liquid RNA 
sample to bridge between the two fibre optic ends before a pulse of xenon light was flashed 
through the sample for analysis. The sample absorbance ratio of 260nm and 280nm was used to 
assess the RNA purity. A ratio within the range of 1.8 to 2.2 was considered pure but a ratio 
below this range would indicate protein or phenol contamination as they both absorb at 280nm. 
Pure RNA samples were stored at -80°C and subsequently used for cDNA synthesis. RNA was 
quantified in ng/µl. 
2.3.3: cDNA synthesis 
Complementary DNA (cDNA) synthesis involved the reverse transcription of RNA into cDNA 
by the action of Moloney Murine Leukemia Virus Reverse Transcriptase (mmLV-RT). In short, 
10µl of total RNA (50ng/µl) was primed for cDNA synthesis by mixing the RNA with 2µg/µl 
Oligo (dT) and 2µg/µl random primer, which both bind to the polyA tail and random 
complementary sequences on the mRNA, respectively, enabling efficient initiation of cDNA 
synthesis (Table 3). The sample mixture was incubated at 72°C for 5 minutes and immediately 
placed on ice for 1 minute. Master mix (Table 3) was added to the RNA sample mixture, which 
was reverse transcribed using a Thermal Cycler (Table 4). Samples were stored at -20°C until 
PCR amplification. 
  





Table 3: Prime mix and Master Mix composition used for reverse transcription. The prime mix containing 
10µl RNA and 0.5µl of Oligo-(dT) and 0.5µl Random Primers were mixed with 9µl Master Mix to make 
up a 20µl reaction mix. 
 
Stage Temperature (°C) Time (Minutes) 
Incubation and Synthesis 42 50 
Heat inactivation 72 15 
Cooling 4 5 
 
Table 4: Thermal Cycler settings for reverse transcription  
 
 Reagent 





Oligo-(dT)  0.5 0.05μg/μl 
Random Primer 0.5 0.05μg/μl 
Master mix 
5 x RT buffer (Promega mmLV-RT kit) 4µl - 
DNase/RNase-free water 0.5µl - 
DTT (400mM) 0.5µl 10mM 
RNasin (40U/µl) 2µl 4U/µl 
dNTP’s (10mM) 1µl 500µM 
mmLV-RT (200U/µl) 1µl 10U/µl 




2.3.4: Polymerase Chain Reaction (PCR) 
PCR is a molecular technique that enables a single sequence of DNA to be amplified to produce 
thousands or even millions of identical copies of the original DNA sequence. The basic 
principle relies on the ability of a heat stable polymerase to join together the nucleotides adenine 
(A), thymine (T), guanine (G) and cytosine (C), which are the essential building blocks of DNA. 
The polymerases require a constant supply of nucleotides in order to achieve this as well as 
primers, which are oligonucleotides that bind to complementary bases on the source DNA and 
help initiate polymerase action, which results in the formation of a new DNA strand (Joshi and 
Deshpande, 2011). There are three main stages for a single PCR: Denaturation, Annealing and 
Extension. The DNA was initially heated to 95°C to separate the strands, which was cooled to 
45-60°C to allow the synthesised primers to hybridise to a specified complementary sequence 
on each DNA strand. Each strand was then primed for extension and heated to 72°C in the 
presence of a heat resistant polymerase along with a supply of nucleotides. This process is 
repeated for 30-40 cycles to ensure sufficient amplification of target DNA, effectively doubling 
the amount of DNA during each cycle (Joshi and Deshpande, 2011). 
PCR experiments in this thesis used cDNAs (50ng/µl) obtained from various tissue sources 
(Table 5). DNA primers were designed using Primer3web software (Untergasser et al., 2012, 
Koressaar and Remm, 2007). All primers were designed between 18-20 base pairs and with a 
guanine: cytosine content between 45-60%. Primers were cross checked with the organism’s 
genome using nucleotide BLAST software (NCBI) to ensure that no conflicting transcripts 
would amplify undesired or non-specific targets (Table 6). 
PCR reactions were prepared in DNase/RNase-free 0.2ml heat sensitive tubes, which contained 
PCR water (DNase/RNase-free), Promega Go-Taq® flexi DNA polymerase, Promega Go-
Taq® Green master mix, Promega PCR nucleotide mix, MgCl2, forward and reverse primers, 
and either mRNAs of interest or PCR water, which served as a negative control (Table 7). The 
amplified cDNA targets and DNA ladder were loaded onto an agarose gel and electrophoresed 
for 40 minutes at 65V before being visualised under UV light to detect the presence of 
amplicons of interest and the DNA ladder (Figure 16). Amplicons were extracted from the 
agarose gel and DNA was isolated using the Qiagen Gel Extraction kit and sequenced by 
Source Bioscience UK Limited (Section 2.3.6). The sequence homology of the DNA in query 
was compared to the actual gene sequence using Nucleotide BLAST software (NCBI) . 
  






Mouse hypothalamus In house 
Mouse islet In house 
Mouse exocrine In house 
MIN6 beta cell line In house  
Human heart Takara Clontech 
Human islet King’s College Hospital islet isolation unit 
Human exocrine King’s College Hospital islet isolation unit 
Human PANC-1 cell line ATCC 
 
Table 5: cDNAs used in PCR amplifications described in this thesis. All cDNAs were used at a 
concentration of 50ng/µl. ATCC: American Type Culture Collection. 
  
































Table 6: Details of primer nucleotide sequences, annealing temperatures and amplicon sizes of primers 
required for cDNA amplification used throughout this thesis. 
 











































































Table 7: Composition of PCR reaction mix used for cDNA amplification 
 
2.3.5: Amplicon visualisation and DNA sequencing 
After PCR amplification 10µl of each product was loaded onto a 2% agarose gel, which was 
made up by dissolving 1g agarose in 50ml 1x Tris-Base-EDTA (TBE) supplemented with 
ethidium bromide (5µg/ml). A pBluescript II SK DNA ladder was synthesised by digestion of 
the pBluescript II SK+ plasmid by the restriction enzyme HapII (Molecular Biology Unit, 
King’s College London), which generated thirteen DNA fragments of different known sizes 







Figure 16: DNA ladder fragments (bp) generated by Hpa II restriction enzyme digest of pBluecript II 
SK+ plasmid. Fragments were made visible on a 2% agarose gel stained with ethidium bromide (5µg/ml). 
The 28 and 33 bp fragments are not visible.  
  
Master mix Volume per reaction (µl) Final concentration 
PCR water (DNase/RNase-free) 10 - 
5 x Green Go Taq® Flexi buffer 4 - 
PCR nucleotide mix (40mM) 0.8 1.6mM 
Forward primer (100µM) 1 5µM 
Reverse primer (100µM) 1 5µM 
MgCl2 2 2.5mM 
Go Taq® DNA polymerase 0.2 0.05U/µl 




2.3.6 Gel DNA extraction 
DNA extraction from multiple cDNA preparations was achieved by excising amplicons of 
interest from agarose gels using Qiagen Gel Extraction kits. In brief, the excised agarose gel 
bands were weighed before adding approximately 3 or 6 volumes of buffer QG (100mg ~300µl 
buffer QG), Table 8, for 1.8% and 2% agarose gels, respectively. The bands were incubated at 
50°C for 10 minutes with brief vortexing every 2-3 minutes to ensure they were completely 
dissolved. Equal volumes of isopropanol were added (e.g. 100mg~100µl), and the samples were 
transferred into a Qiagen spin column and centrifuged (13,000rpm, 1 minute) before discarding 
the flow through and adding 500µl of buffer QG to the spin column. After further 
centrifugation (13,000rpm, 1 minute) 750µl of buffer PE (Table 8) was added to the spin 
column and left to stand for 2-5 minutes. DNA was eluted from the column after centrifugation 
(13,000rpm, 1 minute) by adding 50µl buffer EB (Table 8). DNA was stored it at -20°C. 
Reagent Action 
Buffer QG 
Solubilisation and binding buffer 
(with pH indicator). Helps to bind 
nucleic acids to spin column 
membrane. 
Buffer PE 
Wash buffer for DNA clean up 
procedures 
Buffer EB 
Allows for efficient elution of 
nucleic acids from spin column 
membrane. 
 
Table 8: Reagents used during DNA extraction process from agarose gel. 
 
  




2.3.7 Quantitative PCR (qRT-PCR) 
qRT-PCR was carried out in 96-well plates using the Roche® thermocycler (LightCycler 480) 
and LightCycler® FastStart DNA masterPLUS SYBR green I (Roche®, UK). A reaction mix 
was prepared by mixing mouse or human islet cDNA, primers and SYBR green master mix 
(Table 9). The plate was centrifuged at 1000rpm for 1 minute to ensure all contents were at the 
bottom of the well. The cDNAs were amplified by the LightCycler 480 following pre-set 
conditions (Table 10). qRT-PCR was performed using QuantiTect primers specific for mouse 
and human GPR75, CCR1, CCR3 and CCR5. Primer efficiency, which describes how efficient a 
pair of primers are at copying the template sequence, was calculated by serially diluting the 
cDNA template and determining the Ct value, which is the cycle number at which fluorescence 
increases exponentially. This value was used to determine relative quantification values between 
control and treatment groups. Relative expression of mRNAs was determined after 
normalisation against GAPDH (Gapdh) as an internal reference and calculated by the 2−ΔΔCt 
method (Livak and Schmittgen, 2001).  
 





Total volume 10 
 
Table 9: Preparation of SYBR green Mastermix for relative quantification using qRT-PCR 
 
Step Target Temp. (oC) Time Cycles 







1 65 1min 
97  
Cooling 40 30secs  
 
Table 10: Conditions used by qRT-PCR lightcyler for cDNA amplification and melt curve analysis 
  




2.4: Protein Expression 
2.4.1: Protein extraction 
Lysis buffer was prepared by adding one PhosSTOP Phosphatase Inhibitor Cocktail tablet and 
one cOmplete Protease Inhibitor Cocktail tablet to 10ml of RIPA buffer (Table 11), which was 
kept on ice before commencing cell lysis. The phosphatase inhibitors inhibit alkaline 
phosphatases, acid phosphatases, serine/threonine phosphatases, tyrosine phosphatases and 
dual-specificity phosphatases, to preserve the phosphorylation status of proteins. The protease 
inhibitor contains several protease inhibitors with broad inhibitory specificity serines, cysteines, 
and metalloproteases, to limit protein degradation. RIPA buffer (Table 11) ensures efficient cell 
lysis and protein solubilisation and simultaneously preserves protein integrity. 
MIN6 beta cells were grown on 9cm diameter Petri dishes until 70-80% confluent, briefly 
washed with PBS and 500µl of chilled cell lysis buffer was added on ice for 5 minutes. Cells 
were scraped off the Petri dish surface using a cell scraper and the cell lysates were collected 
into pre-chilled 1.5ml tubes. Islet protein extraction involved briefly washing islets twice with 
PBS and transferred into pre-chilled 1.5ml tubes. 100µl lysis buffer was added to islet pellets and 
left on ice for 30 minutes with vortexing every 10 minutes. The islet lysate was sonicated for 5-
10 seconds and left on ice for 10-15 minutes to facilitate lysis before being centrifuged 
(13,000rpm, 10 minutes) at 4°C. The supernatant was collected and protein quantification was 
determined with 10µl MIN6 beta cell and islet extract (Section 2.4.2). The remaining lysates 
were stored at -20°C in 4x NuPAGE® sample buffer, which optimises protein separation for 
polyacrylamide gel electrophoresis (PAGE) by denaturing and reducing protein disulphide 
bonds.  
Reagent  Concentration 





*IGEPAL® CA-630 1% 
PhosSTOP Phosphatase Inhibitor Cocktail tablet (Roche) - 
cOmplete Protease Inhibitor Cocktail tablet (Roche) - 
 
Table 11: Composition of Cell lysis buffer. pH 8.0. * Nonionic, non-denaturing detergent, chemically 
indistinguishable from Nonidet P-40  
  




2.4.2: Protein quantification 
The BCA (bicinchoninic acid) assay was used to determine protein content of cell extracts. It is 
a copper-based protein assay which relies on peptides chelating with cupric ions (Cu2+) in an 
alkaline environment to produce a violet complex that absorbs light at 540nm (Biuret reaction). 
BCA binds to the reduced cuprous ions (Cu1+) induced by the peptide-mediated biuret reaction 
resulting in removal of the weakly bound peptides to generate an intense purple colour. Thus, 
the increase in absorbance is directly proportional to the protein concentration. Furthermore, 
the released peptides can bind free cupric ions, and therefore the reaction is indefinite subject to 
the presence of excess BCA and copper. To overcome this potential obstacle, standards and 
unknown samples are assayed simultaneously and receive identical incubation periods and 
temperature exposure. The advantage of the BCA assay is that it is highly sensitive and responds 
uniformly to different proteins, yielding consistent and reliable results. Samples of cell lysates 
extracted from MIN6 beta cells, exocrine cells and islets (2.4.1: Protein extraction) were diluted 
to 1:10 and 1:100 with lysis buffer. BSA was used to provide reference standards of known 
protein concentrations (0, 0.025, 0.125, 0.25, 0.5, 0.75, 1, 1.5 and 2 mg/ml). and 25µl of either 
protein standard or sample was added in triplicate into wells of a clear 96 well plate. 200µl of 
BCA solution was added to all wells and the plate was incubated for 30 minutes at 37°C. The 
absorbance was measured at 595nm using an ELISA reader (Hidex Chameleon™V). A standard 
curve was generated by plotting the average absorbance at 595nm against the concentration of 
the BSA standards, and the protein concentration of samples was determined using a standard 








Figure 17: BSA standard curve used for protein quantification of cell extracts. Each BSA concentration 
was prepared in triplicate in which the mean absorbance (595nm) was determined using a Chameleon 
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2.4.3: Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE is a universally accepted method of separating proteins on the basis of their 
molecular weights. It relies on the fact that proteins undergo partial denaturation in the 
presence of SDS, which applies an overall net negative charge to all proteins, ensuring that they 
are separated according to their molecular weight in the presence of an electric field. This 
promotes the migration of negatively charged proteins toward the anode via the porous 
polyacrylamide gel matrix, which is characterized by a mixture of acrylamide and bisacrylamide 
monomers. Thus, large pore acrylamide gels (5%) are useful for separating large proteins (80-
200kDa) whereas small pore acrylamide gels (15%) are useful for separating smaller proteins 
(10-40kDa).  
Pre-cast NuPAGE® Novex® Bis-Tris 12% gels were used to separate proteins, with a 
separation range of 10-80kDa. Equal amounts of MIN6 beta cell, mouse and human exocrine 
and islet protein extracts were loaded onto the polyacrylamide gel (pH 6.4) along with a full-
range rainbow molecular weight marker, which is a mixture of individual coloured proteins of 
defined sizes (Figure 17). The gel was placed in an Xcell SureLock® mini-cell electrophoresis 
system and the inner chamber was filled with antioxidant buffer (Table 12), which maintains 
proteins in a reduced state during PAGE, whilst the outer chamber was filled with 1xMOPS 









Figure 18: Full-Range Rainbow Molecular Weight Markers (GE Healthcare Amersham RPN800E) 
assessed on a 4 - 20% Tris-glycine gradient SDS-PAGE mini-gel. K: kDa.  (Image acquired from GE 
healthcare:https://www.gelifesciences.com/gehcls_images/GELS/Related%20Content/Files/13147874
24814/litdocRPN800EPS%20Rev%20A%202007_20110831125742.pdf accessed 02.01.2014, 14:36). 
  




Reagent  Amount 
1X MOPS running buffer  200ml 
NuPAGE® Novex® Antioxidant  500µl  
 
Table 12: Preparation of antioxidant buffer used for SDS-PAGE. 
 
Reagent Amount in 500ml  Final Concentration 
MOPS 104.6g 1M 
Tris Base 66.6g 1M 
SDS 10g 69.3mM 
EDTA 3g 20.5mM 
 
Table 13: MOPS running buffer (20X). Reagents listed were initially dissolved in 400ml dH2O and then 
adjusted to a final volume of 500ml. The 20X MOPS running buffer was diluted with dH2O to make 1X 
MOPS running buffer for SDS-PAGE and the remaining buffer was stored at 4°C. 
  




2.4.4: Western Blotting 
Western Blotting enables the detection of a protein of interest from a mixture of proteins by 
making use of a specific antibody. Proteins separated by SDS-PAGE were transferred to a 
polyvinylidene difluoride (PVDF) membrane, which has a high protein binding capacity, of 50-
150µg/cm2, making it ideal for this application. The gel was placed within a blotting module, 
filled with 1x NuPAGE transfer buffer (Table 14) and an electric current of 30V was applied 
for 2 hours, which promoted migration of proteins towards the membrane (Figure 19). The 
membrane was removed from the blotting module and incubated in a protein-rich blocking 
buffer (Table 15) for 1 hour at room temperature to prevent non-specific binding of the 
detection antibody to the PVDF membrane. The acrylamide gel was stained with coomassie 
blue to verify protein transfer from gel to the membrane. The membrane was incubated with a 
primary antibody (For antibody dilution see section 3.2.2: Western blotting) raised against the 
target protein overnight at 4°C followed by three subsequent washes with 1x Tris Buffered 
Saline (TBS)-Tween20 (Table 16) for 15 minutes. The blot was then incubated for 1 hour with a 
horseradish peroxidase-conjugated secondary antibody solution (1:5000 dilution) at room 
temperature before being washed with 1x TBS-T. The immunoreactive proteins were identified 
by chemiluminescent detection using ECL reagents (GE Healthcare). Photographic film was 
exposed to the luminescent protein signal on the membrane and protein size was determined by 









Figure 19: Diagram showing the assembly of the polyacrylamide gel/PVDF membrane within 
the blotting module. Briefly, proteins were separated by SDS-PAGE and the acrylamide gel was placed 
into a blotting module. A 30V current was applied for 2 hours to allow the proteins to transfer from the 
gel to the membrane. The membrane was then used to detect proteins of interest using antibodies. 
  




Reagent Amount (ml) 
dH2O  849 
















Table 16: Composition of 10x TBS-T, which was made by dissolving the reagents listed above in 3L of 
dH2O. pH of the solution was adjusted to 7.4 using 1M HCl before being topped up to 4L with dH2O. A 
1x working solution was used for western blotting.   
Reagent Amount 
TBS-T 500ml 
Semi-skimmed milk powder (5% w/v) 25g 
Reagent Amount for 1l (10x) Final concentration (1xTBS) 
Tris base  80g 136mM 
NaCl 60g 50mM 




2.4.5: Immunohistochemistry  
Immunohistochemistry (IHC) was used to provide information on CCL5 and GPR75 
localisation within islets. Mouse and human pancreata were isolated and fixed in formalin 
overnight before being transferred into 70% ethanol and stored at 4°C. The pancreata were 
embedded in paraffin wax and cut into 5-7µm sections using a microtome before being 
mounted onto tissue section slides. Sections were heated (60°C) and the remaining paraffin wax 
was removed by submersion into 100% xylene solution and were gradually rehydrated by a 
series of washes with decreasing concentrations of ethanol and dH2O (Table 17). Tissue 
sections underwent an antigen retrieval protocol to expose antigenic sites that may have been 
masked by formaldehyde induced protein cross-linking during the fixation process. The sections 
were then exposed to citric acid buffer (10mM, 0.05% Tween-20, pH6) and heated in a pressure 
cooker pot for approximately 10-15 minutes before being washed with running water and 
treated with 3% hydrogen peroxide for 10 minutes at room temperature, to block peroxidase 
activity, and then finally washed with dH2O for a further 10 minutes. The pancreas sections 
were then incubated for a further 10 minutes with swine serum at room temperature (1:5 
dilution in 1x TBS) to block non-specific binding of the detection antibodies. Primary 
antibodies were diluted in PBS/0.25% (v/v) Triton X-100/0.25% (w/v) BSA and applied to 
pancreas sections overnight in a humidifying chamber at 4°C. The slides were subsequently 
washed three times with PBS-0.25% (v/v) Triton X-100 (5 minute washes) before commencing 
with either diaminobenzidne (DAB) or fluorescent immunostaining. 
  





Solution Time (minutes) 
Xylene 1 30 
Xylene 2 5 
100% Alcohol 10 
95% Alcohol 5 
70% Alcohol 5 
dH2O 10 
 
Table 17: Protocol for tissue rehydration of mouse and human pancreas sections. 
 
Reagent Amount Final concentration (1xPBS) 
NaCl 80g 136mM 
Na2HPO4 11.6g 8mM 
NaH2PO4 2g 1.7mM 
KCl 2g 2.7mM 
 
Table 18: Preparation of 10x PBS. Reagents were initially dissolved in 900ml dH2O before being adjusted 
to a pH of 7.2, and then made up to a final volume of 1l with dH2O). A 1x working solution was used 
throughout IHC. 
 
Reagent Amount Final concentration (1xTBS) 
NaCl 80g 136mM 
Tris base 60g 50mM 
 
Table 19: Preparation of 10x TBS. A 1x working solution was used throughout IHC 
  




2.4.5a Diaminobenzidine (DAB) immunostaining 
For the detection of immunoreactive proteins by DAB staining, a universal biotinylated link 
antibody was applied to the sections for 30 minutes at room temperature. Sections were briefly 
washed three times with PBS-0.25% (v/v) Triton X-100 before being incubated with 
streptavidin-conjugated horseradish peroxidase for 30 minutes at room temperature after which 
it was washed off with PBS-0.25% (v/v) Triton X-100. DAB-substrate-chromagen was applied 
to the tissue sections. A brown colour was generated as a result of the reaction between the 
peroxidase and the DAB. Once the desired colour development was achieved (10-20 minutes) 
the DAB-substrate chromagen was washed off and the slides were briefly counter stained with 
haematoxylin and eosin to stain for nuclei and cytoplasmic connective tissue. The sections were 
mounted with DPX (1,3-diethyl-8-phenylxanthine) after being gradually dehydrated with 
increasing concentrations of ethanol and a final wash with xylene (Table 20).  
Solution Time (minutes) 
70% ethanol 5 
95% ethanol 5 
100% ethanol 5 
100% Xylene 5 
 
Table 20: Protocol for dehydration process for mounting mouse and human pancreas tissue sections. 
 
  




2.4.5b Fluorescent immunostaining 
Pancreas tissue sections that had been exposed to the primary antibodies shown in Table 21, 
were immunoprobed for 1 hour at room temperature with either AlexaFluor488® or 
AlexaFluor594® antibodies (Table 22), which were made up in PBS/0.25% (v/v) Triton X-
100/0.25% BSA. Immunoreactive protein localisation was determined using a fluorescent 
microscope (Nikon Eclipse TE 2000-U). 
Primary 
antibody 
Description Manufacturer (Cat number) Dilution range 
CCL5 Goat polyclonal IgG R&D systems (AF478) 1:8 to 1:10 
GPR75 Rabbit polyclonal IgG Abcam (ab75581) 1:10 to 1:20 
Insulin Guinea pig polyclonal DAKO (A0564) 1:50 
Glucagon Mouse monoclonal Sigma (G2654) 1:50 
Somatostatin Rat monoclonal Abcam (ab30788) 1:25 
 
Table 21: Primary antibodies used for IHC staining. Antibodies were diluted to within working range by 
making up in PBS/0.25% (v/v) Triton X-100/0.25% (w/v) BSA. 
 
































Table 22: Fluorescent-conjugated secondary antibodies used for IHC. Antibodies were diluted to the 
appropriate dilution in PBS/0.25% (v/v) Triton X-100/0.25% (w/v) BSA. 




2.5: Beta cell and islet function 
2.5.1: Single cell calcium microfluorimetry 
Single cell-calcium microfluorimetry allows for real-time calcium ion measurements within cells. 
Changes in intracellular calcium are usually monitored by calcium-sensitive dual wavelength 
indicators such as FURA-2 (e 2-[6-(bis(carboxymethyl)-amino)-5-methylphenoxy)ethoxy-2-
benzofuranyl]5-oxazole carboxylic acid). When FURA-2 is bound to Ca2+, there is a shift in 
peak excitation wavelength from 380nm to 340nm, which causes fluorescent light to be emitted 
at a higher wavelength of 510nm. The advantage of using a dual wavelength indicator such as 
FURA-2 is because of the ability to detect the Ca2+-free and Ca2+-bound forms of the dye at 
two different wavelengths and therefore obtain a ratiometric measurement since artefacts 
unrelated to changes in intracellular calcium are minimised. Furthermore, FURA-2 is coupled to 
an acetoxy methyl ester (AM), which allows it to cross the plasma membrane and be cleaved by 
endogenous esterases that cleave AM allowing high concentrations of the dye to accumulate 
within the cell (Limke and Atchison, 2001). 
Approximately 50,000 MIN6 beta cells or 80-100 mouse or human islets, which were partially 
dispersed using a non-enzymatic (calcium and magnesium free) cell dissociation solution for 15 
minutes at 37°C (5% CO2/95% air), were seeded onto acidified ethanol-washed coverslips 
(MIN6 beta cells) or Cell-Tak coated acidified ethanol-washed coverslips (islets), Table 24, and 
placed in 6-well plates containing serum-free media and maintained for 2-3 hours to allow the 
cells to adhere to the coverslips. Serum containing media was then added to the wells before 
incubating overnight at 37°C (5% CO2/95% air). The cells were then loaded with 5µM FURA-2 
AM at 37°C for 30 minutes and coverslips were transferred to a temperature controlled 
chamber maintained at 37°C and perifused with agents of interest. A shutter system was used to 
expose the cells/islets to between wavelengths of 340nm and 380nm every 2 seconds. Changes 
in fluorescence (emission at 510nm) were monitored by an epi-fluorescence microscope (Zeiss 
Axiovert135 Inverted microscope). The 340nm/380nm ratio was measured every 2 seconds and 
data were recorded by OptoFluor imaging software. For most protocols, cells were perifused 
with a physiological salt solution (Gey and Gey, 1936), Table 23, supplemented with 2mM 
glucose to establish a stable baseline of intracellular calcium (Table 25). ATP (100µM) and 
Tolbutamide (50µM), served as positive controls. 
  




Reagent  Mass (g) Final Concentration (mM) 
NaCl 26 111 
KCL 1.48 5 
NaHCO3 9.08 27 
MgCl2∙6H2O 0.84 1 
KH2PO4 0.12g 0.22 
MgSO4∙7H2O 0.28 0.28 
 
Table 23: Formulation of 1x Gey and Gey (G&G) formulation, which was made up in 2L dHsO and was 
adjusted to pH 8.4. 
Reagent Volume  
1M NaCl 5μl 
0.1M NaHCO3 (pH 8) 285μl 
BD Cell-Tak® Adhesive Reagent 
(in 5% acetic acid) 
10μl 
 
Table 24: Preparation of Cell-Tak®-coated cover-slips. Cell-Tak® solution was made by initially mixing 
0.1M NaHCO3 with BD Cell-Tak® Adhesive Reagent in a 0.5ml Eppendorf tube before adding 1M 
NaCl just before the solution was pipetted onto a 2.2cm circular acid/ethanol-washed sterile glass cover-
slip. The Cell-Tak® protein comes out of solution and adsorbs to the cover-slips when pH changes from 
2.4 to 7. Cell-Tak® solution was kept on cover-slips at room temperature for 20 minutes to allow 
adsorption. Coated cover-slips were then washed twice with sterile DI H2O, air dried and stored at 4°C 
prior to use. 
 
Reagent Amount Final concentration 
2x G&G 250ml 1x 
dH2O 250ml - 
D-glucose 0.18g 2mM 
CaCl2 (1M) 1ml 2mM 
HEPES 1.2g 10mM 
 
Table 25: Composition of physiological buffer used for calcium microfluorimetry. The solution was 
adjusted to pH 7.4 using NaOH. 
  




2.5.2:  Transient transfection - siRNA mediated GPR75 depletion 
A gene-targeted small interfering RNA (siRNA) was used to down-regulate GPR75 expression 
in MIN6 beta cells. MIN6 beta cells were trypsinised and re-suspended in serum-containing 
medium before counting cell number (2.1.3: Cell counting). 1x106 cells per sample were 
centrifuged (1500rpm, 3 minutes), the remaining supernatant was removed, and the cells were 
gently re-suspended in 100µl Amaxa Nucleofector® transfection reagent, which consisted of a 
4.5:1 ratio of Nucleofector® solution (82µl) to Nucleofector® supplement (18µl) per 100µl 
sample. The cell suspension was combined with 30-300nM gene-targeted siRNA, transferred 
into a cuvette and electroporated using a Lonza Amaxa biosystems Nucleofector II. 500µl of 
pre-warmed serum-containing medium was added immediately to the cell suspension, which 
was transferred into wells of 6 well plates containing 1.5ml pre-warmed serum containing 
medium. Cells were maintained at 37°C (5% CO2/95% O2) for 4-48 hours and the extent of 
GPR75 down-regulation was determined by qRT-PCR (section 2.3.7) and western blotting 
(section 2.4.4). Functional effects of down regulation were observed by calcium 
microfluorimetry (section 2.5.1) and insulin secretion (section 2.6) experiments. 
2.6 Hormone secretion 
Islets of Langerhans are composed of three major endocrine cell types. The glucagon-secreting 
alpha cells and the insulin-secreting beta cell are the most abundant islet endocrine cell types 
and by secreting these hormones they are crucial for glucose homeostasis (Bosco et al., 2010, 
Baetens et al., 1979). Static measurements of insulin secretion allows identification of 
compounds that can initiate, potentiate or suppress islet hormone secretion, under conditions 
where ranges of concentrations of test agents can be examined using the same batch of islets. 
Dynamic measurement of insulin secretion in perifusion is technically more challenging and it 
can be used to identify the kinetics of islet hormone secretion to determine whether the effect 
on hormone secretion is acute or prolonged and to identify whether the changes in secretion are 
rapid in onset and reversible on removal of the test agents. Therefore, measuring islet hormone 
secretion is useful towards identifying compounds that influence islet hormone secretion and 
thus provide information that may be useful in the development of novel drugs towards the 
treatment of type 2 diabetes (Nolan and O’Dowd, 2009).  
2.6.1 Static incubation 
MIN6 beta cells were trypsinised and seeded into 96 well plates at a density of 30,000cells/well 
and maintained in culture overnight at 37°C to allow for cell adherence. The tissue culture 
medium was then tapped off and the cells were incubated with 200µl of physiological buffer 
supplemented with 2mM glucose (Table 26), for 2 hours at 37°C to establish a baseline level of 
insulin secretion. The physiological buffer was aspirated and cells were then treated with 200µl 
of agents of interest for 1 hour at 37°C (5%CO2/95%air), after which 160µl of supernatant was 




collected and assayed by radioimmunoassay for insulin content, where a 1:5 dilution with borate 
buffer was required (Table 28). 
A similar approach was used for isolated mouse and human islets, in which 3 islets per replicate 
were pre-incubated in 600µl physiological buffer supplemented with 2mM glucose (Table 26) 
for 1 hour at 37°C before being aspirated and then treated with agents of interest for 1 hour. 
After incubation 450µl of supernatant was collected and assayed for insulin content by 
radioimmunoassay after a 1:5 dilution in borate buffer. 
2.6.2 Perifusion  
Isolated mouse and human islets were perifused with a physiological buffer (Table 26) in the 
absence and presence of agents of interest to determine the dynamic secretory profile of islet 
hormones in response to those test agents. The perifusion system was maintained at 37°C in a 
temperature controlled environment and consisted of 8-16 chambers, depending on the 
experiment, that contained a 1µm pore membrane that ensured islets cells did not pass into the 
perifusate. 80-100 islets were loaded into each chamber and pre-perifused with the physiological 
buffer supplemented with 2mM glucose for 70 minutes using a multichannel peristaltic pump 
set at a flow rate of 0.5ml/minute during which the perifusate was discarded. The islets were 
then treated with agents of interest and the perifusate was collected every 2 minutes from which 
insulin and glucagon content were measured by radioimmunoassay (section 2.6.3).  
Reagent Amount Final concentration 
2x G&G 250ml 1x 
dH2O 250ml - 
D-glucose 0.36g 2mM 
CaCl2 (1M) 1ml 2mM 
BSA 0.25g 0.5mg/ml 
 
Table 26: Preparation of physiological buffer used for hormone secretion experiments, which  was 
adjusted to pH 7.4 using 5%CO2/95%air. 
  




2.6.3 Islet hormone radioimmunoassay  
Radioimmunoassay (RIA) is used for measuring very low concentrations of immunoreactive 
molecules in solution, making it an extremely sensitive technique in biomedical research. The 
molecular basis behind immunoassay is founded upon the interaction of an antibody to its 
corresponding ligand. The two major islet hormones, insulin and glucagon, are the primary 
ligands of interest in this thesis. 
RIA consists of three variables; the antibody (Ab), antigen (Ag) and the radiolabelled antigen 
(Ag*). The Ag, which is the ligand or molecule of interest, competes with a radiolabelled form 
of the same ligand which is referred to as the tracer and both compete for binding to the Ab. A 
limited amount of Ab is incubated in solution with a mixture of Ag* and known concentrations 
of Ag (Standards) or unknown concentrations of ligand (Samples). The Ab will bind to the Ag 
and as the reaction proceeds towards equilibrium there will be competitive binding between Ag 
and Ag*, with limited availability of Ab binding sites.  
Ab + Ag + Ag* ↔ Ab:Ag + Ab:Ag* + Ag + Ag* 
Therefore, increasing the concentration of Ag will increase the probability of Ab:Ag binding 
and conversely decrease Ab:Ag* binding due to the limited availability of antibody binding sites. 
Furthermore, by keeping the concentrations of Ab and Ag* constant and varying the 
concentration of Ag across a fixed range a standard curve can be generated to quantify ligand 
content.  
To quantify islet hormone content of samples retrieved from static incubations (section 2.6.1) 
or perfusion (section 2.6.2), a standard curve was constructed by serially diluting stock 10ng/ml 
insulin or glucagon (Table 27) with borate buffer (Table 28). The standards were assayed in 
triplicate and samples assayed in duplicate. An equivalent amount of antibody and tracer (125I-
Insulin or 125I-Glucagon) was added to standards, reference tubes and samples, and all assay 
tubes were kept at 4°C for 48 hours to establish equilibrium. The reference tubes include: totals 
(T), which indicate the total amount of radioactivity; non-specific binding (NSB), which 
indicates the binding of antigen in the absence of antibody; and maximum binding B0, which 
specifies how much tracer binding takes place in the absence of unlabelled insulin. The antigen-
antibody complexes were then retrieved following the addition of 1ml of precipitant (Table 29), 
and centrifuged (3000rpm, 4°C, 15minutes) followed by aspiration of the supernatant. The 
radioactivity of the remaining pellet was measured using a Packard Cobra II γ counter as counts 
per minute (cpm). The standard curve was generated by plotting cpm against insulin 
concentration, and it was used to quantify islet hormone concentration (ng/ml) of test samples. 
  







Tracer (125I) Antibody Sample 
Total - 100µl - - 
Non-specific 
binding 
- 100µl - - 
Maximum binding 
(B0) 
- 100µl 100µl - 
0.04ng/ml 100µl 100µl 100µl - 
0.08ng/ml 100µl 100µl 100µl - 
0.16ng/ml 100µl 100µl 100µl - 
0.32ng/ml 100µl 100µl 100µl - 
0.64ng/ml 100µl 100µl 100µl - 
1.25ng/ml 100µl 100µl 100µl - 
2.5ng/ml 100µl 100µl 100µl - 
5ng/ml 100µl 100µl 100µl - 
10ng/ml 100µl 100µl 100µl - 
Samples - 100µl 100µl 100µl 





Table 28: Preparation of borate buffer. The reagents were dissolved in 1.8ml dH2O and adjusted to pH 
8.0 with concentrated HCl before the volume was made up to 2L with dH2O. BSA (100% w/v) was then 




Table 29: Preparation of precipitant used for RIA. The 30% PEG stock solution was prepared by 
dissolving 600g Polyethylene glycol (PEG) in 1L dH2O before being made up to 2L with dH2O.  The 
solution was mixed thoroughly and stored at 4°C. 15% PEG was used for the precipitation process to 
retrieve antigen-antibody complexes during RIA. 
  
Reagents Amount (g/2L) Final concentration (mM) 
Boric acid 16.5 133.0 
NaOH 5.4 10.0 
EDTA 7.4 67.5 
Reagents Amount 
30% PEG 500ml 
dH2O 500ml 




2.7 Cell apoptosis and proliferation 
During apoptosis a set of cysteine proteases, known as caspases, are activated by pro-apoptotic 
stimuli, such that activation of initiator caspases (caspase 8 and 10), cleave and activate effector 
caspases (caspase 3 and 7). This results in the degradation of downstream protein substrates 
within the cell and causes significant morphological changes associated with apoptosis such as 
chromatin condensation, nuclear degeneration and cell dehydration (Emamaullee and Shapiro, 
2006). Beta cell mass is regulated by a fine balance between beta cell replication, beta cell 
apoptosis and neogenesis (Bonner-Weir, 2000a, Finegood et al., 1995). Disruption of these 
finely tuned events, such as reduced beta cell proliferation or enhanced beta cell apoptosis, 
would result in reduced beta cell mass and subsequent reduction in insulin output (Leonardi et 
al., 2003). A reduced beta cell mass, primarily as a result of increased apoptosis, has been 
observed in obese and lean patients with type 2 diabetes, and this is considered to be important 
towards the development of type 2 diabetes (Butler et al., 2003b). Furthermore, beta cell 
proliferation is essential in increasing beta cell mass with reports observing 40-50 fold increases 
in beta cells mass in response to increasing insulin demand (Bruning et al., 1997, Yen et al., 
1994). Type 2 diabetic subjects have been reported to show reduced beta cell mass compared to 
control non-diabetic subjects, suggesting that beta cell mass expansion is important for delaying 
or preventing the onset of diabetes (Butler et al., 2003b, Kloppel et al., 1985). This provides 
strategic opportunities for intervention in preventing type 2 diabetes, by restoring beta cell mass 
(Butler et al., 2003b). 
2.7.1: Measurement of cell apoptosis 
In the experiments described in this thesis, caspase 3/7 activities were measured using a caspase 
3/7 Glo® assay kit (Promega). The principle of this assay involves the cleavage of the 
luminogenic substrate (Z-DEVD-amino-luciferin) by caspase 3/7, and the released free amino-
luciferin acts as a substrate for the luciferase enzyme. This generates a luminescent signal, which 
is directly proportional to caspase 3/7 activities.  
MIN6 beta cells were seeded at density of 20,000cells/well, and mouse or human islets were 
placed into each well of a white walled 96-well plate. The cells and islets were incubated for 24 
hours at 37°C (5% CO2/95% air) in 200µl of DMEM (Table 1) and then treated with agents of 
interest in serum-free DMEM in the absence or presence of cytokines (Table 30) for 21 hours at 
37°C (5% CO2/95% air). Caspase 3/7 activities were then measured by incubating the cells for 
one hour with a mixture containing a Caspase-Glo® substrate and buffer at room temperature. 
The luminescent signal generated was detected quantified using a Veritas luminometer (Turner 
Biosystems).  
  




Cytokine   
 
Stock Concentration Volume used Final 
Concentration 
 
TNF-α 1000U/μl 2μl 1U/μl 
IFN-γ 1000U/μl 2μl 1U/μl 
IL-1β 100U/μl 1μl 0.05U/μl 
 
Table 30: Preparation of cytokine cocktail used to induce apoptosis. The cytokine cocktail was prepared 
by mixing each cytokine together in a 0.5ml centrifuge tube. The cytokine mixture was then added to the 
treatment media in the presence or absence of compounds of interest, which was used to treat MIN6 beta 
cells or islets to induce apoptosis. 
2.7.2: Measurement of cell proliferation 
Cell proliferation was measured using a non-radioactive colorimetric immunoassay based on 5-
bromo-2’-deoxyuridine (BrdU) incorporation into cellular DNA. 15,000 MIN6 beta cells were 
seeded per well into a 96 well plate and incubated for 24 hours at 37°C (5% CO2/95% air) in 
200µl DMEM (Table 1). Afterwards, the medium was gently tapped off and the cells were 
treated with 100µl of agents of interest for a further 24 hours at 37°C (5% CO2/95% air). 10µl 
BrdU (10µM) labelling solution was then added to each well and cells were incubated for a 
further 2 hours at 37°C. The medium was then tapped off and 200µl of a denaturing solution 
that was supplied with the assay kit (FixDenat) was added to each well and the samples were 
incubated for 30 minutes at room temperature. The denaturing solution was tapped off and the 
cells were incubated with a peroxidase-conjugated anti-BrdU antibody for 90 minutes at room 
temperature. Once the DNA had been denatured the antibody was able to bind to the 
incorporated BrdU. The antibody conjugate was tapped off and the samples were washed three 
times with 200-300µl washing solution (Table 31). The cells were then incubated with a 
substrate solution at room temperature until colour development was observed (approximately 
20 minutes). The reaction was stopped by adding 25µl of 1M H2SO4 to each well and after 
incubation on a plate shaker for 1 minute absorbance was measured at 450nm using an ELISA 
reader (Hidex Chameleon™V). Further information regarding the reagents used in this assay are 
shown in Table 31. 
  




Reagent Preparation Use 
BrdU labelling solution (10 mM, 
in PBS, pH 7.4) 
BrdU labelling solution was 
diluted 1:100 with sterile culture 
medium (resulting concentration 
100µM). 
Incorporation into cellular DNA 
for labelling proliferating cells 
Anti-BrdU POD working 
solution [Monoclonal  anti-BrdU 
antibody conjugated with 
peroxidase (POD)] 
Anti-BrdU POD was dissolved 
in 1.1 ml dH2O for 10 minutes 
and mixed thoroughly to make 
the stock solution, which was 
diluted 1:100 with antibody 
dilution solution. 
Binding of POD labelled anti-
BrdU antibody to detect 
incorporated BrdU. 
Washing solution (100ml PBS, 
10X concentrate) 
Wash buffer concentrate was 
diluted 1:10 with dH2O. 
Removal of unbound anti-BrdU 
POD 
Substrate solution (100 ml TMB 
(tetramethyl-benzidine) 
- Detection of immune complexes 
FixDenat - Denature DNA 
 
Table 31: Use of Roche BrdU colorimetric immunoassay.reagents for measuring cell proliferation. 
2.8: Statistical analysis 
Numerical data were expressed as mean ± standard error of mean (SEM) in this thesis. 
Statistical analyses were performed using two-tailed unpaired Student’s t tests when comparing 
two groups or ANOVA as appropriate for multiple groups, which were followed up by a post 





Chapter 3: Expression of CCL5 and its receptors by islet cells 
 
  





Chemokines are small chemotactic cytokines that are essential in orchestrating the movement of 
leukocytes to sites of inflammation or injury (Viola and Luster, 2008). They exert their effects 
by activating chemokine receptors (CCRs), which are GPCRs that are commonly known to 
activate Gαi proteins. Although a majority of chemokine responses are inhibited with treatment 
of pertussis toxin (PTx), consistent with Gαi coupling, some chemokine-induced responses 
persist in the presence of PTx suggesting chemokine receptors may also associate with other G-
proteins, such as Gq/11 (Mellado et al., 2001). The interaction between chemokines and 
chemokine receptors are important for the host’s ability to control infection but it can also be 
detrimental, as chemokines have been implicated in the pathophysiology of infectious and 
inflammatory diseases, such as asthma, atherosclerosis and multiple sclerosis, where 
inflammatory cells are directed towards tissue sites resulting in tissue damage due to the 
accumulation of leukocytes (Viola and Luster, 2008). 
CCL5 is produced by a variety of cells such as T-cells, endothelial cells, smooth muscle cells and 
neurons, and it typically recruits a host of immune cells to sites of inflammation (Levy, 2009). 
This is achieved by activating the conventional chemokine receptors CCR1, CCR3 and CCR5. 
CCL5-induced recruitment of lymphocytes and secretion of inflammatory cytokines by 
lymphocytes through CCR activation has been implicated as a contributing factor towards the 
development of T1DM by promoting the autoimmune destruction of beta cells (Carvalho-Pinto 
et al., 2004). CCR5 is up-regulated in T and B-cells in non-diabetic (NOD) mice. Furthermore, 
CCL5 expression is up-regulated in islets of NOD and BALB/c mice, associating CCL5-CCR5 
interaction with the recruitment of lymphocytes into islets and subsequent beta cell destruction 
and development of diabetes (Carvalho-Pinto et al., 2004). 
In 2006, it was established that CCL5 also activated a novel yet atypical chemokine receptor, 
named GPR75. This GPCR only shared 12-16% sequence homology with conventional 
chemokine receptors, and has an abnormally long C-terminus tail. It also does not possess the 
highly acidic N-terminus tail, which is important for basic chemokine interaction (Pease, 2006). 
GPR75 is expressed at the mRNA level by brain, spinal cord and retina but absent in traditional 
chemokine receptor locations such as thymus, spleen and leukocytes, (Sauer et al., 2001). 
Further studies revealed that mouse GPR75 mRNA was expressed in heart, brain, liver, kidney, 
skeletal muscle and embryo and it showed preferential coupling to the Gαq protein (Ignatov et 
al., 2006). This coupling to PLC was corroborated by CCL5-induced elevations of IP3 in human 
embryonic kidney (HEK293) cells and calcium mobilisation in Chinese hamster ovary (CHO-
K1) cells (Ignatov et al., 2006). Additionally, overexpression of GPR75 in murine hippocampal 
cells also enhanced their cell viability (Ignatov et al., 2006).  




It is well-established that the exocytotic release of insulin from beta cells can be regulated by the 
activation of GPCRs expressed in islets (Amisten et al., 2013). Thus, ligands that couple to the 
Gαs protein cause AC activation and cAMP formation, whereas coupling to Gαq activates PLC 
with the subsequent hydrolysis of PIP2 resulting in the generation of IP3 and DAG, both of 
which have been associated with increases in intracellular calcium, which is a central messenger 
for beta cell stimulus-secretion coupling (Jones and Persaud, 1998b). Furthermore, GPR75 is 
expressed by skeletal muscle, liver and kidney, tissues that are associated with metabolic 
diseases, including diabetes mellitus (Ignatov et al., 2006). Additionally, CCL5, the endogenous 
ligand of GPR75, is also expressed by islets. Thus, if this novel and atypical chemokine receptor 
was expressed by islets it may lead to elevations in intracellular calcium and insulin secretion 
through Gαq coupling. Additionally, T2DM is also associated with a reduction in beta cell mass 
and as overexpression of this receptor has been implicated in enhanced cell survival (Ignatov et 
al., 2006). It is possible that activation of GPR75 on beta cells may enhance beta cell survival to 
maintain or improve beta cell mass.  
The aims of this chapter were to confirm CCL5 expression by islets, to identify CCL5 receptor 
mRNA, including GPR75, expression in mouse and human islets and to determine the cellular 
localisation of both CCL5 and GPR75 in mouse and human islets. 
  






To determine mRNA expression RNAs isolated from MIN6 beta cells, mouse islets, mouse 
acinar cells, human islets, human heart and PANC-1 cells, which is an epithelioid cell line from 
a human pancreatic carcinoma of ductal cell origin and is representative of a human exocrine 
cell line (Lieber et al., 1975), were reverse transcribed to cDNA (50µg/µl) as mentioned earlier 
(section 2.3.1 and section 2.3.3). These were amplified either by RT-PCR or qRT-PCR, 
respectively, using primers that were designed to detect target sequences of interest. PCR 
amplicons were visualised by electrophoretic separation of PCR products on 1.8% or 2% 
agarose gels stained with 0.5µg/ml ethidium bromide. Amplicons of interest were extracted, 
purified and sequenced (section 2.3.5) to determine nucleotide homologies to those of the target 
sequences.  
3.2.2: Western blotting 
Extracts were obtained from MIN6 beta cells, mouse islets and human islets (section 2.4.1) and 
protein levels were quantified using the BCA method (section 2.4.2). Proteins within extracts 
were separated by SDS-PAGE (section 2.4.3) before being transferred to PVDF membranes by 
western blotting. The blots were immunoprobed with a rabbit polyclonal GPR75 antibody (1:50 
dilution) and immunoreactive proteins were detected by ECL (section 2.4.4). 
3.2.3: Chromogenic and fluorescent immunohistochemistry 
Fixed C57BL/6 mouse and human pancreatic sections were initially deparaffinised and 
gradually dehydrated before undergoing antigen retrieval by heating tissue sections in a pressure 
cooker pot for 8-15 minutes in citric acid solution (10mM, pH6) until boiling point (section 
2.4.5). The tissue sections were then immunoprobed for proteins of interest using primary 
antibodies for CCL5 and GPR75 (Table 21), before being detected either by a chromogenic 
detection method (section 2.4.5a) or by a fluorescent detection method involving fluorophore-
conjugated antibodies (section 2.4.5b and Table 22). The same sections were immunoprobed 
for insulin, glucagon or somatostatin (Table 21) before being immunostained with fluorescent-
conjugated secondary antibodies (Table 22).  





3.3.1: Detection of CCL5 mRNA in MIN6 beta cells, and mouse and human islets  
RT-PCR analysis identified mRNA expression of the predicted CCL5 185bp amplicon in the 
predicted mouse acinar and islet cDNA preparations (Figure 20). CCL5 mRNA was also 
detected in the mouse hypothalamus cDNA preparations (Figure 20), which served as a positive 
control. An amplicon of the predicted 185bp representing CCL5 was not detected when using 
MIN6 beta cell cDNA preparations as the template (Figure 20). As expected no products were 
detected in the non-template control, which consisted of molecular grade water (Figure 20). A 
150bp amplicon representative of CCL5 was detected when human heart cDNA was used as a 
template, which served as a positive control (Figure 21). In addition, human islet and PANC-1 
cell cDNAs also produced an amplicon of the correct size, but no products were detected in the 







Figure 20: Ethidium bromide stained 1.8% agarose gel showing CCL5 mRNA expression using 
hypothalamus (positive control), acinar cells, mouse islet and MIN6 beta cell cDNAs. An amplicon of the 
predicted size of 185bp was detected in all cDNA preparations except MIN6 β-cell cDNAs. No products 














































Figure 21: Ethidium bromide stained 1.8% agarose gel showing CCL5 mRNA expression using human 
heart, PANC-1cells and islet cDNAs. An amplicon of the predicted size of 150bp was detected in all 


































3.3.2: Protein localisation of CCL5 in mouse and human islets 
Since PCR amplifications indicated that mouse and human islets expressed CCL5 mRNA, 
further experiments were carried out to identify the cellular localisation of this protein within 
islet (section 3.3.1) using a signal amplification approach involving streptavidin-conjugated 
horseradish peroxidase/biotin-with chromagen DAB. Fixed mouse pancreas sections were 
exposed to an antibody directed against CCL5 (Table 21) and immunoreactive proteins were 
detected. It was evident that CCL5 was expressed at the periphery of mouse islets with no 
expression at the core of the islets Figure 22, suggesting CCL5 was expressed by non-beta cells, 
which was consistent with the observation that CCL5 mRNA was not detected in MIN6 beta 
cells (Figure 20). Consecutive sections were immunoprobed in the absence of the CCL5 
antibody, which served as a negative control, and this confirmed there was no non-specific 
immunoreactivity associated with the use of the biotin/HRP/DAB detection system (Figure 22: 
right panel).  
The use of fluorescent-conjugated secondary antibodies, which allowed immunolocalisation of 
CCL5 and islets hormones on the same pancreas sections, using fluorescent-conjugated 
antibodies, confirmed CCL5 did not co-express with insulin in beta cells at the core of the islet 
(Figure 23), which was consistent with the observation using a chromogenic detection method 
(Figure 22). However, CCL5 did co-localise with glucagon secreting alpha cells at the periphery 
of mouse islets, as evidenced by the yellow/orange regions following merging of the images in 
Figure 24. Furthermore, CCL5 also did not co-express with somatostatin secreting delta cells 
(Figure 25). Consecutive mouse pancreas sections were immunoprobed in the absence of the 
CCL5 antibody, which served as a negative control, and this indicated that there was no 
evidence of any non-specific immunoreactivity associated with the observed CCL5 expression 
in mouse islets (Figure 26). Similar immunohistochemical analyses of human pancreas sections 
indicated that the expression profile of CCL5 within human islets was distinct from that seen in 
mouse islets. Thus, immunoprobing of fixed human pancreas sections with CCL5 antibodies 
detected CCL5 expression in both insulin-secreting beta cells (Figure 27) and glucagon-secreting 
alpha cells (Figure 28). No co-expression was observed with somatostatin-secreting delta cells 
(Figure 29), as observed in mouse islets.  
  









Figure 22: Chromogenic staining of CCL5 expression in mouse islets. Paraffin-embedded mouse 
pancreas sections were immunoprobed with an antibody directed against CCL5 (1:10 dilution). 
Immunoreactivity was detected using an HRP-conjugated secondary antibody, which indicated that CCL5 
was expressed by cells at the periphery of the mouse islet (Left panel). A consecutive section was stained 
with an HRP-conjugated secondary antibody only, which served as negative control (Right panel). These 
sections were 7µm thick and images were taken at x20 magnification.   
  










Figure 23: Fluorescent staining of CCL5 and insulin in mouse islets. Paraffin embedded mouse 
pancreas sections were immunoprobed with a CCL5 polyclonal goat IgG antibody, which was 
subsequently tagged with an AlexaFluor488® anti-goat fluorescent conjugated antibody (Left panel).  
This was followed by incubating the pancreas sections with an insulin polyclonal guinea pig antibody and 
then subsequently stained with an AlexaFluor594® anti guinea-pig antibody (Middle panel). Both images 
were merged to detect for protein co-localisation (Right panel). These sections were 7µm thick and 







Figure 24: Fluorescent staining of CCL5 and glucagon in mouse islets. Paraffin embedded mouse 
pancreas sections were immunoprobed with a CCL5 polyclonal goat IgG antibody, which was 
subsequently tagged with an AlexaFluor488® anti-goat fluorescent conjugated antibody (Left panel).  
This was followed by incubating the pancreas sections with a glucagon monoclonal mouse antibody and 
then subsequently stained with an AlexaFluor594® anti-mouse antibody (Middle panel). Both images 
were merged to detect for protein co-localisation Yellow/orange areas indicate co-localisation (Right 
panel). These sections were 7µm thick and images were taken at x20 magnification. 
  
CCL5 Merged Insulin 
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Figure 25: Fluorescent staining of CCL5 and somatostatin in mouse islets. Paraffin embedded 
mouse pancreas sections were immunoprobed with a CCL5 polyclonal goat IgG antibody, which was 
subsequently tagged with an AlexaFluor488® anti-goat fluorescent conjugated antibody (Left panel).  
This was followed by incubating the pancreas sections with a somatostatin monoclonal rat antibody and 
then subsequently stained with an AlexaFluor594® anti-rat antibody (Middle panel). Both images were 
merged to detect for protein co-localisation (Right panel). These sections were 7µm thick and images 






Figure 26: Negative control showing no CCL5 expression in mouse pancreas in the absence of 
CCL5 polyclonal goat IgG antibody. Paraffin embedded mouse pancreas sections were  incubated 
with PBS/0.25% (v/v) Triton X-100/0.25% BSA. This was followed by incubation with a 
AlexaFluor488® anti-goat fluorescent conjugated secondary antibody. These sections were 7µm thick and 
images were taken at x20 magnification.  
CCL5 Merged Somatostatin 





Figure 27: Fluorescent staining of CCL5 and insulin in human islets. Paraffin embedded human 
pancreas sections were immunoprobed with a CCL5 polyclonal goat IgG antibody, which was 
subsequently tagged with an AlexaFluor488® anti-goat fluorescent conjugated antibody (Left panel).  
This was followed by incubating the pancreas sections with an insulin polyclonal guinea pig antibody and 
then subsequently stained with an AlexaFluor594® anti guinea-pig antibody (Middle panel). Both images 
were merged to detect for protein co-localisation. Yellow/orange areas indicate co-localisation. (Right 
panel). These sections were 7µm thick and images were taken at x20 magnification. 
 
Figure 28: Fluorescent staining of CCL5 and glucagon in human islets. Paraffin embedded human 
pancreas sections were immunoprobed with a CCL5 polyclonal goat IgG antibody, which was 
subsequently tagged with an AlexaFluor488® anti-goat fluorescent conjugated antibody (Left panel).  
This was followed by incubating the pancreas sections with a glucagon monoclonal mouse antibody and 
then subsequently stained with an AlexaFluor594® anti-mouse antibody (Middle panel). Both images 
were merged to detect for protein co-localisation Yellow/orange areas indicate co-localisation (Right 
panel). These sections were 7µm thick and images were taken at x20 magnification. 
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Figure 29: Fluorescent staining of CCL5 and somatostatin in human islets. Paraffin embedded 
human pancreas sections were immunoprobed with a CCL5 polyclonal goat IgG antibody, which was 
subsequently tagged with an AlexaFluor488® anti-goat fluorescent conjugated antibody (Left panel). This 
was followed by incubating the pancreas sections with a somatostatin monoclonal rat antibody and then 
subsequently stained with an AlexaFluor594® anti-rat antibody (Middle panel). Both images were merged 
to detect for protein co-localisation (Right panel). These sections were 7µm thick and images were taken 
at x20 magnification.  
CCL5 Merged Somatostatin 




3.3.3: Detection of CCL5 receptor mRNAs in MIN6 beta-cells, and mouse and human 
islets. 
Confirmation of CCL5 mRNA and protein expression in mouse and human islets led us to 
investigate whether mRNAs for the CCL5 receptors GPR75, CCR1, CCR3 and CCR5 were 
expressed by mouse and human islets and by MIN6 beta cells. mRNAs encoding these 
receptors were detected by qRT-PCR analysis, which revealed that GPR75 was the most 
abundantly expressed CCL5 receptor in mouse islets (5.4% of GAPDH expression) compared 
to the very low mRNA expression of CCR1, CCR3 and CCR5 (<0.0002%, 0.60%, 0.24% of 
GAPDH expression, respectively), Figure 30. A similar expression profile was observed in 
human islets, which revealed that GPR75 mRNA was the most abundantly expressed CCL5 
receptor (2.5% of GAPDH expression), compared to the low or non-existent levels of CCR1, 
CCR3 and CCR5 (0.13%, 0.003%, 0% of GAPDH expression, respectively), Figure 31.  
GPR75 mRNA expression was also confirmed in mouse islets and MIN6 beta cells by a 
standard RT-PCR approach by the detection of a 204bp amplicon, which was of the predicted 
size for the primers used. No amplicon was detected in the non-template control, which 
contained molecular grade water only. Furthermore, the cDNA amplicons were extracted and 
pooled together for sequencing, which revealed 99% sequence homology to that of the 
predicted nucleotide sequence of mouse GPR75 (Figure 32). A predicted amplicon of 261bp 
representative of GPR75 mRNA was identified in human islet and PANC-1 cells. GPR75 
mRNA was also detected in human heart tissue, which served as a positive control, and no 
amplicon was observed in the non-template control. The amplicons were subsequently 
extracted and pooled together from human islet and PANC-1 cell cDNA preparations before 
being sequenced. This revealed a 99% sequence homology to that of the predicted nucleotide 
sequence of human GPR75 (Figure 33). Standard RT-PCR revealed that the mRNA expression 
profile of CCL5 receptors corroborated with data from qRT-PCR experiments. CCR1 mRNAs 
were detected in human islet cDNA preparations by detecting a 155bp amplicon. No amplicon 
was detected in the non-template control (Figure 34). CCR3 mRNAs were also detected in 
MIN6 beta cells, mouse islets and human islets. An 181bp amplicon representing CCR3 was 
detected in MIN6 beta cells and mouse islets with no detection observed in the non-template 
control. Sequencing of the extracted amplicon revealed 100% sequence homology to that of the 
predicted nucleotide sequence of CCR3 in mouse (Figure 35). CCR5 mRNAs were also 
detected in MIN6 beta cells and mouse islets by detecting a 168bp amplicon, which was further 
confirmed by sequencing of these amplicons, which revealed 100% sequence homology to that 
of the predicted nucleotide sequence of CCR5 in mouse. No amplicon was detected in the non-
template control (Figure 36).  





Figure 30: mRNA expression of CCL5 receptors by mouse islets. Quantification of CCL5 receptor 
mRNA in mouse islets, expressed as a percentage of GAPDH mRNA levels in the same samples; values 
are means + SEM; n=3, **p<0.01 vs GPR75. 
 
Figure 31: mRNA expression of CCL5 receptors by human islets. Quantification of CCL5 receptor 
mRNA in human islets, expressed as a percentage of GAPDH mRNA levels in the same samples; values 
























Figure 32: GPR75 mRNA expression in mouse. Ethidium bromide stained 2% agarose gel showing 
GPR75 mRNA expression using MIN6 beta cell and mouse islet cDNA preparations. An amplicon of the 
predicted size of 204bp was detected in both cDNA preparations except the non-template preparation 
(molecular grade water), which served as a negative control (Top panel).  PCR thermal cycler protocol 
followed: initial denaturation at 95°C for 2 minutes followed by 35 cycles of denaturation at 95°C for 40 
seconds; annealing at 54°C for 30 seconds; extension at 74°C for 30 seconds, followed by final extension 
at 74°C for 10 minutes and cooling at 4°C for 5 minutes. Sequence homology between predicted 
nucleotide sequence of GPR75 in mouse and that of the nucleotide sequence of cDNA amplicons 
retrieved and pooled from mouse islets and MIN6 beta cells after RT-PCR analysis. The generated 
sequence was then compared to the mouse genome using Pubmed nucleotide BLAST: Alignment 
























Mouse GPR75 sequence homology 
Identities = 160/161 (99%), Gaps = 1/161 (1%) 
Query  783  CTTACCCTTCTTCTCTGGGCGACCAGCTTTACACTTGCCACCTTGGCTACACTGAGAACC  842 
            |||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GPR75  12   CTTA-CCTTCTTCTCTGGGCGACCAGCTTTACACTTGCCACCTTGGCTACACTGAGAACC  70 
Query  843  AATAAGTCCCACCTGTGTCTCCCCATGTCCAGTCTTATGGATGGGGAAGGGAAAGCCATT  902 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GPR75  71   AATAAGTCCCACCTGTGTCTCCCCATGTCCAGTCTTATGGATGGGGAAGGGAAAGCCATT  130 
Query  903  CTGTCTCTGTATGTTGTTGACTTTACCTTCTGTGTTGCTGT  943 
            ||||||||||||||||||||||||||||||||||||||||| 
































Figure 33: GPR75 mRNA expression in human. Ethidium bromide stained 2% agarose gel showing 
GPR75 mRNA expression using human heart, islet and PANC-1 cDNAs. An amplicon of the predicted 
size of 261bp was detected in both cDNA preparations except the non-template preparation (molecular 
grade water), which served as a negative control. PCR thermal cycler protocol followed: initial 
denaturation at 95°C for 2 minutes followed by 35 cycles of denaturation at 95°C for 40 seconds; 
annealing at 56°C for 30 seconds; extension at 74°C for 30 seconds, followed by final extension at 74°C 
for 10 minutes and cooling at 4°C for 5 minutes. (B) Sequence homology between predicted nucleotide 
sequences of GPR75 in human and cDNA amplicons retrieved and pooled from human islets and 
PANC-1 cells after RT-PCR analysis. The generated sequence was then compared to the human genome 
using Pubmed nucleotide BLAST: Alignment software, which indicated 99% homology. The nucleotide 
mismatch are highlighted in red (Bottom panel). 
  
Human GPR75 sequence homology 
Identities = 215/217 (99%), Gaps = 0/217 (0%) 
Query  1269  AGCCGTGGTCACCTGTGTGATCATTGTGCTGTCAGTCCTGGTGTGCTGTCTTCCACTGGG  1328 
             |||||||||| ||||||||| ||||||||||||||||||||||||||||||||||||||| 
GPR75  13    AGCCGTGGTCNCCTGTGTGANCATTGTGCTGTCAGTCCTGGTGTGCTGTCTTCCACTGGG  72 
Query  1329  GATTTCCTTGGTACAGGTGGTTCTCTCCAGCAATGGGAGCTTCATTCTTTACCAGTTTGA  1388 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GPR75  73    GATTTCCTTGGTACAGGTGGTTCTCTCCAGCAATGGGAGCTTCATTCTTTACCAGTTTGA  132 
Query  1389  ATTGTTTGGATTTACTCTTATATTTTTCAAGTCAGGATTAAACCCTTTTATATATTCTCG  1448 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
GPR75  133   ATTGTTTGGATTTACTCTTATATTTTTCAAGTCAGGATTAAACCCTTTTATATATTCTCG  192 
Query  1449  GAACAGTGCAGGGCTGAGAAGGAAAGTGCTCTGGTGC  1485 
             ||||||||||||||||||||||||||||||||||||| 








































Figure 34: CCR1 mRNA expression by human islets. An amplicon of the correct size representing 
CCR1 (155bp) was detected in human islet cDNA. No amplicon was detected in the non-template 
control, which contained molecular grade water. PCR thermal cycler protocol followed: initial 
denaturation at 95°C for 2 minutes followed by 35 cycles of denaturation at 95°C for 40 seconds; 
annealing at 57°C for 30 seconds; extension at 74°C for 30 seconds. This was followed by final extension 
at 74°C for 10 minutes and cooling at 4°C for 5 minutes. PCR products were run on an ethidium 


























Figure 35: CCR3 mRNA expression by mouse islets and MIN6 beta cells. An amplicon of the 
correct size representing CCR3 (181bp) was detected in mouse islet and MIN6 beta cell cDNA 
preparations. No amplicon was detected in the non-template control, which contained molecular grade 
water. PCR thermal cycler protocol followed: initial denaturation at 95°C for 2 minutes followed by 35 
cycles of denaturation at 95°C for 40 seconds; annealing at 60°C for 30 seconds; extension at 74°C for 30 
seconds, followed by final extension at 74°C for 10 minutes and  cooling at 4°C for 5 minutes. PCR 
products were run on an ethidium bromide stained 2% agarose gel and a pBluescript II SK+-Hpa II 
digest marker was used to determine amplicon sizes (Top panel). Sequence homology between the 
predicted nucleotide sequences of CCR3 in mouse and cDNA amplicons retrieved and pooled from 
mouse islet and MIN6 beta cells cDNA preparations after RT-PCR. The generated sequence was 
compared to the mouse genome using Pubmed nucleotide BLAST: Alignment software, which indicated 
100% homology (Bottom panel). 
  
Mouse CCR3 sequence homology 
 
Identities = 117/117 (100%), Gaps = 0/117 (0%) 
 
Query  831  AATGAATATCTTTGGTCTAGCTCTTCCTCTCCTCATTATGGTTATCTGCTACTCAGGAAT  890 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CCR1   35   AATGAATATCTTTGGTCTAGCTCTTCCTCTCCTCATTATGGTTATCTGCTACTCAGGAAT  94 
 
Query  891  CATTAAAACTCTGCTGAGATGTCCCAATAAAAAAAAACACAAGGCCATCCGTCTTAT  947 
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 







































Figure 36: CCR5 mRNA expression by mouse islet and MIN6 beta cell cDNA. An amplicon of the 
correct size representing CCR5 (168bp) was detected in mouse islet and MIN6 beta cell cDNA 
preparations. No amplicon was detected in the non-template control, which contained molecular grade 
water. PCR thermal cycler protocol followed: initial denaturation at 95°C for 2 minutes followed by 35 
cycles of denaturation at 95°C for 40 seconds; annealing at 59°C for 30 seconds; extension at 74°C for 30 
seconds, followed by final extension at 74°C for 10 minutes and  cooling at 4°C for 5 minutes. PCR 
products were run on an ethidium bromide stained 2% agarose gel and a pBluescript II SK+-Hpa II 
digest marker was used to determine amplicon sizes (Top panel). Sequence homology between the 
nucleotide sequences of CCR5 and cDNA amplicons retrieved from mouse acinar cells, mouse islets and 
MIN6 beta cells after RT-PCR analysis. The generated sequence was compared to the mouse CCR5 































Mouse CCR5 sequence homology 
 
Identities = 120/120 (100%), Gaps = 0/120 (0%) 
 
Query  1028  TTATCTCTCAGTGTTCTTCCGAAAACACATGGTCAAACGCTTTTGCAAACGGTGTTCAAT  1087 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CCR5   25    TTATCTCTCAGTGTTCTTCCGAAAACACATGGTCAAACGCTTTTGCAAACGGTGTTCAAT  84 
 
Query  1088  TTTCCAGCAAGACAATCCTGATCGTGCAAGCTCAGTCTATACCCGATCCACAGGAGAACA  1147 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
CCR5   85    TTTCCAGCAAGACAATCCTGATCGTGCAAGCTCAGTCTATACCCGATCCACAGGAGAACA  144 
 
 




3.3.4: Detection of GPR75 proteins and localisation in mouse and human islets. 
As previously shown in section 3.3.3, GPR75 mRNA was detected in mouse and human islets 
as well as in MIN6 beta cells, using non-quantitative and quantitative RT-PCR. Therefore, it was 
important to investigate GPR75 protein expression in islets and beta cells in particular. Western 
blot analysis detected a 59kDa protein representative of GPR75 in MIN6 beta cell, mouse islet 
and human islet protein extracts (Figure 37). However, western blotting only confirmed GPR75 
protein expression in islets but gave no indication as to the localisation of this receptor within 
islets. Therefore, non-fluorescent (chromogenic) and fluorescent IHC detection methods were 
used to achieve this. In brief, mouse and human pancreas sections were immunoprobed in the 
presence of a GPR75 polyclonal rabbit IgG antibody (Figure 38, top panel, left), or in the 
absence of GPR75 primary antibodies which served as a negative control (Figure 38, top panel, 
right). Immunoreactive proteins were detected by a streptavidin-conjugated horseradish 
peroxidase/biotin-based amplification protocol using chromagen DAB (section 2.4.5a) or using 
a fluorophore-linked secondary antibody (Figure 38, bottom panel). 
GPR75 was abundantly expressed by mouse islets and its central localisation suggested its 
presence in beta cells (Figure 38). Fluorescent staining confirmed that GPR75 co-localised with 
insulin-secreting beta cells (Figure 39) and further revealed its presence in glucagon-secreting 
alpha cells (Figure 40) in mouse islets, but it did not co-localise with somatostatin in delta cells 
(Figure 41). Furthermore, GPR75 did not show any immunoreactivity in the surrounding 
exocrine pancreas acinar cells (Figure 38 to Figure 41), which suggested that GPR75 was an 
islet-specific receptor within the mouse pancreas. Consecutive mouse pancreas sections that 
were incubated in the absence of GPR75 antibodies but with a fluorophore-conjugated 
secondary antibody, which served as negative control, confirmed there was no non-specific 
immunoreactivity associated with the observed GPR75 expression by mouse islets (Figure 42).  
In human islets an identical GPR75 expression profile was observed. Thus, chromogenic 
staining revealed that GPR75 was expressed throughout the islet, most likely in beta cells 
(Figure 43). This was confirmed by, fluorescent IHC staining, which indicates that GPR75 was 
co-expressed with insulin in beta cells (Figure 44) and with glucagon in alpha cells (Figure 45), 
but GPR75 did not co-localise with somatostatin in the delta cell population (Figure 46). 
Furthermore, no GPR75 expression was observed in the exocrine pancreas, which again 
suggested that GPR75 is an islet-specific GPCR within the human pancreas (Figure 43 to Figure 
46). Consecutive human pancreas sections that were incubated in the absence of GPR75 
antibodies but in the presence of a fluorophore-conjugated secondary antibody, which served as 
negative controls, confirmed there was no non-specific immunoreactivity associated with the 
observed GPR75 expression by human islets (Figure 47). 








Figure 37: Detection of GPR75 proteins in MIN6 beta cell, mouse and human islet protein extracts. 50-
60μg protein samples were loaded onto 10% polyacrylamide gels and immunoreactive proteins were 
detected by ECL. The proteins were transferred to a PVDF membrane before a GPR75 anti-rabbit 
antibody (1:50) followed by incubation with a horseradish peroxidase-conjugated secondary antibody 
(1:5000), which was used to identify GPR75 expression in MIN6 beta cell, mouse and human islet protein 
extracts by the detection of a 59kDa immunoreactive protein.. The protein size was determined by 

































Figure 38: Chromogenic staining showing GPR75 and insulin expression by mouse islets. 
Paraffin embedded mouse pancreas sections were immunoprobed in the absence (negative control) or 
presence of a GPR75 polyclonal rabbit IgG antibody (1:20 dilution). The same sections were then 
immunoprobed with a universal biotinylated link antibody and subsequently detected using an HRP-
conjugated secondary antibody. These sections were briefly stained with haemotoxylin (Top panel) or 
immunoprobed with an insulin polyclonal guinea pig antibody, and subsequently stained with an 
AlexaFluor594® anti guinea-pig antibody (Bottom panel). The sections were cut 7µm thick and images 
taken at x20 magnification. 
  
GPR75 Merged Insulin 
GPR75 Negative control 





Figure 39: Fluorescent staining of GPR75 and insulin in mouse islets. Paraffin embedded mouse 
pancreas sections were immunoprobed with a GPR75 polyclonal rabbit IgG antibody, which was 
subsequently tagged with an AlexaFluor488® anti-rabbit fluorescent conjugated antibody (Left panel). 
This was followed by incubating the pancreas sections with an insulin polyclonal guinea pig antibody and 
subsequently stained with an AlexaFluor594® anti guinea-pig antibody (Middle panel). Both images were 
merged to observe protein co-localisation. Yellow/orange areas indicate co-localisation (Right panel). 







Figure 40: Fluorescent staining of GPR75 and glucagon in mouse islets. Paraffin embedded mouse 
pancreas sections were immunoprobed with a GPR75 polyclonal rabbit IgG antibody, which was 
subsequently tagged with an AlexaFluor488® anti-rabbit fluorescent conjugated antibody (Left panel).  
This was followed by incubating the pancreas sections with a glucagon monoclonal mouse antibody and 
subsequently stained with an AlexaFluor594® anti-mouse antibody (Middle panel). Both images were 
merged to observe any protein co-localisation Yellow/orange areas indicate co-localisation (Right panel). 
Sections were cut 7µm thick and images taken at x20 magnification. 
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Figure 41: Fluorescent staining of GPR75 and somatostatin in mouse islets. Paraffin embedded 
mouse pancreas sections were immunoprobed with a GPR75 polyclonal rabbit IgG antibody, which was 
subsequently tagged with an AlexaFluor488® anti-rabbit fluorescent conjugated antibody (Left panel).  
This was followed by incubating the pancreas sections with a somatostatin monoclonal rat antibody and 
subsequently stained with an AlexaFluor594® anti-rat antibody (Middle panel). Both images were merged 







Figure 42: Negative control showing no GPR75 expression in mouse pancreas in the absence of 
GPR75 polyclonal rabbit IgG antibody. Paraffin embedded mouse pancreas sections were  incubated 
with PBS/0.25% (v/v) Triton X-100/0.25% BSA. This was followed by incubation with an 
AlexaFluor488® anti-rabbit fluorescent conjugated secondary antibody. Sections were cut 7µm thick and 
images taken at x20 magnification. 
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Figure 43: Chromogenic staining showing GPR75 and insulin expression by human islets. 
Paraffin embedded human pancreas sections were immunoprobed with a GPR75 polyclonal rabbit IgG 
antibody (1:20 dilution). The same sections were then immunoprobed with a universal biotinylated link 
antibody and subsequently detected using an HRP-conjugated secondary antibody. The same sections 
were immunoprobed with an insulin polyclonal guinea pig antibody and subsequently stained with an 
AlexaFluor594® anti guinea-pig antibody. The sections were cut 7µm thick and images taken at x20 
magnification.  
  
GPR75 Merged Insulin 





Figure 44: Fluorescent staining of GPR75 and insulin in human islets. Paraffin embedded human 
pancreas sections were immunoprobed with a GPR75 polyclonal rabbit IgG antibody, which was 
subsequently tagged with an AlexaFluor488® anti-rabbit fluorescent conjugated antibody (Left panel).  
This was followed by incubating the pancreas sections with an insulin polyclonal guinea pig antibody and 
then subsequently stained with an AlexaFluor594® anti guinea-pig antibody (Middle panel). Both images 
were merged to observe any protein co-localisation. Yellow/orange areas indicate co-localisation (Right 
panel). Sections were cut 7µm thick and images taken at x20 magnification. 
 
 
Figure 45: Fluorescent staining of GPR75 and glucagon in human islets. Paraffin embedded human 
pancreas sections were immunoprobed with a GPR75 polyclonal rabbit IgG antibody, which was 
subsequently tagged with an AlexaFluor488® anti-rabbit fluorescent conjugated antibody (Left panel).  
This was followed by incubating the pancreas sections with a glucagon monoclonal mouse antibody and 
then subsequently stained with an AlexaFluor594® anti-mouse antibody (Middle panel). Both images 
were merged to observe any protein co-localisation Yellow/orange areas indicate co-localisation (Right 





GPR75 Merged Insulin 
GPR75 Merged Glucagon 





Figure 46: Fluorescent staining of GPR75 and somatostatin in human islets. Paraffin embedded 
human pancreas sections were immunoprobed with a GPR75 polyclonal rabbit IgG antibody, which was 
subsequently tagged with an AlexaFluor488® anti-rabbit fluorescent conjugated antibody (Left panel). 
This was followed by incubating the pancreas sections with a somatostatin monoclonal rat antibody and 
then subsequently stained with an AlexaFluor594® anti-rat antibody (Middle panel). Both images were 
merged to observe any protein co-localisation (Right panel). Sections were cut 7µm thick and images 







Figure 47: Negative control showing no GPR75 expression in human pancreas in the absence of 
GPR75 polyclonal rabbit IgG antibody. Paraffin embedded mouse pancreas sections were  incubated 
with PBS/0.25% (v/v) Triton X-100/0.25% BSA. This was followed by incubation with an 
AlexaFluor488® anti-rabbit fluorescent conjugated secondary antibody. Sections were cut 7µm thick and 
images taken at x20 magnification. 
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To date, very little is known about GPR75 and there have been no reports implicating it in the 
development of, or the protection from, disease states. Circumstantial evidence has so far 
indicated that GPR75 may be involved in protecting neuronal cells in Alzheimer patients, but 
experiments have only been carried out using mouse models (Ignatov et al., 2006). Apart from 
this there has been no other publications associating physiological function with GPR75 
activation in primary tissues, even though mRNA encoding this receptor is expressed in a wide 
variety of mouse tissues, including those that have been implicated in metabolic diseases, such 
as liver, skeletal muscle and kidney (Ignatov et al., 2006, Sauer, 2001). It has been reported that 
CCL5, which is the endogenous ligand for GPR75, is also expressed in islets of NOD mice 
(Carvalho-Pinto et al., 2004), which show spontaneous development of T1DM due to the attack 
and destruction of beta cells by activated immune cells (Kachapati et al., 2012, King and 
Sarvetnick, 2011). Therefore, this chapter focused on GPR75 and CCL5 expression by MIN6 
beta cells, mouse islets and human islets, which were used as cellular models for functional 
analyses later on in this thesis. 
CCL5 is expressed by a variety of cell types such as endothelial cells, platelets, T-cells, and 
neurons (Johnstone et al., 1999) and it has also been detected in islets in BALB/c and NOD 
mice (Carvalho-Pinto et al., 2004). It has been reported that chronic low-grade inflammation 
normally precedes T2DM development by several years (Pradhan et al., 2001, Pickup, 2004) 
along with the up-regulation of chemokines, which have also been implicated in the 
development of T2DM. It has been reported that the circulating concentration of CCL5 
significantly increased by 42% in T2DM patients from 19.93ng/ml to 28.29ng/ml (Herder et al., 
2005). Furthermore, CCL5 has also been associated with an increase in T2DM incidence 
(Nomura et al., 2000) and genetic polymorphisms associated with the CCL5 gene are associated 
with the development of DM (Jeong et al., 2010). Thus, the association of CCL5 with DM 
complications led to the investigation of the expression of CCL5 at the mRNA and protein level 
in mouse and human islets as well as MIN6 beta cells. 
CCL5 mRNA was detected in mouse islets but not in MIN6 beta cells (Figure 20), and 
assessment of CCL5 protein expression by mouse islets revealed that it did not co-localise to 
beta cells (Figure 23), which was consistent with the absence of CCL5 mRNA expression in 
MIN6 beta cells. However, CCL5 was expressed by alpha cells of mouse islets (Figure 24). In 
contrast, in human islets CCL5 was present in beta cells (Figure 27) and also in alpha cells 
(Figure 28). Furthermore, CCL5 mRNA was also detected in mouse acinar cells (Figure 20) and 
the human PANC-1 exocrine cell line (Figure 21) but there was no evidence of its expression in 
mouse and human exocrine cells of pancreas sections immunoprobed with an antibody directed 
against CCL5. This may be explained by the CCL5 gene being transcribed but not translated in 




the exocrine pancreas or that the CCL5 protein is expressed at such low levels, that it is 
undetectable by IHC methods used in this study. 
GPR75 mRNA was identified as the most abundantly expressed CCL5 receptor in mouse and 
human islets, whereas, conventional CCL5 receptor mRNAs (CCR1, CCR3 and CCR5) were 
detected at very low or non-existent levels in mouse and human islets, with varied expression 
between the two species (Figure 30 and Figure 31). The low expression of traditional CCL5 
receptors observed in islets may be explained by the fact that healthy islets were used for 
experiments throughout this thesis, with evidence suggesting chemokine receptor expression 
can be up regulated in certain disease states such as obesity, which is characterised by chronic 
low grade inflammation that shows enhanced secretion of inflammatory cytokines and 
chemokines (Matter and Handschin, 2007). In addition, mRNA and protein expression of 
CCL5 and CCR5 are up-regulated in white adipose tissue of obese humans with metabolic 
syndrome (Wu et al., 2007). Similarly, CCR1, CCR3 and CCR5 mRNAs are significantly up-
regulated in adipose tissue of obese patients (Huber et al., 2008). Very little is known about 
CCL5 receptor mRNA expression in islets of T2DM patients, but it might be predicted that 
conventional CCL5 receptors would be up-regulated in the inflammatory environment, which 
might be involved in the islet dysfunction associated with T2DM. Future studies would be of 
obvious interest in determining whether expression of CCL5 receptors is modified in islets of 
obese and T2DM patients.  
mRNA detection methods showed for the first time that GPR75 mRNA was detected in mouse 
islets as well as MIN6 beta cells, which demonstrated that GPR75 is a beta cell expressed 
receptor (Figure 32). Furthermore, GPR75 mRNA was also detected in human islets and 
PANC-1 cells, (Figure 33). This suggested that GPR75 mRNA was not only detectable in 
human islets but also in human acinar cells. Protein expression confirmed that  GPR75 proteins 
were detected in mouse and human islets, consistent with the predicted GPR75 molecular 
weight of 59kDa (Figure 37). This was further supported by chromogenic staining  experiments, 
which revealed abundant GPR75 expression throughout the mouse and human islets (Figure 38 
and Figure 43), and co-incubation with insulin (Figure 39 and Figure 44), glucagon (Figure 40 
and Figure 45) and somatostatin (Figure 41 and Figure 46) antibodies indicated that it was 
expressed by beta cells and alpha cells, but not by delta cells. No GPR75 expression was 
observed in human acinar cells even though GPR75 mRNA was detected in PANC-1 exocrine 
cells, which suggests that GPR75 might be transcribed by acinar cells but not be translated into 
protein or that it may require a particular signal to stimulate GPR75 mRNA translation into 
protein. Another explanation could be the low protein expression level of GPR75 in the 
exocrine environment, which may not be detectable using current detection methods. 




CCL5 is secreted by a variety of cells such as T-cells, platelets, endothelial cells and neurons 
(Schall et al., 1988, Levy, 2009, Appay and Rowland-Jones, 2001). It has previously been shown 
to be expressed by mouse islets (Carvalho-Pinto et al., 2004). So far in this thesis immuno 
detection experiments have identified more specifically that CCL5 is expressed by alpha and 
beta cell populations. This may suggest that CCL5 is released into the intra-islet environment in 
response to an inflammatory insult in order to quickly and efficiently recruit lymphocytes into 
the islet. However, this is likely to occur through the activation of Gαi coupled CCR1, CCR3 
and/or CCR5 and quantitative PCR experiments have identified that these CCRs are expressed 
at very low or undetectable levels in healthy islets. Furthermore, GPR75 is the most abundant 
CCL5 receptor in islets and its expression by beta cells strongly suggests that, in healthy islets at 
least, CCL5 activation of GPR75 may regulate beta cell function in a non-immunological 
environment, which has previously never been identified.   
The species difference in CCL5 expression might be explained by different CCL5 modes of 
action, with CCL5 activation of GPR75 influencing a possible paracrine signalling mechanism in 
mouse islets involving release of CCL5 from alpha cells and activation of GPR75 on alpha and 
beta cells whereas in human islets CCL5 could have autocrine and paracrine effects at beta cells 
and alpha cells. Mouse islets show evident anatomical subdivisions and they consist of a high 
proportion of beta cells ≈80-90%, usually located at the core of the islet, whereas non-beta cells 
(alpha cells ≈10-20% and delta cells ≈<10%) are usually located at the islet periphery (Cabrera 
et al., 2006). In contrast, human islets retain a lower proportion of beta cells (≈60%) and a 
higher proportion of alpha cells (≈30%). Moreover, a larger proportion of beta cells are in close 
proximity to non-beta cells, as discussed in section 1.2.1. This may explain why CCL5 
expression is limited only to the alpha cell population in mouse islets, as this could be sufficient 
to influence beta cell function by activating GPR75, which is expressed by the large number of 
beta cells present in the mouse islet and therefore influence beta cell function in a controlled 
manner, whereas the broader expression pattern of CCL5 in human islets may be required to 
activate GPR75 expressed on beta cells more robustly due to the lower number of beta cells 
present in human islets. It is also possible that the species variability in CCL5 expression may 
demonstrate an evolutionary adaptation to different diet or calorie intake or other 
environmental factors, but further studies are required to support these hypotheses. Therefore, 
it is plausible that CCL5 receptor activation in islets may regulate beta cell function and survival 
during an inflammatory insult or against infectious agents due to the ability of CCL5 to attract 
lymphocytes. However, the CCL5 mode of action on islet function may entirely depend on 
whether CCL5 activates either conventional CCL5 receptors or the novel and atypical CCL5 
receptor, GPR75. Therefore, the following chapters in this thesis primarily focused on the 




Chapter 4: The effect of CCL5 on insulin and glucagon secretion. 
 




As demonstrated in the previous chapter, CCL5 is expressed by mouse and human islets. 
GPR75 is also abundantly expressed compared to conventional CCL5 receptors in mouse and 
human islets. Furthermore, it was determined that GPR75 is specifically expressed by beta cells, 
which secrete insulin in response to elevated blood glucose levels, and alpha cells, which secrete 
glucagon in response to low blood glucose levels. Therefore, it was important to investigate the 
potential effects of CCL5 on islet hormone secretion, which has not been previously studied to 
date. However, chemokines have been implicated in the pathogenesis of T2DM and reports 
have shown significantly higher circulating concentrations of CCL5 in T2DM patients 
compared to healthy control subjects (Nomura et al., 2000, Herder et al., 2005).  
Ignatov and colleagues demonstrated that IP3 formation and calcium mobilisation in GPR75 
expressing cells were elevated in response to CCL5 (Ignatov et al., 2006), which are typical 
hallmarks of receptor association with the Gαq protein that stimulates PLC-mediated hydrolysis 
of PIP2. GPCRs that couple to the Gαq protein have been associated with potentiation of 
glucose-induced insulin secretion (Sassmann et al., 2010, Amisten et al., 2013, Ahren, 2009). 
Activation of Gαq protein coupled receptors results in the activation of PLC, which promotes 
IP3 and DAG formation via the hydrolysis of the membrane bound PIP2. IP3 promotes calcium 
mobilisation from internal stores and thus elevates cytosolic calcium levels (Burant, 2013), 
which is an important signal for promoting the insulin secretory process. For example, GPR40 
is activated by free fatty acids to potentiate insulin secretion (Burant, 2013, Itoh et al., 2003) by 
primarily signalling through the Gαq-PLC pathway, which stimulates calcium mobilisation from 
the endoplasmic reticulum (ER) due to elevations in IP3 formation (Bowe et al., 2009). In 
addition, muscarinic (M3) receptor activation by acetylcholine also enhances glucose-induced 
insulin secretion (Hauge-Evans et al., 2014, Gautam et al., 2006) through DAG-dependent PKC 
activation following PLC cleavage of PIP2 (Jones and Persaud, 1998b). Therefore, identification 
that GPR75 is coupled to Gαq protein in CHO cells and is also expressed in mouse and human 
islets and in particular by beta cells suggested it was important to investigate the potential novel 
role of CCL5 in regulating islet function by mediating islet hormone secretion, which is the 
focus of this chapter. 
  





4.2.1: Insulin and glucagon secretion: Static incubation 
MIN6 beta cells, isolated mouse islets and human islets were used for static measurements of 
insulin secretion. MIN6 beta cells were seeded at a density of 30,000 cells/well in 96 well plates 
and incubated overnight at 37°C (5% CO2/ 95% air) in DMEM (Table 1). MIN6 beta cells were 
pre-incubated with a physiological buffer (Table 23) supplemented with 2mM glucose for 2 
hours and then treated with 200µl of agents of interest for 1 hour at 37°C (5% CO2/ 95% air). 
160µl of supernatant was retrieved and insulin content was quantified by radioimmunoassay 
after diluting samples with borate buffer (1:5 dilution).  
Islets isolated from ICR mice and human pancreases were incubated overnight at 37°C (5% 
CO2/ 95% air) in appropriate media (Table 1). Islets were then pre-incubated with a 
physiological buffer (Table 23) supplemented with 2mM glucose at 37°C for 1 hour after which 
three or nine islets per replicate for insulin and glucagon secretion experiments, respectively, 
were treated with 600µl of agents of interest for 1 hour at 37°C (5% CO2/ 95% air). 450µl of 
supernatant was collected and insulin and glucagon release were measured by 
radioimmunoassay. For quantifying insulin content samples were diluted (1:5) with borate 
buffer, whereas neat samples were used for quantifying glucagon content. 
 4.2.2: Insulin secretion: Perifusion 
Measurement of dynamic insulin secretion from 80-100 isolated mouse and human islets was 
carried out by transferring islets into Swinnex chambers containing 1µm pore-size nylon filters 
and they were pre-perifused with a physiological buffer (Table 23) supplemented with 2mM 
glucose (0.5ml/minute, 70 minutes, 37°C). Islets were then perifused with agents of interest 
(section 2.6.2). Perifusate samples were collected every 2 minutes for the duration of the 
experiments and insulin released from the islets was measured by radioimmunoassay (section 
2.6.3).  
  





4.3.1: Effect of CCL5 on mouse islet hormone secretion 
The endogenous expression of CCL5 by mouse islet alpha cells along with the expression of 
GPR75 by beta cells and alpha cells suggested the importance of investigating the functional 
effects of CCL5 on insulin and glucagon secretion by challenging isolated mouse and human 
islets, as well as MIN6 beta cells, with exogenous CCL5.  
The effects of exogenous CCL5 on insulin secretion from MIN6 beta cells were determined 
prior to experimenting with primary mouse and human islets, due to the limited availability and 
cost associated with the use of primary islets. Treatment of MIN6 beta cells with increasing 
CCL5 concentrations (0.25nM to 250nM) stimulated insulin secretion by approximately 2-fold 
in the presence of 2mM glucose (Figure 48a). Furthermore, 2.5nM CCL5 was also able to 
significantly potentiate insulin secretion from MIN6 beta cell by 63% at 20mM glucose (Figure 
48b), and a 22% increase in glucose-induced insulin secretion was observed with 25nM CCL5 at 
20mM glucose (Figure 48c). The identification of a stimulatory effect of CCL5 on insulin 
secretion from MIN6 beta cells suggested that CCL5 may also stimulate insulin release from 
mouse islets. 
Static incubation experiments using isolated mouse islets demonstrated 25fM to 25nM CCL5 
significantly potentiated insulin secretion at 20mM glucose, in a near dose dependent manner 
with an approximate 40-150% increase in insulin secretion in response to 25fM and 25nM 
CCL5 and an approximate 2.5-fold increase in insulin secretion observed after 2.5pM CCL5 
(Figure 49). As illustrated in Figure 50a, dynamic insulin secretion experiments revealed that 
CCL5 (20nM) reversibly increased insulin secretion from islets by approximately 2-fold at 2mM 
glucose and insulin secretion levels returned to basal upon withdrawal of CCL5.  The same islets 
showed a robust insulin secretory response when challenged with 20mM glucose, which 
demonstrated that CCL5 was not detrimental to islet viability and normal beta cell function was 
preserved. In parallel experiments, insulin secretion was potentiated in mouse islets when 
challenged with 20mM glucose and responded in a typical biphasic fashion, which consisted of a 
transient first phase increase followed by a sustained plateau second phase of insulin secretion. 
This secretory response to glucose was further potentiated (1.9-fold) when islets were 
challenged with 20nM CCL5 (Figure 50b). Furthermore, when the CCL5 stimulus was removed 
insulin secretion failed to return to levels prior to the CCL5 stimulus, which suggested that the 
effects of CCL5 at 20mM glucose may be irreversible (Figure 50b). 
Glucagon secretion was also measured from isolated mouse islets since GPR75 expression was 
identified on alpha cells. Isolated mouse islets were initially treated with 20mM arginine to 
stimulate glucagon secretion before treatment with exogenous CCL5. As illustrated in Figure 51, 




glucagon secretion was significantly stimulated when mouse islets were challenged with 20mM 
arginine and this was significantly potentiated by 60% when islets were exposed to 2.5nM 
CCL5. 
  




Figure 48: The effect of various concentrations of CCL5 on insulin secretion from MIN6 beta 
cells at sub-stimulatory and stimulatory glucose concentrations. MIN6 beta cells seeded at a density 
of 30,000 cells per well were pre-incubated for 2 hours with a physiological buffer supplemented with 
2mM glucose. Cells were then treated with increasing concentrations of CCL5 for 1 hour in a 
physiological buffer supplemented with 2mM glucose (a). Data expressed as Mean ± SEM, n=8, 
***P<0.001, **P<0.01 one way ANOVA: No CCL5 vs CCL5, or 20mM glucose (b & c). Data expressed 






















































































































Figure 49: The effect of increasing concentrations of CCL5 on insulin secretion from mouse 
islets. Isolated mouse islets were pre-incubated with a physiological buffer supplemented with 2mM 
glucose for 1 hour at 37°C. Islets were then treated with increasing concentrations of CCL5 for 1 hour at 
37°C in a physiological buffer supplemented with 20mM glucose. Insulin secretion was quantified by 








































Figure 50: The effect of CCL5 on dynamic insulin secretion from isolated mouse islets at sub-
stimulatory and stimulatory glucose concentrations. Isolated mouse islets were pre-perifused for 70 
minutes with a physiological buffer supplemented with 2mM glucose at 37°C before being perifused with 
exogenous CCL5 in the presence of 2mM glucose (a) or 20mM glucose (b). Data expressed as Mean ± 






























































































Figure 51: The effect of CCL5 on arginine-induced glucagon secretion from mouse islets. Isolated 
mouse islets were pre-incubated for 1 hour with a physiological buffer supplemented with 2mM glucose. 
Islets were then exposed to 20mM arginine in the absence or presence of CCL5 (2.5nM). Glucagon 









































4.3.2: Effect of exogenous CCL5 on human islet hormone secretion 
As illustrated in Figure 52, static incubation experiments demonstrated that exogenous CCL5 
(10nM) significantly potentiated glucose-induced insulin secretion from isolated human islets by 
approximately 2-fold. Dynamic insulin secretion studies also revealed human islets initiated and 
potentiated insulin secretion at 2mM and 20mM glucose, respectively, when challenged with 
10nM CCL5 (Figure 53), which was consistent with observations using isolated mouse islets 
(Figure 50). There was a transient 5.5-fold stimulation of insulin secretion at 2mM glucose in 
response to 10nM CCL5, which was in contrast to a smaller and sustained secretory response 
observed in mouse islets when challenged with CCL5. The human islets showed an appropriate 
secretory response to 20mM glucose after exposure to CCL5, confirming their viability and 
functional preservation (Figure 53a). The response to CCL5 at 20mM glucose showed an 
evident biphasic response consisting of an initial transient increase in insulin secretion of 
approximately 1.9-fold followed by a second phase, in which insulin secretion gradually returned 
to levels prior to the CCL5 stimulus (Figure 53b).  
Furthermore, since GPR75 was also expressed by alpha cells in human islets the effects of 
CCL5 on human islet glucagon secretion were also investigated. As shown in Figure 54, 20mM 
arginine alone significantly increased glucagon secretion from human islets by 4.2-fold. 
However, in contrast to the stimulatory effects of CCL5 on arginine-induced glucagon release 
from mouse islets, arginine-induced glucagon secretion from human islets was significantly 
inhibited by 26% in the presence of 10nM CCL5 (Figure 51).  
  












Figure 52: The effect of CCL5 on insulin secretion from human islets. Isolated human islets were 
pre-incubated with a physiological buffer supplemented with 2mM glucose for 1 hour at 37°C. Islets were 
then treated with CCL5 (10nM) in the presence of a physiological buffer supplemented with 20mM 
glucose for 1 hour at 37°C. Insulin secretion was quantified by radioimmunoassay. Data expressed as 




































Figure 53: The effect of CCL5 on dynamic human islet insulin secretion at sub-stimulatory and 
stimulatory glucose concentrations. Isolated human islets were pre-perifused for 70 minutes at 37°C 
with a physiological buffer supplemented with 2mM glucose. Islets were then perifused with CCL5 
(10nM) in the presence of a physiological buffer supplemented with either 2mM glucose (a) or 20mM 
glucose (b) at 37°C. Insulin secretion was quantified by radioimmunoassay. Data expressed as Mean ± 
SEM, n=4, percentage of insulin secretion at 2mM glucose. ***P<0.001: CCL5 peak stimulation vs basal; 

























































































Figure 54: The effect of CCL5 on arginine-induced glucagon secretion from human islets. 
Isolated human islets were pre-incubated with a physiological buffer supplemented with 2mM glucose for 
1 hour at 37°C. The islets were then treated with a physiological buffer supplemented with 20mM 
arginine in the absence or presence of exogenous CCL5 (10nM). Glucagon was quantified by 















































GPR75 is coupled to the Gαq protein in CHO-K1 cells and CCL5 stimulated calcium 
mobilisation in CHO-K1 cells that overexpressed GPR75 (Ignatov et al., 2006). In addition, 
CCL5-induced calcium mobilisation in CHO-K1 cells was inhibited when they were treated 
with a PLC inhibitor (U73122) but it was not significantly affected by PTx, indicating effects 
independent of Gαi/Gαo signalling (Ignatov et al., 2006). CCL5 also elevated IP3 formation in 
HEK293 cells expressing GPR75 (Ignatov et al., 2006). Gαq protein-coupled receptors are 
known to promote insulin secretion (Amisten et al., 2013, Sassmann et al., 2010). For example, 
cholinergic stimulation of the muscarinic (M3) receptor, which is coupled to Gαq and is 
expressed by beta cells, activates PLC and generates IP3 and DAG via PIP2 hydrolysis. IP3 
induces calcium mobilisation from internal calcium stores (Gilon and Henquin, 2001), whilst 
DAG activates DAG-sensitive PKC isoforms (Gilon and Henquin, 2001, Jones and Persaud, 
1998b). Both of these second messengers promote insulin secretion (Gilon and Henquin, 2001). 
GPR54 is another Gαq coupled receptor that can potentiate GSIS in mouse islets (Hauge-Evans 
et al., 2006, Bowe et al., 2009), and signalling via this receptor can be blocked in the presence of 
U73122 (Bowe et al., 2009). This supports the notion that GPR54 can induce insulin secretion 
by signalling through the Gαq-PLC pathway, which elevates cytosolic calcium presumably 
through IP3 generation and liberation of calcium from the endoplasmic reticulum (Bowe et al., 
2009). Furthermore, GPR54 is also expressed by both alpha and beta cells in mouse islets and is 
activated by kisspeptin (Hauge-Evans et al., 2006). It is worth noting that this is similar to the 
expression profile of GPR75, which is also expressed by alpha and beta cells of both mouse and 
human islets. Therefore, it is possible that GPCRs may regulate islet function in a paracrine 
and/or autocrine manner.  
CCL5 is also endogenously expressed in islets, but in a species-dependent manner. Thus, it is 
expressed in alpha cells of mouse islets, but in alpha and beta cells of human islets. It is 
conceivable that CCL5 may activate GPR75, which may go on to regulate intra-islet hormone 
secretion in a paracrine and/or autocrine manner. Experiments in this chapter showed that 
CCL5 not only initiated insulin secretion but it also potentiated GSIS from MIN6 beta cells 
(Figure 48), mouse islets (Figure 50) and human islets (Figure 53). These data demonstrated for 
the first time that CCL5, presumably through the activation of GPR75, can stimulate insulin 
secretion from beta cells.  
Dynamic insulin secretion experiments using mouse islets (Figure 50a) and human islets (Figure 
53a) demonstrated that CCL5 could initiate insulin secretion at 2mM glucose. To avoid 
inappropriate insulin secretion under hypoglycaemic conditions, receptor-operated 
secretagogues usually potentiate GSIS rather than initiate insulin secretion (Henquin, 2011). It is 
likely that the stimulatory effect of CCL5 in the absence of a glucose stimulus may highlight a 
### 




potential paracrine effect of glucagon, which is known to be released at low glucose 
concentrations and inhibited at high glucose concentrations (Nadal et al., 1999, Ishihara et al., 
2003). It was reported that glucagon could stimulate insulin secretion (Samols et al., 1965) from 
an isolated perfused rat pancreas at 5mM glucose by activating glucagon receptors (GluR) 
expressed on beta cells (Kawai et al., 1995, Wojtusciszyn et al., 2008). Expression of CCL5 and 
GPR75 by alpha cells of mouse and human islets, as described in chapter 3, coupled with 
CCL5-induced glucagon secretion from mouse islets (Figure 51), suggests GPR75 activation on 
alpha cells stimulates glucagon secretion, which may stimulate insulin secretion in a paracrine 
manner. This may be achieved by two possible mechanisms: CCL5 released from alpha cells 
may directly activate GPR75 on beta cells to stimulate insulin secretion; or CCL5 stimulates 
GPR75 expressed by alpha cells and stimulates glucagon release in an autocrine manner and 
thus stimulates insulin secretion by activating GluR expressed on beta cells (Figure 55). This 
direct and/or indirect approach of stimulating insulin secretion via CCL5-GPR75 activation 
could explain why GPR75 is expressed by beta cell and alpha cell populations of mouse and 
human islets. Also, the irreversible effects of CCL5-induced potentiation of insulin secretion at 
20mM glucose (Figure 50b), may be explained by elevations in glucagon induced by CCL5, 
which may activate beta cell GluR and thus continue to stimulate insulin secretion in the 
absence of CCL5.  
The insulin secretory profile from human islets differed to that of mouse islets. Exposure of 
human islets to CCL5 stimulated insulin secretion by 5.5-fold at sub-stimulatory glucose 
concentrations, and also potentiated GSIS by approximately 2-fold (Figure 52 and Figure 53b). 
Both responses were transient and returned to pre-stimulatory levels even before withdrawal of 
the CCL5 stimulus. This was in contrast to the smaller and sustained responses observed in 
mouse islets (Figure 50). The more pronounced stimulatory effect of CCL5 on insulin secretion 
at sub-stimulatory glucose concentrations in human islets (Figure 53a) could be explained by a 
more robust activation of GPR75 by the controlled effects of exogenously administered CCL5 
and that which is endogenously expressed by both beta cell and alpha cell populations in human 
islets. This could potentially result in a higher intra-islet concentration of CCL5 compared to 
mouse islets and thus stimulate insulin secretion either directly, by activating GPR75 expressed 
on beta cells, or indirectly, by stimulating glucagon secretion from alpha cells, which may go 
onto stimulate insulin secretion through GluR activation as previously suggested for mouse 
islets. In human islets, a majority, if not all beta cells are in contact with alpha and/or delta cells 
(Bosco et al., 2010). It has been demonstrated that a single intercellular contact between 
individual isolated human beta cells and alpha cells can stimulate insulin secretion, presumably 
through activation of GluR expressed on beta cells (Wojtusciszyn et al., 2008, Kawai et al., 
1995). Furthermore, islets rich in glucagon have been reported to have a higher sensitivity to 
glucose by secreting more insulin (Jiang and Zhang, 2003, Pipeleers et al., 1985). This indicates a 




paracrine influence of glucagon on neighbouring beta cells and may explain the higher levels of 
insulin secretion from human islets when exposed to CCL5, as previously suggested for mouse 
islets. However, experiments using human islets have demonstrated that CCL5 inhibits arginine-
induced glucagon secretion (Figure 54), which is in contrast to the stimulatory response 
observed with mouse islets. It is conceivable that the higher CCL5-induced insulin secretory 
output observed in human beta cells may activate insulin receptors (InsR) expressed on alpha 
cells, resulting in inhibition of glucagon secretion from alpha cells (Diao et al., 2005, Kawamori 
et al., 2009, Kaneko et al., 1999). Therefore, excessive insulin secretion may inhibit glucagon 
secretion by over-riding the initial stimulatory effect on glucagon secretion associated with 
GPR75 activation by CCL5, and thus provide a protective paracrine mechanism by inhibiting 
glucagon secretion and restricting further insulin output (Figure 57). One way of elucidating the 
true effect of CCL5 on glucagon secretion would be to antagonise the effects of insulin acting 
on alpha cells in isolated islets using antibodies directed against InsR. 
Also, the excessive insulin secretion in human islets in response to CCL5 may explain the 
transient nature of this response by applying the ‘brake’ on CCL5-induced glucagon secretion, 
which would prevent further stimulation of GluR on beta cells and restrict insulin output 
(Figure 57). It is also possible that the robust activation of GPR75 may result in receptor de-
sensitisation (Kelly et al., 2008, Krupnick and Benovic, 1998, Drake et al., 2006) through 
GPR75 internalisation due to high intra-islet concentrations of CCL5 (Figure 57). This would 
also explain why insulin secretion levels start to fall towards pre-stimulus levels due to 
diminished GPR75 activation which would ultimately restrict CCL5-induced glucagon secretion 
followed by a decrease in glucagon-induced insulin secretion. It is worth noting that this is not 
observed in mouse islets, in which the CCL5-induced insulin secretory response was smaller but 
sustained, possibly due to a lower intra-islet concentration of CCL5. The lower insulin secretory 
output may not reach a sufficiently high threshold to activate InsR expressed on mouse islet 
alpha cells and thus unable to repress glucagon-stimulated insulin secretion and therefore 
continue to stimulate insulin secretion in the absence of CCL5. The proposed signalling 
mechanisms downstream of CCL5-induced GPR75 activation in mouse and human alpha and 
beta cells are summarised in Figure 55 to Figure 57.  
  





Figure 55: Schematic diagram showing the direct and indirect effects on CCL5-induced insulin 
secretion from mouse islets. Endogenous CCL5 (solid orange circles) within alpha cells is secreted into 
the intra-islet environment (1). CCL5 can either bind to, and directly activate, GPR75 expressed on a beta 
cell (2), and stimulate insulin (solid blue circles) secretion in a paracrine manner (3), or indirectly stimulate 
insulin secretion by directly activating GPR75 expressed on the alpha cell itself (4) and stimulate glucagon 
(solid red circles) secretion in an autocrine manner (5). The secreted glucagon can then activate glucagon 
receptors (GluR) expressed on the beta cell (6), which further amplifies the insulin secretory response to 
CCL5. 
  





Figure 56: Schematic diagram showing the direct and indirect effects on CCL5-induced insulin 
secretion from human islets. Endogenous CCL5 (solid orange circles) within an alpha cell and a beta 
cell is secreted into the intra-islet environment (1). The high intra-islet concentration of CCL5 may 
robustly activate GPR75 expressed on the beta cell (2), and subsequently stimulate insulin (solid blue 
circles) secretion in a paracrine manner (3), or indirectly stimulate insulin secretion by activating GPR75 
expressed on the alpha cell itself (4) and stimulate glucagon (solid red circles) secretion in an autocrine 
manner (5). The secreted glucagon can then activate glucagon receptors (GluR) expressed on the beta cell 
(6), which further amplifies the insulin secretory response to CCL5. 
  





Figure 57: Schematic diagram showing the effects of high levels of insulin release and its 
subsequent inhibition of glucagon secretion. Endogenous CCL5 (solid orange circles) within an alpha 
cell and a beta cell is secreted into the intra-islet environment (1). The high intra-islet concentration of 
CCL5 may robustly activate GPR75 expressed on the beta cell (2), and subsequently stimulate insulin 
(solid blue circles) secretion in a paracrine manner (3). The elevated levels of insulin may then go onto 
activate insulin receptors (InsR) expressed on the alpha cell (4) and inhibit glucagon (solid red circles) 
secretion (5). Furthermore, the high intra-islet concentration of CCL5 may over-activate GPR75 and lead 
to receptor desensitisation by internalising GPR75 and diminishing the stimulatory effects associated with 
CCL5 (6). This may explain the transient secretion profile of insulin observed in human islets.   
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Chapter 5: Elucidating the GPR75 signalling pathway in beta cells.
 




GPR75 coupling to the Gαq protein has been established by demonstrating insensitivity to 
pertussis toxin and sensitivity to U73122, a phospholipase C (PLC) inhibitor (Ignatov et al., 
2006). CCL5 also elevates the formation of IP3 in HEK293 cells that overexpress GPR75 as 
well as stimulating calcium mobilisation in GPR75-expressing CHO-K1 cells, which was 
inhibited in the presence of U73122 but was unaffected by pertussis toxin (Ignatov et al., 2006). 
In this thesis, mRNA analysis and protein expression experiments identified GPR75 as the most 
abundant CCL5 receptor expressed in mouse and human islets, and that it co-localised with beta 
cell and alpha cell populations of mouse and human islets (Chapter 3). Furthermore, CCL5 also 
stimulates insulin secretion from mouse islets and human islets as well as from MIN6 beta cells, 
whereas, glucagon secretion was stimulated in mouse islets but inhibited in human islets 
(Chapter 4). These data indicate that GPR75 signalling influences islet hormone secretion 
through autocrine and/or paracrine mechanisms, and therefore CCL5 via GPR75 activation 
may influence beta cell function in a non-immunological environment, which has not been 
previously identified.  
Glucose-induced insulin secretion (GSIS) is achieved when glucose enters beta cells and is 
metabolised, which elevates the ATP: ADP ratio and subsequently closes ATP-sensitive K+ 
channels. This causes depolarisation of the beta cell membrane and activates VOCCs. The 
ensuing influx of calcium elevates the cytosolic concentration of calcium, which stimulates 
insulin exocytosis through multiple events involving protein kinase activation and insulin 
granule docking and priming (Ashcroft FM, 1992, Howell et al., 1994, Wollheim and Sharp, 
1981, Rorsman and Renström, 2003). Moreover, non-nutrient stimulation of insulin secretion is 
achieved through receptor activation resulting in second messenger generation and/or protein 
kinase activation. The activation of Gαq protein-coupled receptors results in the generation of 
IP3 and DAG via PIP2 hydrolysis, which mobilise calcium from intracellular calcium stores and 
activate DAG-sensitive PKC isoforms, respectively (Jones and Persaud, 1998b). Secretagogues 
acting on cell surface receptors work through identical intracellular regulators as nutrient stimuli 
to influence insulin secretion (Jones and Persaud, 1998b, Howell et al., 1994). For example, 
carbachol (CCh), which activates the Gαq-coupled muscarinic (M3) receptor, induces beta cell 
depolarisation and subsequent elevations of the calcium second messenger (Biden et al., 1987). 
Furthermore, CCh and peptide hormones such as bombesin, arginine vasopressin (AVP) and 
cholecystokinin (CCK) promote the generation of IP3 and DAG from phospholipid hydrolysis 
by stimulating PLC (Biden et al., 1987, Best and Malaisse, 1983, Zawalich et al., 1987, Swope 
and Schonbrunn, 1988, Gao et al., 1990).  




Identification of GPR75 coupling to the Gαq signalling pathway (Ignatov et al., 2006), and the 
ability of CCL5 to promote insulin secretion from beta cells (Chapter 4) suggests that activation 
of GPR75, which is expressed by beta cells, may potentially restore or preserve normal beta cell 
function. Therefore, this chapter focuses on identifying whether the CCL5-inducing effect on 
insulin secretion is mediated through GPR75 activation as well as elucidating GPR75 signalling 
in beta cells by pharmacologically manipulating components of the Gαq pathway. 
  





5.2.1: Down-regulation of GPR75: Transient transfection 
Gene targeted siRNAs were designed to down-regulate GPR75 expression in MIN6 beta cells 
by using an Amaxa®Cell Line Nucleofector®Kit R (Section 2.5.2). Briefly, 1x106 MIN6 beta 
cells per sample were gently re-suspended with 100µl Nucleofector® transfection reagent, 
which consisted of a 4.5:1 ratio of Nucleofector® solution (82µl) to Nucleofector® supplement 
(18µl) per 100µl sample. The cell suspension was combined with either GPR75 siRNAs 
(150nM) or non-coding RNAs (150nM), which served as control, before being transferred into 
a cuvette. The cells were then electroporated using an Amaxa Nucleofector (Lonza), after which 
500µl of pre-warmed DMEM (Table 1) was immediately added to the cuvette containing the 
cell suspension and then gently pipetted into pre-prepared 6 well plates containing 1.5ml pre-
warmed DMEM (Table 1). The transfected cells were incubated for 48 hours at 37°C (5% 
CO2/95% air). The extent of GPR75 down-regulation was verified by qRT-PCR and GPR75 
mRNA expression was normalised against GAPDH (Gapdh), which served as an internal 
reference and calculated by the 2−ΔΔCt method (Section 2.3.7). GPR75 protein expression was 
determined by western blotting (Section 2.4.4) using a rabbit anti-GPR75 antibody (1:50 
dilution) and equal protein loading was confirmed by immune detection using an anti-beta actin 
antibody (1:200 dilution). Functional effects of GPR75 down-regulation were observed in 
calcium microfluorimetry and insulin secretion experiments. 
5.2.2: Calcium Microfluorimetry 
MIN6 beta cells were seeded at a density of 50,000 cells per acidified ethanol-washed coverslip 
and incubated overnight at 37°C (5% CO2/95% air) in DMEM (Table 1). Cells were then 
loaded with 5µM FURA-2AM for 30 minutes and coverslips were transferred to a temperature-
controlled chamber maintained at 37°C. For most protocols, cells were perifused with a 
physiological buffer (Gey and Gey, 1936), Table 23, supplemented with 2mM glucose to 
establish a stable baseline of intracellular calcium before being challenged with various agents of 
interest (Table 32). Cells were also treated with ATP (100µM) and/or tolbutamide (50µM), 
which served as positive controls. A shutter system was used to expose the cells or islets to 
excitatory wavelengths of 340nm and 380nm every 2 seconds. Changes in fluorescence 
(emission at 510nm) were monitored by an epi-fluorescence microscope (Zeiss Axiovert135 
Inverted microscope). The data were recorded by OptoFluor imaging software (2.5.1: Single cell 
calcium microfluorimetry).  
5.2.3: Measurement of insulin secretion: Static incubation 
MIN6 beta cells were seeded at a density of 30,000 cells per well in a clear 96 well plate and 
incubated for 24 hours in DMEM (Table 1) at 37°C (5% CO2/95% air). The medium was 
tapped off and cells were pre-incubated with a physiological buffer (Gey and Gey, 1936) 




supplemented with 2mM glucose (200µl/well) for 2 hours at 37°C (5% CO2/95% air). The 
physiological buffer was then replaced with 200µl of agents of interest per well (Table 32) and 
cells were incubated for a further hour at 37°C (5% CO2/95% air). 160µl of supernatant was 
collected and diluted in borate buffer (1:5 dilution), which was used to quantify insulin secretion 
by radioimmunoassay (section 2.6.3). 
Isolated mouse and human islets were incubated for 24 hours in RPMI or CMRL (Table 1), 
respectively. Islets were pre-incubated with a physiological buffer (Gey and Gey, 1936) 
supplemented with 2mM glucose for 1 hour at 37°C (5% CO2/95% air) before being treated (3 
islets per replicate) with 600µl agents of interest (Table 32) and incubated for a further hour at 
37°C (5% CO2/95% air). 450µl of supernatant was collected and diluted in borate buffer (1:5 
dilution), which was used to quantify insulin secretion by radioimmunoassay (section 2.6.3). 
  
Chapter 5: Elucidating the GPR75 signalling pathway in beta cells. 
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Reagent Mode of action Working concentration 
Chemokine ligand 5 (CCL5) 










Acute exposure: activates 
conventional and novel (DAG-
sensitive) PKC isoforms  
 
Chronic exposure: degrades 
conventional and novel (DAG-







4α-Phorbol 12, 13-didecanoate 
(4αPDD) 
Inactive anologue of PMA 200nM 
Staurosporine (STP) 
Broad spectrum protein kinase 
inhibitor 
200nM 
U73122 Inhibits PLC 10µM 
KN-62 Inhibits CAMK II 10µM 
Ro-31-8220 Indiscriminate PKC inhibitor 10µM 
GÖ6976 
Inhibits conventional PKC 
isoforms 
1µM 
Diazoxide Opens KATP channels 250µM 
Nifedipine 





tetraacetic acid (EGTA) 
 
Calcium chelator 1mM 
Adenosine Triphosphate 
(ATP) 
Stimulates purinergic receptors 100µM 
Tolbutamide Closes KATP channels 50µM 
 
Table 32: List of reagents, their associated modes of action and final concentrations used for 
manipulating beta cell signalling pathways to elucidate the GPR75 signalling pathways in beta cells by 
measuring their effects on intracellular calcium and insulin secretion. 
  





5.3.1: The effect of CCL5 on intracellular calcium levels in MIN6 beta cells, mouse islets 
and human islets. 
As demonstrated in Figure 58, challenging MIN6 beta cells with increasing concentrations of 
CCL5 caused a robust increase in intracellular calcium levels (0.25nM CCL5: 106±20%;  2.5nM 
CCL5: 99±14%; 25nM CCL5: 86±13%, of maximum response to  tolbutamide). The 
stimulatory responses were sustained during the presence of CCL5 and were reversible upon its 
removal, but they were not concentration-dependent. The cells were still able to respond to 
tolbutamide and ATP after exposure to CCL5 and indicated that CCL5 was not detrimental to 
beta cell function. The response to tolbutamide was sustained and reversible whereas, ATP 
response was transient with intracellular calcium levels falling back to basal before withdrawal of 
ATP (Figure 58). It is worth noting that a smaller response to ATP was observed after 
challenging MIN6 beta cells with tolbutamide as illustrated in Figure 58, which may be 
explained by the fact that the increase in calcium influx in response to tolbutamide may mobilise 
calcium from the endoplasmic reticulum (ER) by calcium-induced calcium release, which would 
diminish internal calcium stores, and result in a diminished response to ATP, which can 
mobilise calcium from the ER. Furthermore, CCL5 induced reversible increases in intracellular 
calcium levels in MIN6 beta cells in a concentration-dependent manner between 25fM to 25pM, 
(Figure 59), which was consistent with insulin secretion studies (Figure 49). However, the 
concentration-dependent effect was lost at 0.25nM. Increasing concentrations of CCL5 
(0.25nM-25nM) also increased intracellular calcium levels in MIN6 beta cells at 20mM glucose 
by 147±29%, 139±23% and 71±29%, of the maximum response to tolbutamide (Figure 60). 
The response was sustained throughout the presence of CCL5 but also reversibly returned to 
basal after CCL5 was withdrawn. MIN6 beta cells were still able to respond to tolbutamide, 
which again suggested CCL5 had no detrimental effect on beta cell viability or cell function at 
stimulatory glucose concentrations. 
The stimulatory effects of CCL5 on intracellular calcium concentrations were also observed in 
partially dispersed isolated mouse islets. Mouse islet beta cells were able to reversibly elevate 
cytosolic calcium levels by 53%-69% of the maximum response to ATP, in response to 
increasing concentrations of exogenous CCL5 (0.25nM-25nM). These cells were also able to 
elevate intracellular calcium levels in response to ATP after being challenged with CCL5, which 
indicated that exogenous CCL5 had no immediate effect on mouse islet beta cell function or 
viability (Figure 61). Furthermore, CCL5 also elevated intracellular calcium levels by 83%-232% 
of the maximum response to tolbutamide in partially dispersed human islet cells that were 
challenged with increasing concentrations of CCL5 (0.1nM-10nM). The human islet cells were 
able to respond to tolbutamide after being challenged with CCL5, which suggested that the cells 




under observation were beta cells, and they also responded to ATP, which demonstrated that 
CCL5 had no detrimental effect on human beta cell function or viability (Figure 62).  
Therefore, the stimulation of insulin secretion by CCL5 is most likely through the elevation of 
cytosolic calcium levels in beta cells. The next phase of this PhD project tried to identify 
whether these stimulatory effects were primarily mediated through the activation of GPR75. 
  





Figure 58: The effect of CCL5 on intracellular calcium concentrations in Fura-2 loaded MIN6 
beta cells. Fura-2 loaded MIN6 beta cells were perifused with a physiological buffer supplemented with 
2mM glucose before being challenged with increasing concentrations of CCL5 (0.25-25nM), as well as 
ATP (100µM) and tolbutamide (50µM), which served as positive controls. Changes in cytosolic calcium 

























































Figure 59: The effect of CCL5 on intracellular calcium concentrations in Fura-2 loaded MIN6 
beta cells. Fura-2 loaded MIN6 beta cells were perifused with a physiological buffer supplemented with 
2mM glucose before being challenged with decreasing concentrations of CCL5 (25pM-0.25nM), as well as 
ATP (100µM) and Tolbutamide (50µM), which served as positive controls. Changes in cytosolic calcium 
concentrations were expressed as 340nm:380nm ratiometric data. Data are expressed as Mean ± SEM, 
n=64 cells (a). Basal to peak response of Fura-2 loaded MIN6 beta cells showing concentration-


































































































Figure 60: The effect of CCL5 on cytosolic calcium concentrations in Fura-2 loaded MIN6 beta 
cells at 20mM glucose. Fura-2 loaded MIN6 beta cells were perifused with a physiological buffer 
supplemented with 2mM glucose before being challenged with increasing concentrations of CCL5 (0.25-
25nM) in the presence of 20mM glucose, as well as ATP (100µM) and Tolbutamide (50µM), which served 
as positive controls. Changes in cytosolic calcium concentrations were expressed as 340nm:380nm 

















































Figure 61: The effect of CCL5 on intracellular calcium levels in mouse islet cells. Isolated ICR 
mouse islets were dispersed and seeded at a density of 80 islets per Cell-Tak coated coverslips. Cells were 
loaded with 5µM FURA-2AM for 30 minutes and perifused with a physiological buffer supplemented 
with 2mM glucose before being challenged with increasing concentrations of CCL5 (0.25nM-25nM), and 
with ATP (100µM), which served as a positive control (a). Image of Fura-2 loaded islet beta cells used for 
experimental analysis (b). Changes in cytosolic calcium concentrations were expressed as 340nm:380nm 



































































Figure 62: The effect of CCL5 on intracellular calcium levels in human islet beta cells. Isolated 
human islets were dispersed and seeded at a density of 100 islets per Cell-Tak coated coverslips. Cells 
were loaded with 5µM FURA-2AM for 30 minutes and perifused with a physiological buffer 
supplemented with 2mM glucose before being challenged with increasing concentrations of CCL5 
(0.1nM-10nM), as well as Tolbutamide (50µM) and ATP (100µM), which served as positive controls. (a). 
Image of Fura-2 loaded human islet beta cells used for experimental analysis (b). Changes in cytosolic 
calcium concentrations were expressed as 340nm:380nm ratiometric data. Data are expressed as Mean ± 


















































5.3.2: The effect of GPR75 down-regulation on beta cell function 
Exposure of MIN6 beta cells to GPR75-targeted siRNAs for 48 hours led to significant 
reductions in GPR75 mRNA expression (Figure 63a). Western blotting also indicated that 
GPR75 protein expression in MIN6 beta cells was diminished after 48 hours compared to cells 
that were transfected with non-coding (NC) RNAs (Figure 63b). All concentrations of CCL5 
used (0.25-25nM) were able to induce reversible increases in intracellular calcium at 2mM 
glucose in MIN6 beta cells that were transfected with NC RNAs (Figure 64a), which was 
consistent to the response profile observed in native MIN6 beta cells (Figure 58a). However, 
this response was absent in MIN6 beta cells transfected with GPR75-targeted siRNAs (Figure 
64b). At 20mM glucose MIN6 beta cells transfected with NC RNAs showed increased 
intracellular calcium levels in response to 0.25-25nM CCL5 (Figure 64c) and this stimulatory 
effect of CCL5 at 20mM glucose was considerably diminished but not completely abolished in 
MIN6 beta cells transfected with GPR75 siRNAs (Figure 64d). This could be explained by the 
incomplete down-regulation of GPR75 in these cells (Figure 63).  
A similar approach of down-regulating GPR75 in MIN6 beta cells was used to identify the 
potential involvement of GPR75 in CCL5-induced insulin secretion from beta cells. 2.5nM 
CCL5 significantly stimulated insulin secretion at 20mM glucose from MIN6 beta cells 
transfected with NC RNAs, which was consistent with observations using native MIN6 beta 
cells. However, this response was abolished in MIN6 beta cells transfected with GPR75 siRNAs 
(Figure 65). 
  




Figure 63: Down-regulation of GPR75 mRNA and protein expression in MIN6 beta cells. GPR75 
was down-regulated in MIN6 beta cells by transient transfection with siRNAs (150nM) directed against 
GPR75. MIN6 beta cells were also transiently transfected with 150nM non-coding RNAs (Control). Cells 
were maintained in culture for 48 hours before analysis of mRNA and protein expression. Transfected 
cells were collected for GPR75 mRNA quantification (a). Data are expressed as Mean ± SEM. *P<0.05, 
and protein expression by western blotting (b) using a rabbit anti-GPR75 antibody (1:50) dilution, with 



























































































































































































































































Figure 64: Effect of GPR75 down-regulation on intracellular calcium levels in MIN6 beta cells. 
GPR75 was down-regulated in MIN6 beta cells by transient transfection with siRNAs (150nM) directed 
against GPR75. MIN6 beta cells were also transiently transfected with 150nM non-coding RNAs (NC), 
which served as controls. Cells were maintained in culture for 48 hours before functional analysis. 
Changes in intracellular calcium concentrations were measured by Fura-2 loading of cells on coverslips. 
The cells that were treated with NC RNAs (a,c) or GPR75 siRNAs (b,d) were challenged with increasing 
concentrations of CCL5 (0.25nM-25nM) in the presence of either 2mM glucose (a-b) or 20mM glucose 
(c-d). Changes in cytosolic calcium concentrations were expressed as 340nm:380nm ratiometric data. 











Figure 65: Effect of GPR75 down-regulation on insulin secretion from MIN6 beta cells. GPR75 
was down-regulated in MIN6 beta cells by transient transfection with siRNAs (150nM) directed against 
GPR75. MIN6 beta cells were also transiently transfected with 150nM non-coding RNAs (NC), which 
served as controls. Cells were maintained in culture for 48 hours before functional analysis. Insulin 
secretion was measured from native and GPR75-depleted MIN6 beta cells following treatment with 
CCL5 (2.5nM) for 1 hour at 37°C. Insulin was quantified by radioimmunoassay. Data expressed as Mean 
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5.3.3: Identification of a calcium ion influx component in the beta cell GPR75 signalling 
pathway. 
The data presented in section 5.3.2 established that GRP75 activation is responsible for CCL5-
induced elevations in intracellular calcium in beta cells. Unstimulated beta cells maintain low 
intracellular calcium concentrations, between 50-100nM, and so the second messenger property 
of calcium relies on the ability of cells to rapidly and markedly elevate cytosolic calcium in 
response to various stimuli (Henquin, 2000). Large calcium stores exist in the lumen of the 
endoplasmic reticulum (ER) and the extracellular compartment (Henquin, 2000). The following 
experiments were designed to determine whether GPR75 activation by CCL5 elevates cytosolic 
calcium through calcium influx and/or mobilisation. 
As illustrated in Figure 66, 0.25nM CCL5 reversibly elevated intracellular calcium in MIN6 beta 
cells in the presence of a physiological buffer supplemented with 2mM calcium (Figure 66a, 
black line). The same cells were still able to respond to ATP (100µM) and tolbutamide (50µM), 
which served as controls, which elevate intracellular calcium by either mobilising calcium from 
the endoplasmic reticulum or permitting calcium influx via VOCCs by closing KATP channels, 
respectively (Figure 66a, black line). However, the response to 0.25nM CCL5 was completely 
abolished when MIN6 beta cells were challenged in a calcium-free physiological buffer 
supplemented with 1mM EGTA, to chelate calcium (Figure 66a, red line). The same cells were 
still able to mobilise calcium and transiently elevate intracellular calcium in response to ATP 
(100µM) but at a lower magnitude compared to cells in the presence of extracellular calcium, 
which may be explained by diminished calcium-induced calcium release from the ER (Figure 
66a, red line). Furthermore, the cells did not respond to tolbutamide (50µM), which was 
expected due to the absence of extracellular calcium which is responsible for calcium influx 
associated with the mode of action of tolbutamide (Figure 66a, red line).  
It was important to identify the mechanism of calcium entry into beta cells since Figure 66 
demonstrates that a calcium influx component was essential in mediating CCL5-induced 
elevations of intracellular calcium in MIN6 beta cells. VOCCs are important for nutrient-
induced calcium influx into beta cells. Beta cells predominantly express L-type VOCCs whose 
activation is important for driving the exocytosis of insulin (Braun et al., 2008). Therefore, 
blockade of L-type calcium channels with nifedipine would indicate whether calcium influx into 
beta cells was via the L-type VOCCs or through another unidentified mechanism. 
As illustrated in Figure 67a, 0.25nM CCL5 increased intracellular calcium (black line), as 
expected, in MIN6 beta cells in the absence of nifedipine. The same cells also responded to 
ATP (100µM) and tolbutamide (50µM), which served as controls. However, MIN6 beta cells 
that were challenged with CCL5 in the presence of nifedipine (10µM) were unable to elevate 
intracellular calcium concentrations (Figure 67a, red line), but the same cells showed a transient 




response to ATP (Figure 67a, red line), clearly demonstrating that MIN6 beta cells were still 
able to mobilise calcium from the internal ER calcium store after exposing the cells to ATP. 
Moreover, tolbutamide was unable to elevate intracellular calcium levels in these cells (Figure 
67a, red line), which supported the notion that a calcium influx component involving L-type 
calcium channels was essential for mediating the effects of tolbutamide on  stimulation of 
cytosolic calcium levels in beta cells. Similar results were obtained in experiments using partially 
dispersed human islets, as illustrated in Figure 68, which showed CCL5 elevated intracellular 
calcium in human beta cells in the absence of nifedipine (Figure 68a) whereas this response was 
absent in beta cells in the presence of nifedipine (10µM), as illustrated in Figure 68b. Both sets 
of cells mounted appropriate responses to ATP (100µM), as expected due to reasons mentioned 
earlier.  
  





Figure 66: Effect of CCL5 on intracellular calcium concentrations in MIN6 beta cells in the 
presence or absence of extracellular calcium. Fura-2 loaded MIN6 beta cells were perifused with a 
physiological buffer supplemented with 2mM glucose containing either 2mM calcium (black) or a 
calcium-free physiological buffer supplemented with 1mM EGTA (red). Cells were then challenged with 
0.25nM CCL5, as well as ATP (100µM) and Tolbutamide (50µM), which served as positive controls (a). 
Changes in cytosolic calcium concentrations were expressed as 340nm:380nm ratiometric data. Data are 
expressed as Mean ± SEM, n=39-63 cells from two separate experiments. Images of Fura-2 loaded MIN6 


























































Figure 67: Effect of CCL5 on intracellular calcium concentrations in MIN6 beta cells in the 
absence or presence of nifedipine. Fura-2 loaded MIN6 beta cells were perifused with a physiological 
buffer supplemented with 2mM glucose in the absence (black) or presence (red) of nifedipine (10µM). 
Cells were then challenged with 0.25nM CCL5, as well as ATP (100µM) and Tolbutamide (50µM), which 
served as positive controls (a). Changes in cytosolic calcium concentrations were expressed as 
340nm:380nm ratiometric data. Data are expressed as Mean ± SEM of two separate experiments, n=28-
35 cells. Images of Fura-2 loaded MIN6 beta cells used for experimental analysis in the absence (b) or 

























































































































































Figure 68: Effect of CCL5 on human islet intracellular calcium levels in the absence or presence 
of nifedipine. Isolated human islets were dispersed and seeded at a density of 100 islets per Cell-Tak 
coated coverslip and loaded with 5µM Fura-2 before being perifused with a physiological buffer 
supplemented with 2mM glucose in the absence (a) or presence (b) of nifedipine (10µM). Cells were then 
challenged with 10nM CCL5, as well as ATP (100µM), which served as a positive control. Changes in 
cytosolic calcium concentrations were expressed as 340nm:380nm ratiometric data. Data are expressed as 
Mean ± SEM of two separate experiments, n=7-17 cells. Images inset shows Fura-2 loaded human islet 
beta cells used for experiment analysis. 
  




5.3.4: Effect of opening beta cell KATP channels on CCL5-induced insulin secretion. 
The identification of a calcium influx component, which was essential for CCL5-induced 
elevations in intracellular calcium, warranted further investigation of the influence KATP channel 
closure has on the open probability of L-type VOCCs upon GPR75 activation by CCL5. 
A static incubation experiment was initially carried out to determine the effect of diazoxide, 
which is a selective ATP-sensitive K+ channel activator, on insulin secretion. As illustrated in 
Figure 69, mouse islets significantly increased insulin secretion by approximately 10-fold in 
response to a glucose stimulus (20mM), as expected, and this response was significantly 
inhibited by 250µM diazoxide, a concentration that has been established to effectively activate 
ATP-sensitive K+ channels. This demonstrated that opening KATP channels preserved the 
hyperpolarised state of the beta cell membrane, which prevented calcium influx from the 
extracellular compartment into the beta cell cytosol and thus prevented glucose from 
stimulating insulin secretion.  
To identify whether GPR75 activation by CCL5 was permitting calcium to enter beta cells via 
KATP channel closure and ensuing membrane depolarisation, mouse islets were treated with 
250µM diazoxide in the absence or presence of CCL5, at 2mm glucose. This glucose 
concentration was selected so that the effect of diazoxide on the secretory response to CCL5 
could be determined separately from its inhibition of GSIS. Diazoxide did not influence insulin 
secretion and demonstrating that closure of KATP channels did not influence insulin secretion at 
sub-stimulatory glucose concentrations but only in the presence of a glucose stimulus (Figure 
70). Mouse islets increased insulin secretion by 72% when challenged with CCL5 at 2mM 
glucose and this response was lost when islets were treated with CCL5 in the presence of 
250µM diazoxide (Figure 70). 
  











Figure 69: Effect of diazoxide on glucose-stimulated insulin secretion from mouse islets. Isolated 
mouse islets were treated with 20mM glucose in the absence or presence of 250µM diazoxide for 1 hour 
at 37°C. Insulin secretion was quantified by radioimmunoassay. Data are expressed as Mean ± SEM. 










Figure 70: Effect of diazoxide on CCL5-induced insulin secretion from mouse islets. Isolated 
mouse islets treated with 25nM CCL5 in the absence or presence of 250µM diazoxide or with diazoxide 
alone for 1 hour at 37°C. Insulin secretion was quantified by radioimmunoassay. Data expressed as Mean 
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5.3.5: Involvement of PLC in the stimulus-secretion coupling of CCL5. 
The newly identified ability of GPR75 activation by CCL5 to induce calcium entry into beta 
cells, presumably via KATP channel closure, warranted investigation into the potential coupling 
of GPR75 to the Gαq protein in beta cells. Calcium microfluorimetry experiments demonstrated 
that CCL5-induced elevation in intracellular calcium concentrations in MIN6 beta cells is 
reduced in the presence of the PLC inhibitor, U73122 (Figure 71 and Figure 72). It is worth 
noting that U73122 did not completely abolish CCL5-induced elevations in intracellular 
calcium. 
The notion that CCL5 mediated its downstream effects through PLC stimulation was further 
supported by insulin secretion studies. Thus, MIN6 beta cells responded to 2.5nM CCL5 by 
elevating insulin secretion in the absence of U73122 but this stimulatory response was abolished 
in the presence of U73122 (Figure 73). In human islets CCh-induced insulin secretion at 20mM 
glucose was abolished in the presence of U73122 (Figure 74a), which confirmed signalling of 
the muscarinic (M3) receptor via the Gαq-PLC cascade. In parallel experiments, human islets 
treated with 10nM CCL5 stimulated insulin secretion at 20mM glucose but the stimulatory 
response to CCL5 was lost in the presence of 10µM U73122 (Figure 74b). 
  





Figure 71: Effect of U73122 on CCL5-induced elevations in intracellular calcium in MIN6 beta 
cells. Fura-2 loaded MIN6 beta cells were perifused with a physiological buffer supplemented with 2mM 
glucose in the absence (black) or presence (red) of U73122 (10µM). Cells were then challenged with 
0.25nM CCL5. Changes in cytosolic calcium concentrations were expressed as 340nm:380nm ratiometric 
data. Data are expressed as Mean ± SEM of two separate experiments, n=47-63 cells. Image inset shows 

























































Figure 72: Effect CCL5 on intracellular calcium concentrations in MIN6 beta cells in the 
presence of U73122. Fura-2 loaded MIN6 beta cells were perifused with a physiological buffer 
supplemented with 2mM glucose before being challenged with 0.25nM CCL5 before or after (2 minutes) 
exposure to U73122 (10µM). Cells were also challenged with ATP (100µM) and Tolbutamide (50µM), 
which served as positive controls. Changes in cytosolic calcium concentrations were expressed as 
340nm:380nm ratiometric data. Data are expressed as Mean ± SEM, n=29 cells (a). Percentage response 
to tolbutamide in the absence or presence of U73122 (10µM). Mean ± SEM, *P<0.05 (b). Image of Fura-
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Figure 73: Effect of U73122 on CCL5-induced insulin secretion in MIN6 beta cells. MIN6 beta 
cells were pre-incubated with a physiological buffer supplemented with 2mM glucose for 2 hours before 
being challenged with 20mM glucose alone or with 2.5nM CCL5 in the absence or presence of U73122 













20mM Glucose 20mM Glucose +
2.5nM CCL5
20mM Glucose +

















































Figure 74: Effect of U73122 on CCL5 and Carbachol (CCh)-induced insulin secretion in human 
islets. Isolated human islets were pre-incubated with a physiological buffer supplemented with 2mM 
glucose for 1 hour before being challenged with either 20mM glucose alone, 500µM CCh (a) or 10nM 
CCL5 (b), in the absence or presence of U73122 (10µM) for 1 hour at 37°C. Data are expressed as Mean 
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5.3.6: Involvement of protein kinases in the GPR75 signalling pathway. 
It has been identified that components of a calcium influx mechanism in beta cells involves 
closure of ATP-sensitive K+ channels and opening of L-type calcium channels, through PLC 
activation, upon GPR75 activation by CCL5. IP3 and DAG are generated from the hydrolysis of 
PIP2 by PLC and it is therefore conceivable that DAG, which is a PKC activator, may have a 
role in the stimulatory effects associated with CCL5 in the beta cell on intracellular calcium and 
insulin secretion. Therefore, experiments were carried out to identify a potential role of PKC 
within the GPR75 signalling pathway. 
The involvement of protein kinases downstream of GPR75 were initially investigated by using 
staurosporine (STP), which is a broad spectrum kinase inhibitor that inhibits 
phospholipid/calcium dependent protein kinases. As illustrated in Figure 75, calcium 
microfluorimetry experiments demonstrated that intracellular calcium concentrations were 
significantly diminished by 40% in Fura-2 loaded MIN6 beta cells that were challenged with 
0.25nM CCL5 in the presence of STP (200nM), as illustrated in Figure 75a. Furthermore, 
CCL5-induced insulin secretion in MIN6 beta cells was abolished in the presence of 200nM 
STP (Figure 76). Surprisingly, insulin secretion levels in MIN6 beta cells that were treated with 
CCL5 (2.5nM) in the presence of STP (200nM) were significantly below to those observed in 
beta cells treated with STP alone, which on its own did not have any effect on GSIS (Figure 76). 
A similar pattern was observed in human islets in which CCL5 potentiation of GSIS was also 
inhibited when treated with 200nM STP (Figure 77).  
The potential role of PKC in the GPR75 signalling pathway was then investigated after 
demonstrating that protein kinase activation was partially required for mediating CCL5-induced 
elevations in intracellular calcium and was essential for insulin secretion. Pharmacological 
inhibition of PKC using Ro-31-8220 (10µM) significantly inhibited CCL5-induced insulin 
secretion from MIN6 beta cells (Figure 78), but this response was not completely abolished. 
The concentration of Ro-31-8220 used may not have been fully inhibiting PKC, or the data may 
also implicate other protein kinases that are involved in insulin secretion associated with CCL5 
activation of GPR75.  
It is worth noting that Ro-31-8220 inhibits all PKC isoforms. To identify which PKC isoforms 
were stimulated upon GPR75 activation an alternative approach of pharmacologically depleting 
phorbol ester-sensitive PKC isoforms by long-term (>24 hours) exposure to PMA was 
implemented. The success of this strategy was verified by calcium microfluorimetry 
experiments, which demonstrated that acute exposure to 500nM PMA failed to elevate 
intracellular calcium concentrations in Fura-2 loaded MIN6 beta cells that were chronically 
exposed to 200nM PMA (Figure 79a). However, MIN6 beta cells treated long-term with 200nM 




4αPDD, which is an inactive analogue of PMA and served as a negative control, were able to 
elevate intracellular calcium levels in response to CCL5 (Figure 79b). Furthermore, 500nM 
PMA induced insulin secretion at 20mM glucose from MIN6 beta cells treated with 200nM 
4αPDD for 24 hours but this response was abolished when MIN6 beta cells were treated for 24 
hours with 200nM PMA, as illustrated in Figure 79c. 25nM CCL5 and 500nM PMA both 
potentiated GSIS by 1.2-fold and 1.9-fold, respectively, from MIN6 beta cells (Figure 80a) and 
similar responses were observed in MIN6 beta cells treated with 4αPDD for 24 hours (Figure 
80b). However, when MIN6 beta cells were treated for 24 hours with 200nM PMA neither 
CCL5 nor PMA were able to potentate insulin secretion (Figure 80c). Similar observations were 
made using human islets. In these experiments islets showed increased insulin secretion in 
response to 10nM CCL5 and 500nM PMA at 20mM glucose (Figure 81a), and this was also 
evident in human islets treated long-term with 4αPDD for 24 hours (Figure 81b). However, 
human islets lost the ability to stimulate insulin secretion in response to CCL5 and PMA when 
treated long-term with 200nM PMA (Figure 81c). 
The preceding data suggest that CCL5-induced insulin secretion is mediated through a phorbol 
ester-sensitive PKC isoform. Therefore, it was important to identify the specific PKC isoform 
that was responsible for mediating the effects of CCL5 on insulin secretion. Both conventional 
and novel PKC isoforms are sensitive to phorbol esters but only the conventional PKC 
isoforms are sensitive to calcium with several PKC isoforms expressed in islets and beta cells, 
which include PKCα, βII, δ, ε, ζ and ι (Kaneto et al., 2002, Carpenter et al., 2004, Tang and 
Sharp, 1998, Tian et al., 1996, Knutson and Hoenig, 1994). GÖ6976, is a PKC inhibitor that 
discriminates between calcium-dependent (conventional) and calcium-independent (novel) PKC 
isoforms by inhibiting the conventional PKC isoforms. As illustrated in Figure 82, 500nM PMA 
increased intracellular calcium levels in Fura-2 loaded MIN6 beta cells and this response was 
inhibited in the presence of 1µM GÖ6976, demonstrating that this was an effective 
concentration for inhibiting conventional PKC isoforms in native MIN6 beta cells. When 
MIN6 beta cells were challenged with 2.5nM CCL5 insulin secretion increased by 1.3-fold 
(Figure 83), and this effect was also seen in the presence of 1µM GÖ6976. This suggests that 
novel PKC isoforms may be stimulated upon GPR75 activation and thus may be a component 
of GPR75 signalling responsible for stimulating insulin secretion from beta cells in response to 
CCL5. 
Pancreatic beta cells express several kinases that are sensitive to calcium and the calcium 
binding protein calmodulin. Calcium/calmodulin-dependent protein kinase II (CAMK II) has 
been implicated in maintaining normal insulin secretory responses to elevated intracellular 
calcium levels (Jones and Persaud, 1998a, Easom et al., 1997, Hughes et al., 1993). Therefore, it 
was important to investigate whether CAMK II activation was part of the GPR75 signalling 




cascade and if it facilitated CCL5-induced insulin secretion. Insulin secretion experiments using 
MIN6 beta cells demonstrated that 10µM KN-62, which is a CAMK II inhibitor, inhibited 
insulin secretion in response to 2.5nM CCL5 (Figure 84). This was also evident in human islets 
where 10µM KN-62 significantly inhibited insulin secretion induced by CCL5 (10nM), as 
illustrated in Figure 85. 
  





Figure 75: Effect of CCL5 in the absence or presence of staurosporine (STP) on intracellular 
calcium in MIN6 beta cells. Fura-2 loaded MIN6 beta cells were challenged with 0.25nM CCL5 in the 
absence or presence of 200nM STP. Changes in cytosolic calcium concentrations were expressed as 
340nm:380nm ratiometric data. Percentage response of CCL5 to tolbutamide in the absence or presence 
of STP (a). Data are expressed as Mean ± SEM. n=37-49 cells. Images of MIN6 beta cells used for 
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Figure 76: Effect of staurosporine (STP) on CCL5-induced insulin secretion from MIN6 beta 
cells. Fura-2 loaded MIN6 beta cells were pre-incubated for 2 hours at 37°C in a physiological buffer 
supplemented with 2mM glucose before being challenged with 2.5nM CCL5 in the absence or presence 
of 200nM STP, or STP alone, for 1 hour at 37°C. Data are expressed as Mean ± SEM. n=5-7.  *P˂0.05, 



























































Figure 77: Effect of staurosporine (STP) on CCL5-induced insulin secretion from human islets. 
Isolated human islets were incubated for 24 hours in serum containing CMRL at 37°C. Islets were then 
pre-incubated for 1 hour at 37°C in a physiological buffer supplemented with 2mM glucose before being 
treated with 10nM CCL5 in the absence or presence of 200nM STP for 1 hour at 37°C.  Data expressed 










Figure 78: Effect of Ro-31-8220 on CCL5-induced insulin secretion from MIN6 beta cells. MIN6 
beta cells were pre-incubated for 2 hours at 37°C in a physiological buffer supplemented with 2mM 
glucose before being challenged with 20mM glucose alone or with 2.5nM CCL5 in the absence or 
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Figure 79: Effect of PKC depletion on intracellular calcium levels and insulin secretion in MIN6 
beta cells when acutely exposed to PMA. MIN6 beta cells were seeded at a density of 30,000 or 
50,000 cells per coverslip or well for measuring intracellular calcium or insulin secretion, respectively. 
Cells were incubated in serum containing DMEM for 24 hours at 37°C before being incubated in the 
presence of 200nM 4αPDD or 200nM PMA for a further 24 hours at 37°C. Calcium measurement 
studies involved 4αPDD (a) or PMA (b) treated cells that were loaded with 5µM Fura-2 for 30 minutes 
before being acutely challenged with 500nM PMA, as well as with 50µM Tolbutamide, which served as 
positive control. Data are expressed as Mean ± SEM. n=27-37 cells (images inset shows MIN6 beta cells 
used for calcium measurement studies). Insulin secretion studies involved pre-incubating cells with a 
physiological buffer supplemented with 2mM glucose for 2 hours at 37°C before being challenged with 
20mM glucose in the absence or presence of 500nM PMA for 1 hour at 37°C. Data are expressed as 
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Figure 80: Effect of PKC depletion on CCL5-induced insulin secretion from MIN6 beta cells. 
MIN6 beta cells seeded at a density of 30,000 cells per well were incubated for 24 hours in DMEM, 
which served as a control (a) or in DMEM supplemented with 200nM 4αPDD (b) or 200nM PMA (c) at 
37°C. Cells were then challenged with 25nM CCL5 or 500nM PMA in the presence of 20mM glucose for 
1 hour at 37°C. Data are expressed as Mean ± SEM, n=6-8, *P<0.05, ***P<0.001.  
  










































































































Figure 81: Effect of PKC depletion on CCL5-induced insulin secretion from human islets. 
Isolated human islets were treated with CMRL, which served as a control (a) or with CMRL 
supplemented with 200nM 4αPDD (b) or 200nM PMA (c) at 37°C for 24 hours. Cells were then pre-
incubated with a physiological buffer supplemented with 2mM glucose for 1 hour at 37°C before being 
challenged with 10nM CCL5 or 500 PMA in the presence of 20mM glucose for 1 hour at 37°C. Data are 
expressed as Mean ± SEM, n=5-8, *P<0.05, ***P<0.001.  
 
Figure 82: The effect of PMA on intracellular calcium in MIN6 beta cells exposed to GÖ6976. 
Fura-2 loaded MIN6 beta cells were challenged with 500nM PMA in the absence or presence of 1µM 
GÖ6976. Cells were also challenged with 100µM ATP and 50µM Tolbutamide, which served as positive 
controls. Changes in cytosolic calcium concentrations were expressed as 340nm:380nm ratiometric data. 




























































Figure 83: Effect of GÖ6976 on CCL5-induced insulin secretion from MIN6 beta cells. MIN6 beta 
cells were pre-incubated for 2 hours at 37°C in a physiological buffer supplemented with 2mM glucose 
before being challenged with 20mM glucose alone or supplemented with 2.5nM CCL5 in the absence or 
presence of 1µM GÖ6976 and incubated for 1 hour at 37°C. Data are expressed as Mean ± SEM. n=5-7. 
 
 
Figure 84: Effect of KN-62 on CCL5-induced insulin secretion from MIN6 beta cells. MIN6 beta 
cells were pre-incubated for 2 hours at 37°C in a physiological buffer supplemented with 2mM glucose 
before being challenged with 20mM glucose alone or with 20mM glucose + 2.5nM CCL5 in the absence 
or presence of 10µM KN-62, or KN-62 alone, for 1 hour at 37°C. Data are expressed as Mean ± SEM. 
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Figure 85: Effect of the KN-62 on CCL5-induced insulin secretion from human islets. Isolated 
human islets were pre-incubated for 1 hour at 37°C in a physiological buffer supplemented with 2mM 
glucose before being challenged with 20mM glucose alone or with 20mM glucose + 10nM CCL5 in the 
absence or presence of 10µM KN-62, or KN-62 alone, for 1 hour at 37°C. Data are expressed as Mean ± 











































Data in chapter 3 in this thesis have indicated that GPR75 is the most abundantly expressed 
CCL5 receptor in mouse and human islets and it co-localises with alpha and beta cell 
populations. Furthermore, CCL5 is endogenously expressed in islets and it can stimulate insulin 
secretion. Conventional CCL5 receptors, which are coupled to the inhibitory Gα protein, are 
expressed at extremely low or non-existent levels and it is therefore presumed that the 
stimulatory effect of CCL5 on insulin secretion is mediated via the activation of the Gαq-
coupled GPR75. This chapter focused on two main aspects associated with the stimulus-
secretion coupling of CCL5, which was to identify whether GPR75 is responsible for mediating 
the stimulatory effects of CCL5 in beta cells, and, if so, deduce the beta cell GPR75 signalling 
pathway.  
The primary response of beta cells to nutrient secretagogues such as glucose, is to elevate 
intracellular calcium concentrations (Rorsman et al., 1984, Gylfe et al., 1991), which are 
maintained at approximately 100nM in unstimulated beta cells and can increase to in excess of 
500nM following stimulation with secretagogues (Draznin, 1988, Prentki and Wollheim, 1984). 
The elevation of intracellular calcium is considered to be the key event in regulating the insulin 
secretory process (Hellman et al., 1994, Jones et al., 1985). GSIS is inhibited when intracellular 
calcium concentrations exceed 10mM, but extracellular calcium concentrations ranging between 
0.1mM and 1mM fail to promote insulin release even though calcium influx is observed, 
whereas extracellular calcium concentrations ranging between 1-5mM can trigger the onset of 
insulin release (Wollheim and Sharp, 1981, Curry et al., 1968). Physiological secretagogues can 
either promote calcium influx and/or mobilise calcium from internal calcium stores such as the 
endoplasmic reticulum or mitochondria (Draznin, 1988). Non-nutrient-induced insulin 
secretions via activation of Gαq protein-coupled receptors expressed by beta cells, such as 
GPR54, have been associated with elevations in intracellular calcium concentrations in beta cells 
(Hauge-Evans et al., 2006, Bowe et al., 2009). GPR75 couples to the Gαq protein and its 
overexpression has been implicated in CCL5-induced elevations in intracellular calcium in 
CHO-K1 cells  (Ignatov et al., 2006).  
Calcium microfluorimetry experiments demonstrated that intracellular calcium concentrations 
were reversibly elevated in response to increasing concentrations of CCL5 at a sub-stimulatory 
glucose concentration in Fura-2 loaded MIN6 beta cells (Figure 58 and Figure 59), mouse islet 
beta cells (Figure 61) and human islet beta cells (Figure 62). This supports earlier findings in this 
thesis which demonstrated that CCL5 initiated insulin secretion at 2mM glucose in MIN6 beta 
cells (Figure 48a). Furthermore, CCL5 also reversibly increased intracellular calcium 
concentrations in MIN6 beta cells at 20mM glucose (Figure 60), which also supported the 
ability of CCL5 to potentiate insulin secretion at a stimulatory glucose concentration in MIN6 




beta cells (Figure 48b-c). It is likely that the stimulatory effects of CCL5 on insulin secretion 
from the beta cell are closely regulated by changes in intracellular calcium concentrations.  
Down-regulation of GPR75 expression, which was achieved by using GPR75 targeted siRNAs 
(Figure 63), was carried out to identify if GPR75 activation was responsible for the stimulatory 
effects of CCL5 on intracellular calcium and insulin secretion. These experiments demonstrated 
that the stimulatory effects of CCL5 on intracellular calcium were substantially reduced 
following GPR75 depletion (Figure 64) and the insulin secretory response to CCL5 was absent 
in GPR75 down-regulated MIN6 beta cells (Figure 65). These novel findings directly implicate 
GPR75 activation in the stimulation of cytosolic calcium and insulin secretion in beta cells in 
response to CCL5 (Figure 86). 
Non-nutrient secretagogues have been implicated in elevating cytosolic calcium concentrations 
by activating beta cell GPCRs (Bowe et al., 2009, Burant, 2013, Hellman and Gylfe, 1986, Li et 
al., 2010, Romero-Zerbo et al., 2011, Amisten et al., 2013). Changes in intracellular calcium in 
beta cells result from either calcium entry from the extracellular compartment via VOCCs 
located on the plasma membrane (Curry et al., 1968, Islam, 2002) or through the mobilisation of 
calcium from the endoplasmic reticulum (Islam, 2002). Calcium release from the ER is regulated 
by ryanodine receptor (RYR)-gated or IP3 receptor (IP3R)-gated calcium channels. An 
important feature of RYR is that they are sensitive to cytosolic calcium and can amplify the 
calcium signal elicited from calcium influx via VOCCs or calcium release upon IP3R, activation, 
thus providing a mechanism of calcium-induced calcium release (Islam, 2002, Lemmens et al., 
2001). Although, cAMP does not directly stimulate calcium release, its activation of PKA has 
been shown to release the RYR calcium channel from the inhibition of high magnesium (Mg2+) 
concentrations, which brings the channel to an excitable state for it to be activated by calcium 
entering via L-type VOCCs (Lemmens et al., 2001, Fabiato, 1992). RYR can also be activated in 
a PKA-independent manner and promotes calcium release through cAMP activation of cAMP-
regulated guanine nucleotide exchange factor 2 (Epac2) by interacting with Rap1b (Kang et al., 
2001). Calcium mobilisation via IP3R gated calcium channels can be activated directly by IP3 
generated from PLC-mediated PIP2 hydrolysis or indirectly activated by depolarisation-induced 
calcium. However, it is not involved in the amplification process of calcium-induced calcium 
release in beta cells, which is primarily mediated by the activation of RYR-gated calcium 
channels (Lemmens et al., 2001).  
Calcium microfluorimetry experiments identified a calcium influx component downstream of 
GPR75 activation, as illustrated in Figure 86, in which CCL5 stimulated intracellular calcium 
levels in MIN6 beta cells in the presence of extracellular calcium (Figure 66a: red line), but this 
stimulatory response was abolished in the absence of extracellular calcium (Figure 66a: black 
line). This ruled out the possibility of the mobilisation of calcium from the endoplasmic 




reticulum, which is a conventional hallmark associated with Gαq protein coupled receptors 
(Persaud et al., 1989). Furthermore, ATP, which acts via purinergic (P2Y) receptors and induces 
calcium mobilisation (Green et al., 1997, Gylfe and Hellman, 1987), was still able to elevate 
intracellular calcium in MIN6 beta cells in the absence of extracellular calcium (Figure 66a: red 
line). This demonstrated that these cells did not lose their capacity to mobilise calcium from the 
endoplasmic reticulum after being challenged with CCL5, which suggests that calcium influx is 
solely responsible for CCL5-induced elevations in intracellular calcium. 
In addition, insulin secretion from beta cells is tightly coupled to calcium influx through L-type 
calcium channels, which is considered to be the predominant calcium channel responsible for 
elevating glucose-induced intracellular calcium concentrations in beta cells (Ashcroft et al., 1994, 
Braun et al., 2008). Calcium microfluorimetry experiments confirmed that calcium influx into 
beta cells was achieved by opening of L-type calcium channels, as responses to CCL5 (Figure 
67a: Black line) were abolished when L-type calcium channels were blocked with nifedipine in 
MIN6 beta cells (Figure 67a: Red line) and human islets (Figure 68). Therefore, this implies 
CCL5 may stimulate insulin secretion via a calcium influx component involving L-type VOCCs. 
However, further experiments are required to measure CCL5-induced insulin secretion in 
response to blockade of L-type VOCCs. 
  




Figure 86: Diagram illustrating the calcium influx component of the GPR75 signalling pathway 
in beta cells. CCL5 (Solid orange circles) binds to GPR75 and activates the heterotrimeric G-protein 
subunit, causes the dissociation of the Gαq protein from the Gβγ subunit. This activation is presumably 
responsible for the elevation of intracellular calcium levels, which enters the beta cell via L-type calcium 
channels, and acts as the predominant signal for driving the insulin secretory process in beta cells. This 
rules out the possibility of calcium mobilisation.  
  




VOCCs play an important regulatory role in mediating the calcium-dependent effects of CCL5 
on insulin secretion. Beta cell membrane depolarisation is detected by VOCCs, which are 
activated and allow calcium influx across the cell membrane and ultimately elevate cytosolic 
calcium concentrations (Ashcroft and Rorsman, 1989, Tarasov et al., 2004, Henquin et al., 2003, 
Henquin et al., 2006). Insulin secretion experiments show CCL5-induced insulin secretion was 
abolished when mouse islets were treated with diazoxide (Figure 70), which maintains the open 
state of KATP channels and prevents beta cell membrane depolarisation. Therefore, these data 
suggest that GPR75 activation by CCL5 induces closure of KATP channels, which presumably 
opens L-type calcium channels by depolarising the cell membrane and allowing calcium entry 
into beta cells. 
It has been reported that Gαq protein-deficient mouse beta cells demonstrated a higher open 
probability of KATP channels, with a lower percentage of beta cells that were able to elicit action 
potentials when compared to controls (Sassmann et al., 2010). PIP2 has also been implicated in 
increasing the open probability state of KATP channels (Shyng and Nichols, 1998, Baukrowitz et 
al., 1998) by binding to the C-terminus of the Kir6.2 subunit of KATP channels (MacGregor et 
al., 2002, Baukrowitz et al., 1998). Furthermore, co-expression of KATP channels with PLC-
coupled purinergic receptors (P2Y) in xenopus oocyte, demonstrated decreased KATP-mediated 
currents when stimulated with ATP, which was attributed to diminished PIP2 concentrations as 
a result of increasing hydrolysis invoked by PLC stimulation (Baukrowitz et al., 1998). 
Therefore, receptor-mediated activation of PLC may reduce the open probability of KATP 
channels by reducing the availability of PIP2 and may abrogate its binding to the Kir6.2 subunit 
of the KATP channel thus representing a possible mechanism of phospholipid-mediated 
regulation of beta cell membrane excitation (Figure 87). 
GPR75 couples to the Gαq protein in HEK and CHO cells (Ignatov et al., 2006) but the evident 
calcium influx component in beta cells, upon GPR75 activation by CCL5 is atypical of 
established Gαq protein coupled receptors, which usually mobilise calcium from the ER. PLC is 
activated by Gαq protein coupled receptors and is responsible for the generation of IP3 and 
DAG from the hydrolysis of PIP2. PLC activation is essential for CCL5-induced mobilisation of 
calcium in CHO-K1 cells expressing GPR75 (Ignatov et al., 2006) and experiments in this 
chapter, as demonstrated in Figure 71 and Figure 72, show CCL5-induced elevations in 
intracellular calcium concentrations were diminished but not abolished in Fura-2 loaded MIN6 
beta cells that were treated with a PLC inhibitor (U73122) at 10µM. However, CCL5-induced 
insulin secretion was completely abolished in MIN6 beta cells (Figure 73) and human islets 
(Figure 74b) that were also treated with 10µM U73122. The disparity between the partial loss of 
CCL5-induced elevations in intracellular calcium and the absolute inhibition of CCL5-induced 
insulin secretion in beta cells treated with identical concentrations of U73122 suggests that 




CCL5-induced insulin secretions is a PLC-dependent process but the ability of CCL5 to elevate 
intracellular calcium may involve PLC-dependent and independent mechanisms that converge 
downstream to regulate insulin secretion. For example, a PLC-independent mechanism may 
involve the Gβγ complex, which can stimulate cAMP accumulation in human fibroblast cells 
(Ahmed and Heppel, 1997) and subsequently stimulate protein kinase A (PKA) and cAMP-
activated GTP-exchange factors (Epacs). PKA can activate L-type calcium channels and is 
known to increase the open probability state of VOCCs (Britsch et al., 1995, Kanno et al., 1998, 
Ammala et al., 1993, Bünemann et al., 1999, Gao et al., 1997). In theory, this may elevate beta 
cell intracellular calcium concentrations in the presence of U73122 but this may fail to reach the 
threshold required to promote insulin secretion (Figure 87). This is supported by a study, which 
demonstrated insulin secretion was only observed when extracellular calcium concentrations 
exceeded 1mM, whereas extracellular calcium concentrations ranging between 0.1mM and 1mM 
permitted influx of calcium into beta cells but did not stimulate insulin secretion (Curry et al., 
1968). Identification of a possible PLC-independent mechanism on elevating intracellular 
calcium upon GPR75 activation by CCL5 would warrant further investigation by measuring 
cAMP and/or PKA levels in beta cells. 
  




Figure 87: Diagram illustrating the possible association of KATP channel closure and calcium 
influx component of the GPR75 signalling pathway in beta cells. CCL5 (Solid orange circles) binds 
to GPR75, which activates the heterotrimeric G-protein subunit and causes the dissociation of the Gαq 
protein from the Gβγ subunit. This activates PLC, which decreases cellular concentrations of PIP2 by 
stimulating the generation of IP3 and DAG, resulting in reduced binding of PIP2 to the Kir6.2 subunit of 
KATP channels. This subsequent reduced open probability state of KATP channels will depolarise the beta 
cell membrane and elevate intracellular calcium levels, by activating L-type calcium channels, which acts 
as the predominant signal for driving the insulin secretory response to CCL5. In addition, PLC-
independent effects may elevate intracellular calcium levels via a PKA-dependent mechanism by 
activation of L-type VOCCs by PKA.  
  




Several classes of protein kinases whose activities are modulated by calcium, cyclic nucleotides 
and products of phospholipid hydrolysis have been identified in islets and insulin secreting beta 
cell lines (Jones and Persaud, 1998b). The regulation of the phosphorylation state of specific 
intracellular protein kinases are important for regulating insulin secretion (Harrison et al., 1984). 
There are three distinct groups of serine/threonine protein kinases that have been identified in 
islets: calcium/phospholipid-dependent protein kinase C (PKC), calcium/calmodulin-
dependent kinase (CAMK) and cAMP-dependent kinase (PKA). The stimulatory effects of 
GPR75 activation by CCL5 on insulin secretion via a PLC-dependent process, coupled with its 
ability to elevate intracellular calcium warranted further investigation of the potential 
involvement of protein kinases in these effects. 
As illustrated in Figure 75, MIN6 beta cells that were challenged with staurosporine (STP), a 
broad spectrum protein kinase inhibitor (Persaud et al., 1993), diminished CCL5-induced 
elevations in intracellular calcium at 2mM glucose, which implicated protein kinase involvement 
in mediating the downstream effects of GPR75 activation on intracellular calcium in beta cells. 
However, CCL5-induced insulin secretion was completely abolished by STP in MIN6 beta cells 
(Figure 76) and human islets (Figure 77), which suggested that GPR75 signalling is 
predominantly mediated through protein kinases, which influence intracellular calcium and/or 
insulin exocytosis. Intracellular calcium can be regulated by protein kinases at various events 
associated with stimulus-secretion coupling in beta cells. For example, KATP channels and the 
sulphonylurea receptor (SUR1) have several potential phosphorylation sites for PKC and PKA 
(Inagaki et al., 1995b), as do L-type VOCCs (Seino et al., 1992, Seino, 1995). PKC can regulate 
calcium influx by altering the phosphorylation state of L-type VOCCs (Arkhammar et al., 1994). 
PKA can also phosphorylate VOCCs in a mouse beta cell line (Leiser and Fleischer, 1996) and 
thus has been shown to enhance the open probability of L-type calcium channels (Bünemann et 
al., 1999, Gao et al., 1997, Kanno et al., 1998). Therefore, protein kinases can potentially modify 
calcium influx by phosphorylating either KATP channels or VOCCs. In addition, protein kinases 
can also directly regulate insulin secretory granule transport and insulin exocytosis by 
phosphorylating cytoskeletal elements (Jones and Persaud, 1998b) such as actin (Calle et al., 
1992), myosin (Penn et al., 1982, MacDonald and Kowluru, 1982) and tubulin (Colca et al., 
1983). Also, PKA and CAMK II have been shown to influence vesicle fusion with the cell 
membrane by phosphorylating v-SNARES (VAMP) (Hirling and Scheller, 1996), whereas, 
glucose and GLP-1 can also phosphorylate t-SNARES (SNAP-25) but the kinase/s responsible 
are yet to be identified (Zhou and Egan, 1997). 
Insulin secretion experiments were performed to identify the protein kinases involved in the 
stimulus-secretion coupling of CCL5 in beta cells. As illustrated in Figure 78, CCL5-induced 
insulin secretion was diminished but not completely lost in the presence of Ro-31-8220, a non-




selective pharmacological inhibitor of PKC (Harris et al., 1996). The continued effects of CCL5 
the presence of Ro-31-8220 may be explained by the use of a concentration that did not 
completely inhibit PKC activity. Therefore, an alternative approach of depleting DAG-sensitive 
conventional and novel PKC isoforms by prolonged exposure to PMA, which causes PKC to 
translocate from the cytosol to the cell membrane where it is degraded (Howell et al., 1994), 
provided an alternative way of measuring the PKC-mediated effects of the GPR75 signalling 
pathway on beta cell function. CCL5-induced insulin secretion was shown to be primarily 
mediated through DAG-sensitive PKC activation in mouse (Figure 80) and human (Figure 81) 
beta cells. This is consistent with previous findings in this thesis that implicate PLC involvement 
in CCL5 effects in beta cells as PLC hydrolyses PIP2 to generate DAG, which is a known 
activator of PKC, and may increase the open probability of L-type calcium channels 
(Arkhammar et al., 1994), as well as KATP channel opening as the SUR1 component acts as its 
substrate (Inagaki et al., 1995a) and promote calcium influx via VOCCs in response to 
membrane depolarisation, in which VOCCs have been shown to stimulate DAG-sensitive PKC 
isoforms (Mogami et al., 2003). PKC can also promote the exocytosis of calcium sensitive 
insulin secretory granules by sensitising the insulin secretory machinery to calcium (Wan et al., 
2004). Furthermore, PKC also has the ability to transduce its effects through cAMP dependent 
signalling pathways (Sugita et al., 1997), but these effects are assumed to take place at the levels 
of signal recognition and/or second messenger generation rather than the latter stages of the 
insulin secretory pathway after protein kinase activation by second messengers (Basudev et al., 
1995) but this mechanism is yet to be identified in beta cells. These findings highlight the 
importance of PKC and its involvement in regulating insulin secretion. It is worth noting, 
depletion of DAG-sensitive PKC isoforms by long-term exposure to PMA does not 
discriminate between conventional and novel PKC isoforms. MIN6 beta cells were still able to 
secrete insulin in response to CCL5 in the presence of GÖ6976, a conventional PKC inhibitor, 
and therefore discriminates between conventional and novel PKC isoforms (Ishikawa et al., 
2005). It has been reported that novel PKC isoforms (PKC-δ and/or ε) are involved in CCh-
induced insulin secretion in rat islets (Ishikawa et al., 2005), which may indicate that novel PKC 
isoforms are involved in mediating the effects associated with the activation of the GPR75 
signalling cascade in response to CCL5.  
Beta cells express a variety of calcium-sensitive proteins that may be involved in sensing 
changes in cytosolic calcium levels. CAMK II can transduce calcium mobilising signals into a 
secretory response (Jones and Persaud, 1998b). Glucose or depolarising concentrations of K+ 
have been shown to increase CAMK activity as a result of calcium influx through VOCCs 
(Wenham et al., 1994). There is a strong correlation between CAMK II dependence on glucose 
concentrations and insulin secretion and it has been reported that increases in CAMK II activity 
usually precedes insulin secretion (Babb et al., 1996). It has been reported that CAMK II is 




important for calcium entry via VOCCs, with reduced basal cytosolic and ER calcium stores 
upon CAMK II inhibition (Dadi et al., 2014). It has been established that CAMK II is involved 
in promoting the trafficking and docking of insulin secretory granules by  phosphorylating 
proteins such as synapsin-1 and microtubule-associated protein-2 during insulin exocytosis 
(Easom, 1999) and CAMK II inhibition with KN-62 inhibits nutrient-induced insulin secretion 
(Li et al., 1992, Wenham et al., 1992, Niki et al., 1993). KN-62 is a competitive inhibitor at the 
calmodulin binding site of CAMK II and has no effect on PKC in beta cells (Wenham et al., 
1992). Experiments in this thesis demonstrate that CCL5-indiuced insulin secretion is also 
abolished in MIN6 beta cells (Figure 84) and human islets (Figure 85) when challenged with 
KN-62, which is likely to work downstream of PKC activation and calcium elevations within 
the beta cells. This reaffirms the importance of protein kinases such as PKC and CAMK II in 
the GPR75 signalling pathway that mediate the associated effects of CCL5 in the beta cell 
(Figure 88). It would be interesting to identify PKA activity, which may indicate the possible 
association of cAMP-dependent pathways in the GPR75 signalling cascade in beta cells, but 
there was not sufficient time to carry out experiments with PKA inhibitors during this thesis. 
  




Figure 88: Diagram illustrating the role of protein kinases in the GPR75 signalling pathway in 
beta cells. CCL5 (Solid orange circles) binds to GPR75, which activates the heterotrimeric G-protein 
subunit and causes the dissociation of the Gαq protein from the Gβγ subunit. The Gαq protein activates 
PLC and subsequently stimulates the generation of DAG, which may activate DAG-sensitive novel PKC 
isoforms. PKC can go on to affect multiple events associated with the stimulus-secretion pathway of 
CCL-GPR75 involving VOCCs, insulin exocytosis and possible cAMP dependent signalling pathways.  
Furthermore, CCL5 can mediate its effects on insulin secretion via CAMK II, which is activated by the 
binding of calcium-calmodulin, which is activated in response to the elevation in intracellular calcium 
levels associated with calcium influx via L-type calcium channels. 
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Chapter 6: GPR75 activation regulates beta cell mass. 





T2DM is caused by two major defects: insulin resistance and defective beta cell function 
(DeFronzo, 1988). The decline in insulin secretory function is paralleled by a reduction in beta 
cell mass (Lupi and Del Prato, 2008), which is a dynamic process involving the fine balance 
between beta cell expansion (hyperplasia and/or neogenesis) and involution (necrosis and/or 
apoptosis). Apoptosis is considered to be the key regulator of beta cell mass, with a report 
suggesting that beta cell mass was reduced in T2DM subjects by 63%, which was attributed to 
apoptosis while beta cell regeneration was similar between control and T2DM islets (Butler et 
al., 2003a). Furthermore, electron microscopy studies of islets from T2DM pancreatic donors 
have shown an approximate 60-70% decrease in the number of beta cells compared to that of 
non-diabetic islets, which was associated with increased expression of caspases (Marchetti et al., 
2004). Obese patients with T2DM exhibit an approximate 60% reduction in beta cell mass, 
which was attributed to a 3-fold increase in beta cell apoptosis (Butler et al., 2003c). These 
findings collectively indicate that the reduction in beta cell mass observed in T2DM is likely to 
be a result of increased beta cell apoptosis (Lupi and Del Prato, 2008, Donath and Halban, 
2004).  
Apoptosis is a coordinated sequence of events that results in the programmed execution of cell 
death. It plays a key role in maintaining islet health by removing infected or mutated cells (Lupi 
and Del Prato, 2008). Beta cell apoptosis can be triggered by three pathways, which include 
cytokine-induced death by the activation of cell surface death receptors (Wajant, 2002, Curtin 
and Cotter, 2003), mitochondrial dysfunction, and activation of the ER stress pathway.  
Although information on the role of GPR75 in regulating cell apoptosis and survival is currently 
limited it has already been implicated in providing cell protective effects in mouse hippocampal 
cells (HT22), in which exposure to CCL5 significantly enhanced cell viability (Ignatov et al., 
2006). The hippocampus is one of the areas affected in patients with Alzheimer’s disease, which 
is predominantly caused by the aggregation of amyloid-β peptide (Cummings et al., 1998). It is 
understood that the amyloid-β peptide is able to induce chemokine production in neuronal cells, 
which subsequently results in neuro-inflammation and eventual cell death (Cartier et al., 2005, 
Bajetto et al., 2001). Islets of T2DM patients also exhibit amyloid deposits in the extracellular 
compartment and amylin, also known as islet amyloid pancreatic polypeptide (IAPP), which is 
the major constituent of islet amyloid plaques (Cooper et al., 1987), is also co-secreted with 
insulin (Moore and Cooper, 1991). The build-up of islet amyloid is termed islet amyloidosis (IA) 
and has been implicated in the loss of beta cells in T2DM by inducing apoptosis (Matveyenko 
and Butler, 2006, Lorenzo et al., 1994). IA can cause cell death by occupying the extracellular 
compartment which starves islets of nutrients and oxygen uptake (Guardado-Mendoza et al., 




2009). Furthermore, small IAPP oligomers can form non-selective cation channels that can lead 
to excessive calcium influx, ER stress and apoptosis (Huang et al., 2007, Mirzabekov et al., 
1996, Ritzel et al., 2007) and can disrupt cell membrane integrity resulting in the loss of cell 
synchrony within the islet (Ritzel et al., 2007). It has been reported that human IAPP can 
promote beta cell death in RINm5F cells by activating p38 MAPKs and caspase-3 (Rumora et 
al., 2002). 
Experiments reported in chapters 3 of this thesis have demonstrated that GPR75 is the most 
abundantly expressed CCL5 receptor in islets and that CCL5 is also endogenously expressed in 
islets. Unfortunately, due to insufficient time, the effects of GPR75 activation by CCL5 on islet 
amyloid deposits within islets could not be determined but it can be presumed that GPR75 
activation by CCL5 may enhance beta cell viability. Therefore the focus of this chapter aimed to 
identify the potential regulatory role of GPR75 activation by CCL5 on beta cell mass by 
studying the effects of CCL5 on islet and beta cell apoptosis as well as on beta cell proliferation. 
  





Apoptosis assay: Measurement of caspase 3/7 activities in MIN6 beta cells, mouse 
islets and human islets. 
20,000 MIN6 beta cells or 5 islets were seeded into white-wall 96-well plates and incubated for 
24 hours (5% CO2/95% air, 37°C) in 200µl serum-containing medium (Table 1). Cells or islets 
were then treated with various concentrations of exogenous CCL5 in the absence or presence 
of a cytokine cocktail, which consisted of IL-1β (50 U/ml), TNF-α (1000 U/ml) and IFN-γ 
(1000 U/ml), and incubated for a further 21 hours (5% CO2/95% air, 37°C). Caspase 3/7 
activities were measured by preparing the CaspaseGlo® reagent as described in section 2.7.1, 
which was added to each well followed by 1 hour incubation at room temperature. 
Luminescence was measured using a Veritas luminometer. 
BrdU colorimetric assay: Measurement of MIN6 beta cell proliferation. 
MIN6 beta cells were seeded into clear 96 well plates at a density of 15,000 cells per well and 
incubated for 24 hours (5% CO2/95% air, 37°C) in 200µl serum-containing medium (Table 1). 
The cells were then treated with various concentrations of exogenous CCL5 for a further 21 
hours (5% CO2/95% air, 37°C), then incubated with 10µM BrdU labelling solution for 2 hours 
at 37°C before being denatured and tagged with a peroxidase-conjugated anti-BrdU antibody, as 
described in section 2.7.2. Absorbance was measured at 450nm using an ELISA reader (Hidex 
Chameleon™V). 
  





6.3.1: The effect of CCL5 on cytokine-induced apoptosis in MIN6 beta cells as well as 
mouse and human islets.  
As shown in Figure 89, 25nM CCL5 did not affect the basal level of MIN6 beta cell apoptosis. 
As expected, a cytokine cocktail (IL-1β, TNF-α and IFN-γ) induced MIN6 beta cell apoptosis, 
which was measured by an 8.6-fold increase in caspase 3/7 activities. Moreover, when MIN6 
beta cells were challenged with CCL5 in the presence of a cytokine cocktail, apoptosis was 
significantly reduced such that caspase 3/7 activities increased by only 4.3-fold. These data 
indicate that CCL5 confers MIN6 beta cell protection by suppressing cell apoptosis by 
approximately 50%. Similar data were observed in experiments using isolated mouse islets, in 
which CCL5 did not affect basal levels of apoptosis. However, a 4.4-fold increase in caspase 
3/7 activities was observed when mouse islets were treated with cytokines alone but when 
mouse islets were treated with 2.5nM and 25nM CCL5 apoptosis decreased to levels not 
significantly different from basal apoptosis observed in the absence of cytokines but in the 
presence of cytokines apoptosis was significantly diminished (Figure 90). In human islets, 
cytokine-induced apoptosis increased by approximately 4-fold, as expected, but the pro-
apoptotic effects  of the cytokines were significantly reduced, by up to 50% when human islets 
were treated with 0.01nM-1nM CCL5, as shown in Figure 91.  
  





Figure 89: The effect of CCL5 on MIN6 beta cell apoptosis. MIN6 beta cells were treated with 
25nM CCL5 in the absence or presence of a cytokine cocktail (IFNγ:1000U/μl, TNF-α:1000U/μl and IL-
1β:100U/μl) in serum-deprived DMEM and incubated for 21 hours at 37°C (5% CO2/95% air). 
Apoptosis was detected by measuring Caspase 3/7 activities by incubating the cells for 1 hour with a 
mixture containing a Caspase-Glo® substrate and reagent at room temperature. The luminescent signal 














































Figure 90: The effect of CCL5 on mouse islet apoptosis. Isolated mouse islets were treated with 
25nM CCL5 in the absence or presence of a cytokine cocktail (IFNγ:1000U/μl, TNF-α:1000U/μl and IL-
1β:100U/μl) in serum-deprived RPMI and incubated for 21 hours at 37°C (5% CO2/95% air). Apoptosis 
was detected by measuring caspase 3/7 activities by incubating the islets for 1 hour with a mixture 
containing a Caspase-Glo® substrate and reagent at room temperature. The luminescent signal generated 
was detected and measured using a luminometer. Data expressed as Mean ± SEM, n=6-7. **P<0.01. No 














































Figure 91: The effect of CCL5 on human islet apoptosis. Isolated human islets were treated with 
CCL5 (0.01nM–1nM) in the absence or presence of a cytokine cocktail (IFNγ:1000U/μl, TNF-
α:1000U/μl and IL-1β:100U/μl) in serum-deprived CMRL for 21 hours at 37°C (5% CO2/95% air). 
Apoptosis was detected by measuring caspase 3/7 activities by incubating the islets for 1 hour with a 
mixture containing a Caspase-Glo® substrate and reagent at room temperature. The luminescent signal 
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6.3.2: The effect of GPR75 down-regulation on MIN6 beta cell apoptosis. 
To identify whether endogenous signalling through GPR75 protects beta cells from apoptosis, 
the effects of GPR75 down-regulation on apoptosis of MIN6 beta cells was investigated, under 
conditions where siRNAs induced approximately 40% reduction in GPR75 expression (Figure 
63). Basal levels of MIN6 beta cell apoptosis increased by 3.5-fold (Figure 92) in MIN6 beta 
cells. As expected, treatment of control MIN6 beta cells, which had been exposed to non-
coding (NC) RNAs with a cytokine cocktail increased caspase 3/7 activities by approximately 7-
fold. However, cytokine-induced apoptosis increased by 12-fold in MIN6 beta cells that were 
treated with GPR75 siRNAs, which represented a 177% increase in caspase 3/7 activities 
compared to controls (NC RNA). 
 
Figure 92: The effect of GPR75 down-regulation on MIN6 beta cell apoptosis. GPR75 was down-
regulated in MIN6 beta cells by transiently transfecting siRNAs (150nM) directed against GPR75. MIN6 
beta cells were also transiently transfected with 150nM non-coding RNAs (NC), which served as controls. 
Cells were maintained in culture for 48 hours at 37°C (5% CO2/95% air) in the absence or presence of a 
cytokine cocktail (IFNγ:1000U/μl, TNF-α:1000U/μl and IL-1β:100U/μl) in serum-free DMEM. 
Apoptosis was detected by measuring caspase 3/7 activities by incubating the cells for 1 hour with a 
mixture containing a Caspase-Glo® substrate and reagent at room temperature. The luminescent signal 

















































6.3.3: Effect of CCL5 on MIN6 beta cell proliferation. 
Cell proliferation was also measured by BrdU incorporation into DNA of MIN6 beta cells after 
21 hour exposure to CCL5 and these experiments indicated that proliferations was significantly 









Figure 93: The effect of CCL5 on MIN6 beta cell proliferation. MIN6 beta cells were treated with 
CCL5 (0.25nM and 2.5nM) in serum-free DMEM for 21 hours at 37°C (5% CO2 95% air). Cell 
proliferation was measured using an ELISA colorimetric immunoassay kit based on BrdU incorporation 
during DNA synthesis. Cells were incubated with 100µM BrdU labelling reagent for 2 hours, denatured 
and then incubated with an HRP-conjugated anti-BrdU antibody for 90 min. Antibody binding was 
visualised by incubation (20 minutes) with an HRP substrate (tetramethylbenzidine). The reaction was 
terminated by the addition of 1 M H2SO4, and the coloured product was assessed by measuring the 
















































T2DM is characterised by impaired insulin action (insulin resistance) in peripheral target tissues 
such as liver, adipose and muscle, as well as being associated with a defective insulin secretory 
mechanism in response to elevated levels of glucose. Conventional pharmacological treatments 
for T2DM tend to focus on lowering blood glucose levels through various mechanisms but 
these hypoglycaemic agents lose their efficacy over time leading to deterioration in beta cell 
function and worsening of glycaemic control. This has partially been attributed to a progressive 
loss in beta cell mass (Baggio and Drucker, 2006). Several studies have demonstrated that beta 
cell mass is reduced in T2DM subjects compared to non-diabetic controls, despite normal beta 
cell replication and neogenesis (Saito et al., 1979, Maclean and Ogilvie, 1955, Butler et al., 2003a, 
Yoon et al., 2003, Pick et al., 1998). The regulation of beta cell mass is a combined result of: 
beta cell replication, beta cell differentiation (neogenesis) and beta cell apoptosis (Bonner-Weir, 
2000b, Bonner-Weir, 2000a). An increase in beta cell apoptosis is commonly observed in 
subjects with T2DM (Butler et al., 2003a, Pick et al., 1998), which is thought to be invoked by 
oxidative stress, ER stress, islet amyloid deposition, chronic hyperglycaemia and inflammatory 
cytokines (Donath and Halban, 2004, Rhodes, 2005). As current T2DM medication have failed 
to address the progressive loss of beta cells there has been an increasing interest in the 
development of therapeutic targets that preserve and/or restore beta cell mass, especially by 
inhibiting beta cell apoptosis (Baggio and Drucker, 2006). 
The results in this chapter demonstrate CCL5 exhibits protective effects in MIN6 beta cells 
(Figure 89), mouse islets (Figure 90) and human islets (Figure 91), as measured by a reduction in 
caspase 3 and caspase 7 activities. Furthermore, down-regulation of GPR75 using gene-specific 
siRNAs demonstrated that MIN6 beta cells were more susceptible to basal and cytokine-
induced apoptosis compared to those cells transfected with non-coding RNAs (Figure 92). This 
suggests that the protective effects in beta cells are mediated via GPR75, most likely forming its 
activation by islet derived CCL5. This is consistent with a previous study demonstrating that 
CCL5 reduced HT22 cell death induced by amyloid-β deposits, which endogenously expresses 
GPR75 but not conventional CCL5 receptors (Ignatov et al., 2006). Furthermore, CCL5 also 
stimulated MIN6 beta cell proliferation (Figure 93). 
GPR75 activation is thought to confer protective effects on CV-1 cells by activating the 
PLC/PI3K/Akt/p42/p44 MAPK cell survival pathway (Ignatov et al., 2006). Previous 
experiments in this thesis have established that GPR75 signals through PLC in beta cells 
(Section 5.3.5). Those studies were tasked on the role of the GPR75/PLC cascade on beta cell 
function but the data presented in this chapter of reduced beta cell apoptosis and increased beta 
cell proliferation downstream of GPR75 activation suggest that there may be a possible PLC-
dependent cell survival pathway in beta cells.  




Activation of PI3K results in the generation of phosphatidylinositol-3,4,5-trisphosphate (PIP3) 
from phosphatidylinositol-3,4-bisphosphate (PIP2) at the plasma membrane, which activates 
Akt (Fresno Vara et al., 2004). It has been shown that the Gq-coupled muscarinic receptor 1 
(M1) can activate Akt in COS-7 cells in a PI3K-dependent manner (Murga et al., 1998). 
Furthermore, the Gα and the Gβγ subunits of M1 receptors can promote Akt activity, with 
further identification of a Gβγ-sensitive PI3Kγ, which can go on to stimulate Akt (Murga et al., 
1998), which indicates of a potential link between Akt stimulation and activation of Gq-coupled 
GPR75. It has been reported that activation of an uncharacterised Gαs-coupled receptor for the 
peptide hormone ghrelin was able to protect beta cells from apoptosis by Akt and MAPK 
pathways (Granata et al., 2007). Overexpression and hyper-activation of Akt has been associated 
with reduced susceptibility to apoptosis and increased cell growth and proliferation, respectively 
(Lawlor and Alessi, 2001, Downward, 2004). In addition, inducing Akt activation stimulates beta 
cell replication and  increases beta cell mass in the developing pancreas of mouse (Hakonen et 
al., 2014). Akt mediates its pro-survival effects through the phosphorylation of pro-apoptotic 
substrates such as Bad, Caspase 9 and forkhead transcription factors resulting in their inhibition 
(Downward, 2004, Khwaja, 1999, Lawlor and Alessi, 2001, Nakamura et al., 2000) (See section 
1.3.2 for in additional information on cell apoptotic pathways). This supports experiments in 
this chapter, which demonstrate CCL5-mediated reduction in caspase 3 and caspase 7 activities 
most likely though GPR75 activation of Akt. It has also been demonstrated that the PI3K/Akt 
survival pathway can cross-talk with other survival pathways such as the NFkB pathway 
(Hussain et al., 2012), which can regulate cell survival and apoptosis by transcriptionally 
activating pro-survival and anti-apoptotic genes such as Bcl-2, Bcl-XL, IkB-α, IAPs (Sethi et al., 
2008).   
Cell proliferation involves two essential tasks of replicating DNA without errors (S phase) and 
separating the duplicated chromosomal DNA into two daughter cells during mitosis (M phase). 
Both the S and M phases are separated by gap phases (G). G1 separates the M and S phases, 
whereas the G2 phase separates the S and M phase. The G1 is the interval in the cell cycle that 
can respond to extracellular signals and can determine the cell’s ability to enter the S phase or 
render the cell cycle into a quiescent state (G0). Once the cells are committed to entering the S 
phase the cell cycle is irreversible. The point of cell cycle irreversibility in the G1 phase is 
referred to as the “restriction point” (Sherr, 2000). The cell cycle phase transitions are 
controlled by cyclin dependent kinases (cdks), which associate with cyclins. In general, cyclin D 
associates with cdk-4 and cdk-6 during early G1 phase, whereas cyclin E activates cdk-2 during 
the cell’s transition from G1 to the S phase. Thus, phosphorylation of specific amino acid 
residues on cyclin/cdk complexes can regulate cell cycle progression. Furthermore, cyclin-
dependent kinase inhibitors (CKIs) such as p21, p27 and p52 can inhibit cyclin/cdk complexes 




and inhibit cell cycle progression into the S phase hence inhibit cell proliferation (Sherr, 2000, 
Lee et al., 1999). 
Akt has also been implicated in promoting cell proliferation by regulating transcription of p27. 
Overexpression of Akt down-regulates cellular levels of p27 and thus promotes cell 
proliferation (Gesbert et al., 2000, Graff et al., 2000, Sun et al., 1999). Furthermore, forkhead 
transcription factors are required for p27 transcription, and studies have shown that Akt 
phosphorylation sequesters forkhead transcription factors into the cell cytosol and thus inhibits 
p27 transcription (Nakamura et al., 2000, Medema et al., 2000). Maintenance of beta cells and 
beta cell proliferation requires activation of the cdk4/cyclin D complex, which is up-regulated 
by Akt by phosphorylation of cyclin D1, which is critical for cell cycle progression and 
maintenance of beta cell mass (Kushner et al., 2005, Chang et al., 2003, Georgia and Bhushan, 
2004). Increased cyclin D activity can also sequester p27, which is the principle cell cycle 
inhibitor in beta cells. It is known to accumulate in the beta cell nucleus of obese mice and 
inhibit beta cell expansion (Uchida et al., 2005, Sherr, 2000). It has been reported that mouse 
beta cells overexpressing Akt show marked expansion of beta cell mass, which has been 
attributed to increased levels of cyclin D1 and cyclin D2, and parallel inhibition of p27 
transcription by the inactivation of the FOXO1 forkhead transcription factor (Fatrai et al., 
2006).   
Eukaryotic cells also express multiple mitogen-activated protein kinases (MAPK) that mediate 
the effects of extracellular signals on a variety of biological processes. p42/p44 MAPK nuclear 
translocation is predominant in relaying the mitogenic signal from the cytoplasm into the 
nucleus (Chen et al., 1992, Lenormand et al., 1993) and is activated by a cascade of small G 
protein Ras-Raf followed by MAP3K activation. It has been reported that PMA, a PKC 
activator, can increase activity of the 44kDa MAPK isoform in the INS-1 beta cell line but its 
activation was not associated with an increase in insulin secretion (Frödin et al., 1995). 
However, it may suggest a possible role for MAPK in regulating beta cell mass, which has been 
reported to promote MIN6 beta cell proliferation upon p42/p44 MAPK activation (Burns et al., 
2000). This is consistent with previous experiments shown in this thesis that demonstrate 
CCL5-mediated activation of GPR75 activates PKC (Section 5.3.6). p42/p44 has been shown 
to progress the cell cycle of fibroblasts from the G1 to the S-phase (Brondello et al., 1995) by 
stimulating cyclin D1 activity (Lavoie et al., 1996). Furthermore, p42/p44 MAPK can also 
inhibit pro-apoptotic Bcl-2 family members Bad (Harada et al., 2001) and Bim (Biswas and 
Greene, 2002) and activate Caspase 9 (Park et al., 2013).  
Experiments in this thesis have demonstrated that GPR75 signals through PLC to mediate its 
effects on beta cell secretory function. The data presented in this chapter suggest that GPR75 
activate the PLC-dependent cell survival pathway in beta cells as it has previously been shown 




that GPR75 signals through PLC (Section 5.3.5), and is consistent with findings that GPR75 
activation by CCL5 results in the activation of the PLC/PI3K/Akt/p42/p44 MAPK cell 
survival cascade in CV-1 cells (Ignatov et al., 2006). Activation of Akt can inhibit pro-apoptotic 
proteins such as Bad and forkhead transcription factors, and regulate proteins involved in cell 
proliferation such as cyclin D and p27. Akt can also activate p42/p44 MAPKs (Ignatov et al., 
2006), which have been implicated in stimulating cell cycle progression from the G1 restriction 
point by stimulating cyclin D1 activity, as well as simultaneously inhibiting pro-apoptotic 
proteins. Therefore, future experiments should investigate the role of Akt and p42/p44 MAPK 
downstream of GPR75 on beta cell protection and proliferation and ultimately identify the 
pathways and regulatory mechanisms influencing GPR75-mediated beta cell apoptosis and 
proliferation (Figure 94). This would lay further claim to the potential T2DM therapeutic target 
of GPR75 due to its ability to not only improve beta cell secretory function but to also maintain 
or restore beta cell mass.  
  





Figure 94: Schematic diagram illustrating the potential GPR75-mediated cell protective effects 
on beta cell mass. CCL5 (solid orange circles) binds to GPR75 expressed on beta cells, which stimulates 
Akt through phospholipase C (PLC)-mediated activation of phosphatidylinositol-3 kinase (PI3K). Akt 
can inhibit apoptosis by inhibiting the actions of caspase 9 (Cas9) and thus caspase 3 (Cas3) and caspase 7 
(Cas7), inhibiting cytochrome c (C) release from the mitochondria, inhibiting pro-apoptotic substrates 
such as Bad and Bim and sequestering forkhead transcription factors (TFs) in the cytosol. This would 
subsequently prevent transcription of pro-apoptotic and anti-proliferative molecules such as Fas ligand 
and p27, respectively. Akt and PKC can also activate p42/p44 mitogen-activated protein kinases, which 
stimulate cell proliferation through the activation of cdk-4/cyclinD1 (cyD1) complex, which promotes 
cell cycle progression. This is further complemented by the ability of p42/p44 to inhibit Bad and Bim as 




Chapter 7: General discussion  




It is predicted that 592 million people will develop DM by 2035, of which 439 million people 
will develop T2DM (IDF, 2011, Chamnan et al., 2011, IDF, 2013). In 2011 alone, T2DM 
accounted for more than 4.6 million deaths (Olokoba et al., 2012, IDF, 2011). Lifestyle changes 
such as exercise and dietary modifications are the first line of T2DM intervention but when this 
fails to prevent the progression of T2DM then pharmacological intervention is required 
(Section 1.1.4). Therefore, there is a current impetus within the biomedical and pharmaceutical 
industry to develop the next generation of T2DM therapies, which not only improve long-term 
glycaemic control but can also delay T2DM progression, minimise the onset of secondary 
complications such as cardiovascular disease, kidney failure and retinopathy, but also minimise 
pharmacological side effects.  
GPCRs have become prominent pharmacological targets within biomedicine (Lappano and 
Maggiolini, 2011). They are the largest family of cell surface receptors, and they transmit 
extracellular stimuli into intracellular signals to regulate a variety of physiological functions. 
GPCRs expressed by islets are becoming promising candidates as therapeutic targets in the fight 
against T2DM (section 1.4.1). With over 250 GPCRs expressed by human islets, a majority of 
which have undocumented effects on islet hormone secretion it is evident that there is a 
knowledge gap in the current understanding between ligand-GPCR interactions and islet 
function, which could potentially aid the development of novel and safer T2DM therapeutics 
(Amisten et al., 2013).  
GPR75 was identified as a novel and atypical CCR (Tarttelin et al., 1999), and has been 
established to promote IP3 and DAG formation as well as elevating intracellular calcium levels 
in in HEK293 and CHO-K1 cells, respectively, by coupling to the Gαq protein when activated 
by its endogenous ligand CCL5 (Ignatov et al., 2006). Elevations in IP3 and DAG, which is a 
potent activator of PKC, have been implicated in stimulating insulin secretion (Chen and Hsu, 
1995, Arkhammar et al., 1994, Carpenter et al., 2004, Persaud et al., 1989). In addition, 
activation of endogenously expressed GPR75 in mouse hippocampal cells enhanced cell 
survival (Ignatov et al., 2006), therefore, if GPR75 has similar cell protective effects in beta cells 
it could possibly prevent beta cell loss and restore and/or improve beta cell mass. Furthermore, 
GPR75 is also expressed by a variety of tissues such as liver, skeletal muscle and kidney 
(Tarttelin et al., 1999, Ignatov et al., 2006), which have been implicated in the pathogenesis of 
T2DM. Thus, the experiments mentioned in this thesis aimed to determine the expression and 
function of GPR75 in islets of Langerhans and whether it could be a potential T2DM 
therapeutic target (section 1.4.4).  
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As described in Chapter 3, experiments involving qRT-PCR, IHC and Western blotting 
demonstrated that CCL5 mRNA was detected in mouse and human islets, which was consistent 
with a previous study which reported endogenous CCL5 expression in islets of NOD mice 
(Carvalho-Pinto et al., 2004). However, CCL5 mRNA was not detected in MIN6 beta cells and 
this was supported by the IHC studies described in this thesis, which demonstrated species–
dependent expression of CCL5. In mouse islets CCL5 co-localised with glucagon-secreting 
alpha cells whereas in human islets CCL5 was present in alpha and beta cells. CCL5 receptor 
mRNA expression revealed that GPR75 was the most abundant CCL5 receptor expressed by 
mouse and human islets, with minimal or non-existent expression of traditional CCL5 receptors 
CCR1, CCR3 and CCR5. Western blotting detected GPR75 proteins in mouse and human islets 
and in MIN6 beta cell protein extracts, and IHC studies revealed that GPR75 was expressed by 
alpha and beta cell populations in mouse and human islets.  
The expression of CCL5 in mouse and human islets, and the abundant expression of GPR75 by 
alpha and beta cells led to the next set of experiments, which aimed to determine the functional 
effects of exogenous CCL5 on insulin and glucagon secretion. As described in Chapter 4, static 
and dynamic islet hormone secretion experiments demonstrated that CCL5 was able to 
reversibly stimulate insulin secretion in mouse and human islets at sub-stimulatory and 
stimulatory glucose concentrations. However, the functional effect of CCL5 on arginine-
induced glucagon secretion differed between species as CCL5 stimulated glucagon secretion 
from mouse islets whereas it inhibited glucagon secretion from human islets. This could be 
explained, at least in part, by the fact that human islets have a higher number of alpha cells than 
their mouse counterparts and glucagon binding to GluR on alpha cells (Kawai et al., 1995, 
Wojtusciszyn et al., 2008), has been shown to increase glucose sensitivity and insulin output of 
beta cells (Jiang and Zhang, 2003, Pipeleers et al., 1985). The inhibitory effect of CCL5 on 
human islet glucagon secretion may be indirect, secondary to the higher insulin output observed 
from human islets in response to CCL5, which may override the stimulatory effect of CCL5-
stimulated glucagon on insulin secretion by binding to InsR expressed on alpha cells to inhibit 
glucagon release (Kawamori et al., 2009, Diao et al., 2005, Kaneko et al., 1999). 
Chapter 5 aimed to determine whether the stimulatory effect of CCL5 on insulin secretion was 
mediated though GPR75 activation and to identify potential signalling pathways elicited in the 
presence of a CCL5 stimulus. GPR75 knock down experiments using gene specific siRNAs 
demonstrated that the stimulatory effects of CCL5 on insulin secretion and intracellular calcium 
levels in beta cells were solely attributed to the activation of GPR75. This was consistent with 
previous findings in Chapter 3, which established that GPR75 was the most abundant CCL5 
receptor expressed in mouse and human islets and thus it was probable that CCL5 could 
mediate its beneficiary effects on beta cell function through GPR75. Further experiments with 




islets and MIN6 beta cells reaffirmed the notion that GPR75 was a Gαq coupled protein 
receptor, in which CCL5 was able to stimulate PLC activity to elevate intracellular calcium 
levels. Furthermore, a calcium influx component was identified upon removal of calcium from 
the extracellular compartment and blockade of L-type VOCCs. In addition, closure of KATP 
channels upstream of VOCCs was identified as playing a role in propagating the GPR75 signal 
into an insulin secretory response, most likely by depolarising the beta cell membrane and 
subsequently activating L-type VOCCs to permit calcium influx into the beta cell cytosolic 
compartment.  
As mentioned earlier, PLC activation is a pre-requisite for GPR75 signal propagation in the beta 
cell and it has been reported that GPR75 activation promotes the formation of IP3 and DAG 
via PLC-mediated PIP2 hydrolysis in HEK293 cells (Ignatov et al., 2006). DAG is a potent 
activator of PKC, and therefore it was conceivable that PKC and/or calcium activated CAMK 
II may in some way be involved in the GPR75 signalling pathway. Thus, pharmacological 
inhibition of protein kinases using STP, a broad spectrum protein kinase inhibitor, 
demonstrated that protein kinases were essential in mediating the stimulatory effect of CCL5 on 
intracellular calcium levels and insulin secretion. Moreover, specific pharmacological depletion 
and/or inhibition of PKC and CAMK II revealed that both protein kinases were required in 
mediating the stimulatory effects of CCL5 on insulin secretion. PKC has been reported to 
influence signalling components in beta cells. For example, several phosphorylation sites for 
PKC have been identified on the SUR1 subunit of KATP channels (Inagaki et al., 1995b), PKC 
regulates L-type VOCC activity via phosphorylation (Seino et al., 1992, Seino, 1995, 
Arkhammar et al., 1994) and directly alters the phosphorylation status of cytoskeletal elements 
involved in insulin exocytosis (Jones and Persaud, 1998b). Inhibition of conventional PKC 
isoforms failed to inhibit CCL5-induced insulin secretion, and thus may implicate a potential 
role for novel DAG-sensitive PKC isoforms in mediating the stimulatory effect of CCL5 on 
insulin secretion from beta cells. Furthermore, CAMK II most likely couples the elevations of 
intracellular calcium and insulin exocytosis in response to the CCL5-GPR75 interaction since it 
was shown that inhibition of CAMK II using KN-62 abolished CCL5-induced insulin secretion 
from MIN6 beta cells and human islets. It has been reported that CAMK II promotes vesicle 
fusion with the beta cell membrane by phosphorylating v-SNARES such as VAMP (Hirling and 
Scheller, 1996), and this maybe a mechanism by which CCL5 activation of GPR75 stimulates 
insulin secretion stimulates insulin secretion. 
GPR75 activation has also been implicated in promoting mouse hippocampal cell survival 
(Ignatov et al., 2006). Therefore, experiments measuring apoptosis and cell proliferation 
described in Chapter 6 aimed to investigate the effect of CCL5 and GPR75 activation on beta 
cell survival. CCL5 was shown to have cell protective effects on mouse and human islets as well 




as MIN6 beta cells. Consistent with this, knock-down studies of GPR75 using gene specific 
siRNAs revealed that beta cells were more susceptible to apoptosis compared to controls, 
indicating that GPR75 signalling is associated with protection against apoptosis. Furthermore, 
CCL5 also stimulated MIN6 beta cell proliferation, consistent with reports suggesting GPR75 
activates a PLC/PI3K/Akt/ MAPK cell survival pathway in CV-1 cells (Ignatov et al., 2006). 
Elements of this survival pathway have been implicated in beta cell survival. For example, over 
expression of Akt is associated with reduced susceptibility to apoptosis and enhanced cell 
proliferation (Downward, 2004, Khwaja, 1999, Lawlor and Alessi, 2001, Nakamura et al., 2000). 
Akt can also expand the beta cell mass by stimulating cyclin D1 levels with concomitant 
inhibition of CKIs such as p27 (Fatrai et al., 2006). Akt can also activate p42/p44 MAPK 
(Ignatov et al., 2006), which has been implicated in stimulating cell cycle progression by 
stimulating cyclin D1 activity (Lavoie et al., 1996). Furthermore, p42/p44 MAPK activation has 
been implicated in promoting the expansion of beta cell mass (Rafacho et al., 2009). 
The overall aim of this thesis was to determine the role GPR75 and its endogenous ligand 
CCL5 in islets of Langerhans and the main observations illustrated in Figure 95 and can be 
summarised as follows: GPR75 is the most abundantly expressed CCL5 receptor at the mRNA 
level in mouse and human islets and it has been detected at the protein level in islets in alpha 
and beta cells. Its activation by CCL5 stimulates insulin secretion from beta cells via GPR75 
coupling to the Gαq protein, activation of PLC, elevations in intracellular calcium via calcium 
influx promoted by closure of KATP channels. Although the exact mechanism of how PLC 
activation is coupled to the closure of KATP channels remains unknown it is conceivable that it 
may involve the activation of DAG-sensitive novel PKC isoforms. Furthermore, GPR75 
activation by CCL5 also enhances beta cell survival in islets, most likely by signalling through 
survival pathways. Therefore, GPR75 shows promising potential to improve glycaemic control 
and improve beta cell mass, and thus it is an attractive therapeutic target for future T2DM 
therapies. 
  




Figure 95: Schematic diagram summarising the GPR75 signalling pathways involved in 
stimulating insulin secretion and expansion of beta cell mass. GPR75 activation by CCL5 activates 
PLC, which stimulates the formation of IP3 and DAG. This activates DAG-sensitive novel PKC 
isoforms, which may regulate the open state KATP channels and L-type VOCC activity. Closure of KATP 
channels results in beta cell membrane depolarisation, which subsequently activated L-type VOCCs and 
thus promotes calcium influx into the cytosolic compartment. Elevations in intracellular calcium stimulate 
CAMK II, which promotes insulin exocytosis. GPR75 activation also enhances beta cell survival and this 
may be achieved by activating a PLC/PI3K/Akt/MAPK cell survival pathway, however further 
experiments are required to establish this in beta cells. 
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7.2 Future perspectives  
The experiments described in this thesis provide a firm foundation for further studies on the 
role of GPR75 in islets. Future experiments should identify the GPR75 signalling pathway in 
beta cells in greater detail, with a focus on the role of PKC in this pathway. Experiments should 
also be carried out to identify the pathways responsible for promoting beta cell survival upon 
GPR75 activation. It would be worthwhile measuring Akt and p42/p44 MAPK 
phosphorylation in response to GPR75 activation and observing the effects on apoptosis 
and/or proliferation by pharmacological inhibition of PLC (with U73122) or PI3K (with 
wortmannin) in islets and MIN6 beta cells.  
It would also be of interest to determine expression levels of GPR75 and traditional CCL5 
receptors in islets from obese and/or T2DM models. It has been reported that circulating levels 
of CCL5 are elevated in T2DM (Herder et al., 2005), whereas CCR5 mRNA is down-regulated 
in NOD mice, and CCR5-/-NOD mice display accelerated insulitis (Solomon et al., 2010, 
Cameron et al., 2000). However, it has also been shown that CCR5 is also up-regulated in white 
adipose tissue (WAT) of diet-induced obese (DIO) mice with CCR5-/- mice showing protection 
from insulin resistance and glucose intolerance (Kitade et al., 2012). Therefore, it is conceivable 
that GPR75 in beta cells may be down-regulated during the pathogenesis of T2DM, which may 
cause beta cells to alter their function and become more susceptible to cell damage. 
Furthermore, GPR75 mRNAs have been detected in liver and skeletal muscle (Ignatov et al., 
2006), which are key sites for glucose production and utilisation, and therefore it is possible that 
GPR75 may regulate various glucoregulatory processes in peripheral tissues.  
Future experiments should also include functional studies using GPR75 and CCL5 knock out 
(KO) mice when they become available, in order to determine the effects on islet hormone 
secretion, beta cell apoptosis and proliferation, as well as to determine other functional 
alterations such as glycogen synthesis in the liver or glucose uptake in adipose tissue and skeletal 
muscle, which should be further complemented with in vivo studies to determine plasma insulin 
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